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Abstract 
Sporadic Creutzfeldt-Jakob Disease (sCJD) is the most common form of human prion 
disease. It is a rapidly progressive dementia with other associated neurological 
abnormalities which is invariably fatal, usually within 4-6 months of first symptoms, 
and affects around 80-100 patients in the UK each year. It is caused by propagation 
around the central nervous system of PrPSc, an abnormal conformational form of the 
host PrPC protein, which causes the transformation of PrPC to PrPSc, essentially self-
replicating. This process causes neuronal loss and other pathological abnormalities, 
explaining the clinical presentation. sCJD is believed to occur as a de novo 
convolutional change which seems to occur as an unfortunate chance event. 
 
The existence of other forms of CJD, including variant CJD (vCJD) and iatrogenic CJD 
(iCJD) highlight the fact that the abnormally folded forms of the prion protein are 
infective agents, which can be transmitted by diet (from bovine spongiform 
encephalopathy – BSE – in cattle to humans in vCJD), or by medical intervention 
(predominantly from contaminated dura mater grafts, and cadaveric pituitary 
derived growth hormone in iCJD). These two routes of transmission can be associated 
with long intervals (up to around 40 years has been described) between exposure to 
the infective agent and subsequent symptom onset. 
 
It is possible that some cases classified as sCJD may in fact be acquired through other 
means of transmission. As part of the UK National CJD Surveillance process, the 
NCJDRSU collect data on potential routes of CJD transmission. In this thesis, I 
describe and analyse the data concerning three potential such routes for the definite 
or probable cases of sCJD reviewed by the NCJDRSU between 2010 and 2015 
inclusive: 
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1) Packed red cell blood transfusion has been associated with iatrogenic transmission 
of variant CJD. We found no evidence of such transmission in sporadic CJD.  I also 
describe the first two reported cases of sCJD occurring in patients with clotting 
disorders who had received numerous transfusions and other blood products; there 
have been no further published cases since this report, and these two cases are 
considered likely both to represent the chance development of sCJD.  
 
2) Tissue and organ transplantation is another recognised route, with iatrogenic 
transmission of CJD described in corneal transplantation. A small number of sCJD 
patients have undergone surgery involving transplantation of tissues or organs.  
Although a few cases of interest were identified as recipients of potentially infective 
materials, including three patients who are suspected to have received dura mater 
grafts and one patient who underwent definite corneal transplantation, it was not 
possible to confirm the exact nature and source of these materials, meaning it is not 
certain that these cases definitely represent iatrogenic transmission. Therefore, I 
found no evidence that tissue or organ transplantation is responsible for the 
development of cases of iCJD among this patient cohort.  
 
3) Other surgical procedures may convey the risk of transmission of PrPSc through 
incomplete sterilisation of instruments. I assessed the potential for UK sCJD patients 
to have come into contact with instruments used on another CJD patient, looking at 
associations between surgical procedures occurring within the same year, at the same 
hospital, and within the same surgical domain. While some such associations were 
identified, interpreting these associations is extremely difficult, in large part due to 
the absence of a suitable control group, as well as incomplete data availability. 
 
Overall, this work has identified no definite transmission of iCJD masquerading 
among the sCJD 2010-2015 patient cohort. There are significant limitations to each 
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aspect of this work, in large part pertaining to incomplete medical records; these 
limitations are addressed in the relevant chapters. Some of these limitations may be 
difficult to overcome if future these studies are repeated in the future with a new 
cohort.   
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Lay Abstract 
Sporadic Creutzfeldt-Jakob Disease (sCJD) is the most common form of human prion 
disease. It is a rapidly progressive dementia (usually memory and language loss) with 
other associated neurological abnormalities (such as coordination problems and 
involuntary jerking movements), and is invariably fatal, usually within 4-6 months of 
first symptoms. It affects around 80-100 patients in the UK each year. It is caused by 
the spread around the brain and spinal cord of PrPSc, an abnormally shaped version 
of a protein found in all humans (and many other animals) which is called PrPC when 
found in its normal, healthy form. This PrPSc protein replicates itself by changing the 
normal protein into the abnormal, diseased form. This process causes damage to, and 
loss of brain cells, as well as other abnormalities which are detectable both 
pathologically (looking at tissue under the microscope) and biochemically (using 
molecular techniques to study the proteins themselves, which are too small to see 
directly with a microscope). The damage to, and loss of, brain cells explains 
symptoms experienced by patients. sCJD is believed to occur as a spontaneous 
protein shape change which occurs as an unfortunate chance event. 
 
Other forms of CJD have been transmitted by diet – from bovine spongiform 
encephalopathy (BSE) in cattle to humans as variant CJD (vCJD) – or by medical 
procedures –called iatrogenic CJD (iCJD). This medical transmission predominantly 
occurred through injection of hormones extracted from glands located next to the 
brain of deceased humans, and through implantation dura mater grafts. The dura 
mater is a tough membrane which surrounds and protects the brain.  Until 1992, dura 
mater obtained post mortem from human cadavers was commonly used as a patching 
material in neurosurgery, for example to repair cerebrospinal fluid leaks, and also in 
some other (non-neurosurgical) procedures. The fact CJD can be transmitted in these 
forms highlights that the abnormal protein, PrPSc is an infectious particle which can 
transmit certain forms of the disease. 
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It is possible that some cases which are believed to be the sporadic (random, chance) 
form of CJD may in fact have been acquired through contact with other patients who 
have suffered from CJD, perhaps through transplantation of body tissues or whole 
organs, or through contaminated blood transfusion or the use of surgical instruments. 
In this thesis, I describe and analyse the data collected by me and others at the 
National CJD Research and Surveillance Unit to look for evidence of transmission of 
CJD by these means for patients with sCJD referred to the NCJDRSU between 2010 
and 2015 inclusive.  
 
1) Packed red cell transfusion has been associated with accidental medical 
transmission of variant CJD, but we found no evidence of such transmission in 
sporadic CJD.  I also describe the first two reported cases of sCJD occurring in patients 
with clotting disorders who had received numerous transfusions and other blood 
products; these two patients are thought most likely to have developed sCJD by 
chance, and there have been no further published cases of sCJD among clotting 
disorder patients.  
 
2) A small number of sCJD patients have undergone surgery involving 
transplantation of organs or suspected implantation of relevant tissues. There are 
significant limitations to the available data, meaning it is not possible to be completely 
certain regarding the details and origins of these organs and tissues. There was no 
evidence of tissue and transplant transmission of CJD among the patient group 
studied.  
 
3) Other surgical procedures convey the risk of transmission of PrPSc through 
incomplete sterilisation of instruments. I assessed the potential for UK sCJD patients 
to have come into contact with one another through associations between surgical 
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procedures occurring within the same year, at the same hospital, and within the same 
surgical domain. While such connections were identified between pairs of patients, 
without a non-CJD group to compare for the same connections, it is not clear what 
these connections represent, as such connections could occur by chance alone. There 
are also significant limitations caused by incomplete data availability which further 
hampers any analysis. 
 
Overall, while this work has identified no definite transmission of CJD by blood or 
blood product transfusion, or tissue and organ transplantation.  Although it is 
possible that sCJD patients may have contact with one another by surgical 
instruments, these episodes of potential interconnection may represent chance 
occurrences, and a non-CJD control group would help interpretation of these results, 
if further data was collected in the future. There are significant limitations of the 
analysis possible from NCJDRSU data, which are detailed in the relevant chapters. 
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The Neuroepidemiology of  
Human Prion Disease 
  




Prion diseases affect both humans and other animals, and comprise a number of rare 
and ultimately fatal neurodegenerative conditions that result from the accumulation 
in the central nervous system (CNS) of an abnormal form of a naturally occurring 
protein, called the prion protein (4).  This protein, coded for by the prion protein gene 
(PRNP), is widely expressed in many different tissues although it is predominantly 
found in the CNS (5). In its normal, protease sensitive, form, designated PrPC, it is 
thought to be neuroprotective even though its exact function remains unclear. In 
disease states, the PrPC is converted to an abnormal form, designated PrPSc, following 
a “seeding” event. The PrPSc is protease resistant and able to propagate through 
further contact with PrPC, building up over extended incubation periods and causing 
pathology in the CNS tissues affected. 
 
Prion diseases in humans are characterised clinically by prolonged incubation 
periods (in the forms where the timepoint of exposure is known) followed by a 
relatively rapid progressive loss of cognitive and motor functions. Case identification 
relies principally on the investigation of suspected cases by neurologists and 
neuropathologists, although other specialities, for example general medicine, 
geriatric medicine, and old age psychiatry may also be involved. Clinical diagnostic 
criteria include abnormal neurological features and investigation results, the latter 
principally involving magnetic resonance imaging brain scans and cerebrospinal 
fluid tests. Definitive diagnosis, however, requires neuropathological evidence – 
usually obtained at post mortem – of aggregated  PrPSc, gliosis, neuronal loss and 
brain tissue vacuolation or spongiform change (6) (see also      
http://www.cjd.ed.ac.uk/sites/default/files/criteria_0.pdf, accessed 31.07.17). 
Currently there are no diagnostic blood tests for pre-clinical disease, although this is 
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an area of ongoing research in vCJD (further details concerning blood testing in vCJD 
can be found on page 26). 
 
Human prion diseases can be classified as genetic, sporadic or acquired, according to 
the initial seeding event thought to have occurred (see Figure 1.1).  Genetic (or 
familial) prion disease in humans is associated with the presence of (one or more of) 
over 30 established PRNP mutations that destabilise PrPC and cause or predispose to 
conversion (7).  In sporadic disease, the initial seeding event is thought to be a 
spontaneous protein misfolding event, likely associated with a somatic mutation or a 
chance conversion of PrPC to PrPSc of unknown cause. Acquired disease results from 
exposure to exogenous PrPSc, from an animal or another human. A methionine-valine 
polymorphism at codon 129 of the PRNP gene affects disease phenotype as well as 
susceptibility, with methionine homozygosity at this locus predisposing to prion 
disease and the presence of valine generally associated with longer incubation 
periods and slower disease progression (8, 9).  
 
Figure 1.1: Simplified schematic of the prion hypothesis. 
Source: Mark Head, NCJDRSU, Edinburgh, UK. 
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In recent years there has been increased interest in the field of human prions, with 
evidence that the proteins associated with other neurodegenerative diseases, for 
example Aβ associated with Alzheimer’s disease, may also propagate in a prion-like 
manner (10). However, I have not included these other conditions in this thesis, 
instead focusing on the classical definition of prion disease. The focus is on all forms 
of Creutzfeldt-Jakob Disease (CJD), although we will mention other forms of human 
prion disease, as well as animal prion diseases relevant to humans. 
 
 
Sporadic Creutzfeldt-Jakob Disease 
 
Clinical-pathological features: 
CJD was first described in 1920 by Neuropathologist Hans Creutzfeldt (11) and 
shortly afterwards by Neurologist Alfons Jakob (12). Although rare, CJD is the most 
common human prion disease and the majority of cases are idiopathic, occurring 
sporadically worldwide. Most sporadic CJD patients suffer rapidly progressive 
cognitive decline with myoclonus, ataxia, cortical visual impairment, pyramidal 
and/or extrapyramidal signs, progressing to akinetic mutism before death.  Disease 
duration from first symptoms to death is usually short, with a median of around 4 
months, however there can be significant variation, with death occurring within one 
month of onset or after several years.  Sporadic CJD is, however, clinically 
heterogenous, with the patient’s PRNP codon 129 methionine-valine polymorphism 
status and the subtype (type 1 or type 2) of the protease-resistant component of PrPSc  
found when investigating PrPSc by Western Blot, designated PrPres, associated with 
the clinical phenotype; together, codon 129 status and PrPSc subtype are used to define 
the strains of sporadic CJD (8, 13).  Longer survival has been associated with younger 
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age at onset, female sex, PRNP codon 129 methionine-valine heterozygosity and type 
2A PrPres (14).  
 
Incidence and basic demographics: 
Sporadic CJD occurs at rates of between 1 and 2 cases per million population 
worldwide (see http://www.eurocjd.ed.ac.uk/surveillance data 1.html, accessed 
31.07.17). It affects males and females approximately equally, and is a disease mainly 
of the older population. In the United Kingdom (UK), the median age at death is 68 
(range 20-95) with a peak in mortality between 65 and 79 years of age and fewer cases 
in individuals either under 50, or above 80 years of age, although cases have been 
reported (outside the UK) in adolescents, and in adults over 90.  
 
In the UK and other countries with well-established surveillance systems, annual 
mortality rates for sporadic CJD have increased over time (15) (see figure 1.2 overleaf).  
This may reflect better ascertainment of cases across all ages, particularly in older 
patients who – as a group – have perhaps become better investigated as new 
treatments and diagnostic tools are developed for certain forms of dementia.  
However, the low rate of disease seen in the most elderly is noteworthy, in that 
perhaps more cases might be expected in this age-group from a sporadic protein 
misfolding event. It is unclear whether this decline in incidence at older ages is real, 
or perhaps reflects incomplete case ascertainment in the most elderly, with these 
“missed” diagnoses perhaps being lost amongst more common dementias, resulting 
in cases of prion disease being misidentified (16, 17). 
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Figure 1.2: Age -specific mortality from sporadic CJD in the UK, 1995-2016 




Codon 129 of the prion gene may be regarded as a risk factor for the development of 
sporadic CJD, with overrepresentation amongst cases of the homozygote states, 
particularly methionine, relative to the general population (18). 
 
Although some exposures to tissues containing abnormal prion proteins (PrPSc) from 
patients with sporadic CJD in medical settings have resulted in transmission from 
person to person, associated with the accidental transplantation of infective tissue or 
inoculation of small amounts of residual tissue adhering to reusable surgical 
instruments (see section on iatrogenic CJD below), no consistent risk factors for the 
development of sporadic CJD have been identified. Some case-control studies have 
identified an increased risk of sporadic CJD associated with prior surgical exposure 
(19-21) or through blood transfusion (22) but this has not been convincingly 
demonstrated by others (19, 23, 24). In addition, there is no evidence of any increased 
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occupational risk (25), even though people employed in certain professions, for 
example neuropathologists or neurosurgeons, might be exposed to infectivity in the 
course of their work. Very occasionally, sporadic CJD cases are identified in people 
who have lived close together at some point in their lives, raising the possibility that 
the cases may be linked, for example, a husband and wife pair, both of whom 
developed sporadic CJD (26). One analysis has also provided evidence of increasing 
geographic clustering of sporadic CJD cases with increasing time interval before 
disease onset, consistent with some sporadic CJD cases perhaps resulting from a past 
exposure to a common external factor (27). Identifying a common source of 
transmission many years after the event is difficult, however, and there are other 
limitations to the above studies, not least bias and confounding factors (28). But while 
it is plausible that a small number of cases classified as sporadic CJD have resulted 
from transmission associated with other, as yet unidentified, causative factors, the 
evidence for this is weak. Overall the findings are consistent with the hypothesis that 
sporadic CJD is not an acquired disease. 
 
 
Variably Protease Sensitive Prionopathy 
 
Recently a new disease called variably protease sensitive prionopathy (VPSPr) has 
been identified with distinct biochemical characteristics: the accumulating PrPSc 
shows a markedly different response to the proteases used in biochemical analysis 
than as is seen in other forms of CJD, with variable sensitivity in different brain 
regions (29, 30). The disease affects those in mid-to-later life (range 48-81), patients 
have a non-specific clinical profile and a duration of illness ranging from under 1 to 
over 5 years; the neuropathology at post mortem would be atypical for sporadic CJD.  
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Currently, the true incidence and underlying epidemiology of this novel prion 
disease are uncertain. Diagnosis is neuropathological and consequently case 
identification has been retrospective, with most cases of VPSPr worldwide having 
been identified in the UK (13 cases reported to date, see 
http://www.cjd.ed.ac.uk/sites/default/files/figs_4.pdf, accessed 31.07.17), as well the 
USA and other parts of Europe. Cases have been identified in all codon 129 PRNP 
polymorphism groups, but the disease has predominantly been identified in valine 
homozygotes, the rarest codon 129 status. Although research suggests that VPSPr has 
limited transmission potential (31), its longer disease course and non-specific early 
clinical findings may mean VPSPr is falsely diagnosed as other forms of dementia and 
likely to be under-ascertained. 
 
 
Variant Creutzfeldt-Jakob Disease 
 
Clinical-pathological features: 
In 1996 a new disease, variant Creutzfeldt-Jakob Disease (vCJD), was identified in the 
UK (32). It was differentiated from the more commonly encountered sporadic form 
of CJD by the young age of patients (the median age at death based on UK cases 
observed to date is 28, range 14-75) and unusual neuropathological and clinical 
features. Cases typically presented with a neuropsychiatric prodrome of apathy or 
withdrawal, followed by early ataxia, early and prominent sensory features, and a 
notable absence in early stages of memory problems or dementia. Neuropathological 
examination identified plaques of PrPSc deposition, described as “florid” and largely 
distinct from any seen in other forms of CJD, alongside the more typical features of 
spongiform changes, loss of neurones and astrocytosis, as seen in other prion 
diseases. Cases had a longer disease duration from symptom onset to death than was 
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typical of other forms of CJD; the median duration based on UK cases is currently 14 
months (range 6-114) (15).  
 
Incidence worldwide: 
Following reports of the first vCJD cases in 1996, the vCJD epidemic comprised a 
single wave of epidemic cases, peaking in the UK in 2000, later elsewhere, and 
subsequently declining to under 1 new diagnosis currently reported per year 
worldwide (see Figure 1.3). At the time of writing, a total of 231 cases of vCJD have 
been identified worldwide, mostly (178, 77%) within the UK (see 
http://www.cjd.ed.ac.uk/sites/default/files/worldfigs_0.pdf, accessed 31.07.17). The 
non-UK vCJD cases have occurred mainly in France (27 cases), with no more than 5 
cases reported in each of a small number of other countries in Europe and the rest of 
the world. 
 
Figure 1.3. BSE and vCJD deaths by year in the UK and other European Union (EU) 
countries.
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Figure 1.3 source: NCJDRSU, Edinburgh, UK and World Organisation for Animal 
Health. Please note different units for UK and EU BSE cases. 
 
Biochemical similarities, transmission studies and strong geographic and temporal 
associations with the animal zoonotic bovine spongiform encephalopathy (BSE) have 
provided strong laboratory and epidemiological evidence that vCJD and BSE are 
linked (33-36). BSE is addressed in more detail in the section on animal prion diseases 
that follows in this chapter (page 38), but those aspects of direct relevance to the vCJD 
epidemic are covered within this section. The first cases of BSE were reported in the 
UK in 1986 (37, 38). In total, one million cattle are thought to have been infected 
during the ensuing BSE epidemic, with over 400,000 of these animals estimated to 
have entered the human food chain (39). The epidemic peaked in 1992 and 1993, and 
then subsequently declined to one or two cases per year (see 
http://www.oie.int/en/animal-health-in-the-world/bse-specific-data/ accessed 
31.07.17).  Far fewer BSE cases have been diagnosed outside the UK (e.g. Ireland 
reported 1656 between 1989-2016 inclusive, while France reported 1026 within the 
same time period, see http://www.oie.int/en/animal-health-in-the-world/bse-
situation-in-the-world-and-annual-incidence-rate/number-of-reported-cases-
worldwide-excluding-the-united-kingdom/ accessed 15.08.18). 
 
Risk factors: 
The identification of the vast majority (178 of 231, see 
http://www.eurocjd.ed.ac.uk/surveillance%20data%201.html and 
https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf both accessed 15.08.18) of vCJD 
cases among individuals resident within the UK for more than six months between 
1980-1996 is attributed to the transmission of the BSE agent to humans between 1980 
(when BSE is thought first to have begun circulating) and 1996 (when the final 
controls to protect animal and human food chains were put into place). The 53 non-
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UK vCJD cases have been attributed either to exposure to BSE from UK exported 
cattle, meat or animal products – rather than necessarily representing infection 
outside the UK  – or to the individual patient spending time in the UK during the 
period of probable BSE exposure (40, 41). The greatest risk to humans is thought to 
have been the dietary consumption of meat products which could have been 
contaminated with the BSE agent by the extraction techniques required in the 
production of mechanically recovered meat (42) or by contact with brain and other 
CNS material from infected animals during butchering (43), particularly prior to the 
UK ban in 1989 of certain tissues of cattle, sheep and goats (including brain, spinal 
cord and other material) considered likely to be infective. It is certainly noteworthy 
that no UK vCJD cases have been seen in people born after 1989, indicating the 
significant public health impact of the introduction of this ban.  
 
Another important risk factor is age. Despite the fact that most BSE exposure occurred 
in the UK in the late 1980s and early 1990s, the median age at onset of vCJD (26 years, 
range 12-74 years) has remained the same, consistent with those born in the 1980s 
being infected later in the BSE epidemic when they were older, rather than at the 
beginning (see http://www.cjd.ed.ac.uk/data-and-reports/incidence-variant-cjd-uk, 
accessed 31.07.17). This may reflect lower age-related susceptibility to infection (44) 
or reduced exposure to BSE in food in the very young (45).  
 
Codon 129 genotype is also important: until 2016, all neuropathologically confirmed 
cases of vCJD who were tested (119 tested of 123 confirmed cases) were found in 
methionine homozygous individuals. In 2016 the first pathologically confirmed case 
of vCJD in a methionine-valine heterozygous patient was identified (46). Whether this 
case represents the beginning of a second epidemic wave of vCJD amongst other 
genotypes, or is an isolated case remains to be seen.  The incubation period between 
exposure to infection and vCJD symptom onset is estimated to be 15 years, however 
in non-methionine homozygous individuals this is likely to be longer (47). An earlier 
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case of suspected vCJD has been reported in a codon 129 methionine-valine 
heterozygote; the patient lacked the supportive investigations to be classified, 
according to World Health Organisation criteria, as either a definite or probable case 




Despite early fears of a very large epidemic, far fewer vCJD cases have arisen than 
anticipated. The reasons for this are unclear. Given the extensive exposure of the 
human population to BSE, it is likely that there is a substantial species barrier, but 
other factors may also be involved, including effect of dose, age related- and genetic 
susceptibility and the presence of co-factors necessary for infection and the 
development of disease (49, 50). 
 
However, a recent study of the prevalence of PrPSc deposition in appendix tissue in 
the UK has indicated 1 in 2000 among those born 1941-85, the age group considered 
most exposed to BSE, carry the abnormal convolutional form of the prion protein (51).  
The exact interpretation of this PrPSc deposition is uncertain, particularly given that it 
is observed at a frequency far higher than the observed symptomatic cases, but one 
interpretation is of an asymptomatic carrier state following BSE exposure. Moreover, 
such PrPSc deposition was found across all codon 129 genetic subgroups, with a 
higher proportion of valine homozygotes (25% of positive specimens) than would be 
expected in the normal population (11 % (18)). A subsequent UK study noted rates of 
PrPSc appendix deposition carriage consistent with the above, but in time periods 
outside the period 1980-1996, when the population has not previously been 
considered to be exposed to BSE (52).  While such deposition is of unknown 
significance to the individuals’ risk of developing vCJD, or as yet to interpreting the 
general population exposure to BSE, it is a significant public health concern. 




In vCJD, PrPSc is deposited outside the CNS at significantly higher levels compared 
to other forms of CJD, most likely due to the route of exposure to BSE across the gut 
(53). This peripheral, predominantly lymphoreticular, pathogenesis outside the CNS 
in patients with vCJD has led to concerns regarding the potential for iatrogenic 
transmission of vCJD by procedures related to a wider range of (non-CNS) tissues 
than in other forms of CJD where pathology and PrPSc is largely limited to the CNS. 
This is a particular concern given the current absence in routine clinical and infection 
control practice of both decontamination methods that can fully remove PrPSc from 
surgical instruments, and of a validated early blood test for pre-clinical disease (see 
page 26 for further details).  
 
There is no evidence of mother-to-child vertical transmission (54), or from case 
control studies of a risk of vCJD associated with occupation or past surgery (42). 
Dental instruments may provide a route of transmission, as animal studies have 
demonstrated that  PrPSc can be identified in the dental pulp and gingival margin after 
small bowel challenge with infective material (55), although no dental risk factors 
were identified in an analysis of UK cases (56). Lookback studies have also not 
identified any associations between cases linked to tissue or organ transplantation 
(57), however depending on the mass of tissue transplanted, the site of transplant and 
infectivity of the tissues involved such procedures may carry a risk of passing on 
vCJD infection if the donor were to be infective.  
 
Crucially, however, vCJD has been transmitted through blood. To date three such 
instances of vCJD transmission have been identified worldwide, all occurring in the 
UK, where a patient received a non-leucodepleted red cell transfusion from a donor 
who subsequently developed vCJD (2, 58). These three cases, two of whom received 
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blood from the same donor, became symptomatic at 6.5, 7.8 and 8.3 years after 
receiving the implicated transfusion; each shorter than the 15 year estimated mean 
incubation period of vCJD after dietary exposure to BSE (the exact range of incubation 
periods in patients with dietary vCJD is not known, as it is not clear when each 
individual patient was exposed, and many may have had multiple exposures over 
many years, but it took 10 years from identification of BSE to the detection of vCJD 
(59)). In addition, asymptomatic infection has been identified in the spleens of two 
patients who died of non-neurological illness. The first was a recipient of vCJD-
implicated non-leucodepleted blood, transfused 5 years prior to the death of the 
recipient (60) and the other was treated with multiple UK sourced blood products, 
including batches of clotting factors derived from donors who subsequently 
developed vCJD (61). The second individual died 14 years after first exposure to vCJD 
implicated factor VIII, 12 years after a second exposure, and 10 years after 3 unit 
transfusion with non-leucodepleted red cells. It is considered statistically unlikely 
that these splenic deposits of PrPSc were acquired through dietary means and this is 
supported by the absence of detectable PrPSc in their tonsils or gut associated 
lymphoid tissue.  Each of these individuals were codon 129 methionine-valine 
heterozygous; it is unknown whether, had they lived longer after the exposure, they 
might have developed clinical vCJD.  
 
The occurrence of the blood/blood product-associated cases, together with laboratory 
evidence that indicates that the vCJD strain is not altered significantly following 
transfusion transmission (62, 63), suggests that transfusion of blood from donors who 
are in a presymptomatic phase of vCJD may be an efficient means of transmission. To 
try to prevent (the at that point theoretical) transmission of vCJD through blood 
transfusion, leucodepletion was implemented in 1999 in the UK, based on 
experimental data suggesting that lymphocytes were involved in early pathogenesis, 
and there have been no further reports of blood or blood product associated 
transmission of vCJD subsequently (1).  
Page 26 of 220 
 
 
A direct detection assay was developed by the MRC Prion Unit to try to identify PrPSc 
in the blood of patients with vCJD; they published their work in February 2011 (64); 
further work by that group was published in April 2014, suggesting the test had 
sufficient sensitivity  to have potential utility as a presymptomatic screening test for 
vCJD (65). This test appeared to detect PrPSc in blood of many vCJD patients, with a 
sensitivity when testing blood from patients who were symptomatic of vCJD of 
around 70%. It is unknown whether the observed sensitivity in symptomatic 
individuals would translate to those not yet symptomatic of vCJD as it is thought 
there would be smaller levels of circulating PrPSc early in the disease course. This test 
would require validation in the at risk population – those resident in the UK and 
exposed to beef products during the BSE epidemic – but such validation would prove 
problematic due to the extremely small numbers of new vCJD patients, with only a 
single individual seen in the UK between 2014 and 2018 inclusive (46)  (see also 
https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf, accessed 15.08.18). At least two 
other groups are also working in this field, both using protein misfolding cyclic 
amplification (PMCA), which appears to yield higher sensitivity and specificity (each 
approaching 100%) than the direct detection assay technique. In both studies (66, 67). 
Bougard et al. were also able to identify presymptomatic infection in 2 vCJD patients 
for whom blood samples were available prior to the development of clinical features 





Kuru was first described in Western literature in 1957 (68) although according to local 
verbal histories it may have dated back to around 1920.  Originally known as “the 
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shaking palsy” (the term Kuru is derived from the local word meaning “to shake with 
fear”), the disease was characterised by ataxia, tremor and other movement disorders, 
and emotional lability; it had a typical duration of 4 to 24 months from symptom onset 
to death. 
 
Kuru affected individuals in the Fore region of the eastern highlands of Papua New 
Guinea, disproportionately affecting women (67% of Kuru patients) and 
children/adolescents of both sexes (23%); it was caused by ritual funeral 
endocannibalism.  It is hypothesised that the epidemic began when an individual 
who died from sporadic CJD was consumed by their family members.  Women were 
responsible for preparation of the mortuary feast, and women and children were 
significantly more likely to consume brain tissue during the ritual than men; 
furthermore, men tended not to eat materials from female relatives (69).  The 
incubation period for the disease has proven to be widely variable, between around 
5 and 50 years, with codon 129 heterozygotes having longer incubation periods and 
methionine homozygous individuals having earlier onset and more aggressive 
presentations (70). Following the prohibition of cannibalism in the late 1950s, the 
number of cases declined steadily, first in the younger age groups born after the 
alteration in practice, with no new cases identified in individuals born after 1959.  The 
last reported patient died in 2005; as such Kuru is now regarded as an historical 
disease. The epidemic is therefore thought to have spanned 85 years, with more than 
2700 deaths between 1954 and 2005 (70). 
 
A genetic polymorphism at codon 127 of the PRNP gene, not reported in other 
populations, has been identified among survivors of the Kuru epidemic and appears 
to completely protect against prion diseases in animal studies, illustrating the very 
strong selection pressure exerted during the Kuru epidemic (71, 72). 
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Iatrogenic Creutzfeldt-Jakob Disease 
 
Incidence and sources of infection: 
More than 460 CJD cases worldwide have been acquired as a result of medical 
interventions, although the incidence varies from country to country due mainly to 
differences in the medical practices that exposed the patients to CJD infectivity (73, 
74). The main routes of transmission comprise human pituitary derived growth 
hormone and dura mater grafts, produced from cadaveric tissues presumed to be 
derived from cases of sporadic CJD or asymptomatic carriers who had died from an 
unrelated illness. There have also been a small number of CJD cases acquired through 
other iatrogenic routes. All these cases of secondary transmission of CJD have been 
associated with parenteral exposure to contaminated materials – materials which 
were extracted from, or were in close proximity to, brain tissue (75).  
 
Human pituitary derived hormones: 
Starting in the late 1950s, intramuscular injection of human pituitary derived growth 
hormone was used to treat short stature in children. By 1985, when the first related 
CJD cases occurred (76-78), around 30,000 children had been treated worldwide. To 
date, around 230 cases have been identified worldwide, with deaths still occurring. 
More than half of these have occurred in France, where all of the cases received 
human pituitary derived growth hormone injections between December 1983 and 
July 1985, strongly suggesting that a batch of injections used in this time period was 
contaminated (79). Smaller numbers have been seen in other countries, mainly the 
UK and USA (73, 74). Human gonadotropin was also extracted from cadavers around 
the same time period and subsequently injected as a fertility treatment.  There have 
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been 4 cases of CJD reported among recipients of this hormone in Australia, the first 
reported in 1990 (80), the most recent in 1995. The production of all human pituitary 
derived hormones involved pooling of thousands of donated cadaveric pituitaries, 
increasing the potential for contamination before extraction of the relevant hormone. 
The use of human pituitary derived hormones was stopped in 1985 in most countries, 
and since then has been replaced with synthetic treatments, making new exposures 
through this route unlikely to occur.  
 
The clinical features of human pituitary derived hormone-related CJD differ from 
sporadic CJD cases, in that most cases typically present with a progressive cerebellar 
ataxic syndrome of duration 8-18 months, with dementia occurring infrequently and, 
if at all, typically late in the illness (75).  Incubation periods estimated from the 
midpoint of treatment exposures until symptom onset in each individual range from 
5 to 42 years and are widely variable between countries, reflecting inter-country 
variation in dosage regimes and durations of treatment, as well as the levels or dose 
of infectivity to which individual cases were exposed.  The estimated average 
incubation period is 13 years in France, 20 years in the UK and 22 years in the US; the 
incubation period observed in the 4 recipients of gonadotrophin was from 12 to 16 
years (73). As in other human prion diseases, codon 129 polymorphisms impact upon 
incubation periods and susceptibility to the condition; methionine-valine 
heterozygosity is associated with longer incubation periods, and methionine 
homozygosity at codon 129 is more common among growth hormone iatrogenic CJD 
patients than the population in general. However, differences in the codon 129 
distribution of human pituitary derived growth hormone transmitted CJD have been 
also noted between the populations of different countries, which might be due to 
infection with different contaminating strains of the CJD agent (79). 
 
Recent evidence of Aβ seeding in the brains of UK recipients of human pituitary 
derived growth hormone has raised concerns regarding the potential for transmission 
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of these proteins too through iatrogenic routes, which may include through surgery 
and other routes already shown to be means of iatrogenic prion transmission (81). 
Although there is no evidence to date that Alzheimer’s disease itself has been caused 
in this way, research into the potential transmissibility of non-prion 
neurodegenerative disorders will continue to be important to clarify these issues in 
the future. 
 
Cadaveric dura mater grafts: 
The dura mater is a tough membrane which surrounds and protects the brain.  Until 
1992, dura mater obtained post mortem from human cadavers was commonly used 
as a patching material in neurosurgery, for example to repair cerebrospinal fluid 
leaks, and also in some other surgical domains.  The first reported CJD death in a dura 
mater graft recipient occurred in 1979, and since then over 230 cases have been 
reported from 19 different countries worldwide (73, 74). The clear majority of these 
cases have been associated with a single brand, Lyodura® (for the remainder of cases, 
often the brand cannot be identified (82)), which was introduced in 1969. Most 
patients who developed iCJD after Lyodura® implantation were treated between 
1981 and 1987, after which the production process was modified to include 
disinfection using sodium hydroxide, a processing step which may denature PrPSc, 
reducing infectivity. It is suspected that Lyodura® was contaminated by harvesting 
dura from a cadaver who died of sCJD (or perhaps died of some other cause in a 
presymptomatic phase of the disease), and that there was subsequent cross-
contamination in the production process (75).  Incubation periods for dura mater 
associated CJD from exposure to symptom onset have varied between 1 and 30 years, 
with a mean of 12. Most cases occurred between 1990-2000, but small numbers 
continue to be reported.  
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Worldwide, more than 60% of dura mater graft related iatrogenic CJD has occurred 
in Japan, where grafts were used more frequently than in other countries, particularly 
for neurosurgery relating to vascular disease, hemifacial spasm and trigeminal 
neuralgia (83). Lyodura® was used predominantly, while other product brands were 
used with greater frequency in other countries. Codon 129 methionine homozygosity 
is far more common in Japan than in many other studied populations, found in 92% 
of the population and appears to convey susceptibility to the development of human 
dura mater graft associated iatrogenic CJD. Cadaver derived dura mater usage was 
reduced substantially after 1991 with the development of synthetic substitutes, but 
may not have ceased until 1997. 
 
Two distinct clinical and neuropathological phenotypes have been identified among 
the dura mater associated iatrogenic CJD patients (84). Two thirds of patients present 
similarly to sporadic CJD, but in some cases there is a prominent, isolated ataxic 
syndrome at onset and widespread plaque deposition on neuropathological 
assessment.  It is thought that these differences might arise from differences in the 
strains of sporadic CJD that contaminated the grafts. The concept of strains is 
mentioned very briefly on page 15. In summary, more than one form of PrPSc has been 
identified in human (and other animal) prion diseases, and this, combined with codon 
129 polymorphism status, is used to describe CJD strain (8, 13). Different strains 
convey slightly different clinical and pathological phenotypes, and can be suggested 
using neuropathological examination, identified using biochemical and genetic 
testing, and confirmed with animal transmission studies (8). The group of dura mater 
associated iCJD patients that mimic typical sporadic CJD presentations are suspected 
to have been exposed to dura mater grafts which were contaminated by a source of 
either codon 129 methionine homozygous type 1 PrPSc, or methionine-valine 
heterozygous type 1 PrPSc sporadic CJD; those with the atypical presentation are 
thought most likely to have originated from a valine homozygous type 2 PrPSc 
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subtype sporadic CJD donor. This suggests there was more than one exposure of dura 
mater graft production to sCJD contaminated material. 
 
Other iatrogenic risk factors: 
More rarely, cases of iatrogenic CJD have also been associated with corneal grafts, the 
use of infected neurosurgical instruments, and electroencephalogram (EEG) depth 
electrodes (73-75). The first evidence of iatrogenic transmission of CJD was reported 
in 1974 in the recipient of a corneal transplant. The cornea had been sourced from the 
cadaver of a person subsequently found to have died from sporadic CJD (85).  The 
cornea recipient became symptomatic 18 months after grafting, and died 8 months 
later.  A second case was reported in 1997, the recipient dying 30 years after the 
corneal graft (86).  It is likely that the implicated grafts in both these cases included 
small quantities of retinal tissue, which is continuous through the optic nerve with 
brain tissue and can contain PrPSc in cases of CJD (87, 88). Typically, cornea is 
classified as an anterior eye tissue; such anterior tissues are not recognised to contain 
high levels of infectivity (89, 90). There have also been multiple reports of death by 
CJD in recipients of corneal grafts where it has not been possible to identify the cause 
of death of the cornea donors; these cases might represent further cases of iatrogenic 
transmission of CJD, but are more likely to reflect the relatively common occurrence 
of corneal transplantation as an ophthalmological procedure combined with the 
chance development of sCJD.  
 
There have been a small number of iatrogenic CJD cases associated with the re-use of 
stereotactic EEG depth electrodes (2 cases, both linked to earlier use in a single patient 
later confirmed as having died of CJD, with subsequent animal transmission of CJD 
using the same electrodes adding support to this suggestion) (91) or neurosurgical 
instruments (4 cases) (92-94) previously used on patients subsequently discovered to 
have CJD. The full details of these 6 cases (EEG and neurosurgical iatrogenic 
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transmission) are covered in these references and are not repeated here. The 
instruments were likely to have carried infectivity, allowing direct intracerebral 
inoculation of the infectious agent to the recipient’s brain. Consequently, these 
procedures have been associated with shorter incubation periods than for other forms 
of iatrogenic CJD: between 1 and 2 years: 16 and 20 months for the two cases of EEG 
electrode transmission, and between 12 and 28 months for the four reported cases of 
neurosurgical instrument-related transmission (73). Although PrPSc remains resistant 
to standard decontamination processes, there have been no new descriptions of 
surgical transmission through these routes reported since 1997, perhaps reflecting 
greater awareness of the potential for transmission, and efforts to minimise this risk 
through instrument quarantine after usage on potential prion patients, as well as 
increased usage of disposable surgical instruments in this group. 
 
 
Genetic prion diseases 
 
Incidence and geographic distribution: 
Genetic forms of prion disease account for around 10 to 15% of human prion disease, 
and are caused by over 30 known mutations within the PRNP prion protein gene (95); 
they are often termed as familial CJD (fCJD), although genetic CJD (gCJD) is also used 
in the literature. These mutations alter the sequence of amino acids within the prion 
protein, resulting in an increased likelihood of conversion of PrPC to PrPSc (96). They 
are associated with different clinical-pathological phenotypes of disease, for example 
affecting age at onset of symptoms and duration of disease. There are considerable 
differences in the prevalence of genetic prion disease between countries and regions 
(97, 98). 
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Clinical-pathological features: 
There is significant variation in clinical phenotype and pathological findings at post 
mortem between the different forms of genetic prion disease (97, 99, 100). Familial 
CJD is most commonly associated with the E200K mutation and has a disease 
presentation and course indistinguishable from sporadic CJD without genetic testing, 
although it is typically associated with a slightly younger (usually 30 – 60 years) 
disease onset than would be typical in sCJD (these age ranges overlap considerably, 
meaning genetic analysis of the PRNP gene is essential if E200K mutations – and 
therefore fCJD – are not to be missed among presumed sCJD patients). 
 
Gerstmann-Straussler-Scheinker syndrome (GSS, most frequently associated with 
P102L mutation) and Fatal Familial Insomnia (FFI, D178N paired with 129M within 
the mutated PRNP gene) can present at a marginally earlier age than most other forms 
of familial CJD (onset from 20-60 years for GSS, and 18-60 years in FFI), but with a 
slower disease course (2-5 years) (101).  GSS presents as a slowly progressive 
cerebellar ataxia and pyramidal syndrome, with later dementia. FFI patients present 
with insomnia and autonomic failure, unusual for the human prion diseases. 
Sporadic Fatal Insomnia (sFI) is clinically and pathologically indistinguishable from 
FFI without genetic testing, but lacks any FFI-associated PRNP mutation and is 
thought to be a rare subtype of sporadic CJD.  
 
Risk factors: 
All the genetic forms of human prion disease are inherited in an autosomal dominant 
fashion, which means that if only one parent has the mutation there is a 50% chance 
of any offspring inheriting this mutation (97, 99). Despite this autosomal dominant 
inheritance, most clinicians involved in CJD surveillance are aware of fCJD cases 
identified in individuals with no known history in other family members (the figures 
quoted in the literature vary widely between 12% and 88% (97)), and even in those 
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families where the disease is known, it can appear to skip a generation. These 
occurrences of fCJD without a family history may occur for biochemical reasons 
which might allow to the relatives of a patient to carry a mutation, but not go on to 
develop fCJD (age-dependent penetrance, discussed below) or due to de novo 
mutation, or could be occur due to inaccuracies in family history information, for 
example due to incorrect diagnoses in deceased relatives, stigma around dementia 
preventing family discussion, undisclosed adoption, non-paternity, etc.  
 
The concept of an age-dependent penetrance of the mutation requires some 
explanation. Any mutation which predisposes towards PrPC instability may require 
time for such instability to occur as a chance event, meaning carriers of a mutation 
may not harbour PrPSc for the majority of their lifespan until some timepoint before 
they become symptomatic of the disease. For example, the E200K point mutation has 
penetrance of 0.45 by 60 years (i.e. 45% of E200K carriers will have developed clinical 
features of fCJD and may have died of the condition by the age of 60), increasing to 
0.96 around 80 years (96% will have either died of fCJD or become symptomatic by 
the age of 80), meaning that individuals may die of other causes before they develop 
genetic prion disease (99). This reflects the fact that each mutation is a potent risk 
factor for the development of clinical disease, rather than causing onset of the 
pathology from birth or early childhood years, as might be seen in many other genetic 
conditions. Age-dependent penetrance varies for each mutation. 
 
Blood relations of patients with genetic prion disease may be eligible for 
presymptomatic testing, depending on the practices of local genetics services, to 
identify whether they carry the mutation and are at risk of developing the condition 
subsequently. In the UK, any first order relative of a patient who has (or who has died 
with) fCJD could be referred to a genetics clinic for genetic counselling prior to 
presymptomatic testing; such testing can have significant psychosocial implications 
for the individual tested, including mental health complications, and implications for 
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future financial applications (life insurance, mortgages, etc.), as well as implications 
for other (untested) family members (102). 
 
In the UK it is assumed that exposure in the medical setting to PrPSc in patients with, 
or potentially incubating (i.e. mutation carriers), genetic prion disease can result in a 
transmission risk, although no such cases are known to have arisen to date. The 
particular at-risk period is likely to occur in the window between the early formation 
of PrPSc and subsequent clinical development of the disease; prior to that point, an 
individual does not harbour PrPSc and there is no risk of onward transmission, and 
after that point, as the disease symptoms become increasingly evident, the symptoms 
should prompt investigation and diagnosis of the condition, with subsequent efforts 
to minimise onward transmission. Animal studies have identified transmissibility of 
fCJD PrPSc in primate and transgenic mice models for many mutations (103-105). 
Therefore, public health precautions are taken for individuals with a recognised risk 
of developing genetic prion disease later in life, namely those with a known PRNP 
mutation, or the presence of a PRNP mutation in a blood relative, or for other 
individuals who have not been tested, those with two or more relatives with any form 
of prion disease (106). The nature of the public health precautions for human prion 
diseases are discussed in Chapters 2, 3 and 4 in relation to blood transfusion, tissue 
and organ transplantation, and surgery respectively. 
 
 
Animal prion diseases 
 
This section is not intended to be a comprehensive review of prion diseases of non-
human animals, since not all animal prion diseases have direct relevance to the 
potential iatrogenic transmission of CJD in humans, although there are areas of 
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general interest and of public health relevance. As such, below follows a brief 
overview of animal prion diseases deemed of relevance when considering human 
prion diseases and their onward transmission.   
 
Scrapie: 
Scrapie cases were first reported in the 1730s among sheep in England, and the 
disease has since been found in most countries where sheep are farmed, except 
Australia and New Zealand (107). It is an acquired disease, associated with 
transmission through direct contact with infected animals and environmental 
contamination, where infectivity can persist for years. The classical form of the 
disease presents with intense pruritis, leading to rubbing and scraping which 
damages the wool, and provides the name of the disease. The disease has an 
incubation period of over 2 years and is fatal within 2 weeks to 6 months of onset. 
Atypical scrapie differs on clinical, epidemiological and neuropathological features 
and is not known to be transmissible among sheep through environmental routes. 
Further details about the epidemiology of scrapie in sheep, and concepts about 
disease outbreaks can be read in work by Hoinville (108) and by Matthews et al. (109). 
The Matthews et al. paper discusses the concept of the basic reproduction number, R0, 
a measure of how many secondary cases follow each infected individual. If R0 is less 
than 1, an infection will fail to reproduce itself, and the number of infected individuals 
will dwindle; if R0 is greater than 1, an outbreak will replicate and multiply, at least 
as long as the number of hosts is not limiting. 
 
Work by Cassard et al. on transgenic animal models overexpressing human PrPC has 
demonstrated transmission of scrapie to those animals, perhaps indicating the 
potential for onward transmission to humans, and if that was to occur, the authors 
stipulate such transmission might appear similar to sCJD (110). This study was 
reviewed by the European Food Safety Authority who comment that the results “do 
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not provide evidence that transmission can or does take place under field conditions” 
(111).  Epidemiological evidence against scrapie transmission to humans includes the 
observation of similar incidence of sCJD in countries without scrapie – such as 
Australia – compared to countries where scrapie has been endemic (suggesting that 
scrapie is unlikely to be a significant causative factor in human prion disease) (see 
http://www.health.gov.au/internet/main/publishing.nsf/content/cda-cdi4003k.htm 
accessed 25.08.18); and the observations of an Icelandic study, showing lower 
incidence of sCJD in Iceland compared to most countries with surveillance systems 
despite a significant scrapie burden (112).  Nevertheless, public health and veterinary 
health authorities remain vigilant to the possibility of scrapie transmission. 
 
Bovine Spongiform Encephalopathy: 
BSE was first reported as a new disease in 1986 in the UK, the first case coming to the 
attention of a veterinary surgeon in December 1984 and dying in early 1985, shortly 
before further cows in the same herd developed similar signs (37, 38).  The disease 
was noted to have similar neuropathological features to scrapie, Kuru and CJD, 
causing spongiform changes in the brain and spine of affected animals.  The animals 
displayed an altered mental state, becoming fearful and aggressive, they also 
developed exaggerated startling to minor stimuli, and gait ataxia.  
 
The disease is thought to have been spread among cattle through dietary 
supplementation (particularly given to young calves of dairy herds) using feed 
containing contaminated meat and bone meal (MBM), a protein rich product derived 
from cattle carcass waste products and used in intensive agriculture from the 1940s 
(113).  The incubation period of the disease was judged to be around 5 years (114), 
estimated in part by the delayed peak number of cases occurring in 1992-3 following  
the removal of MBM from cattle feed in 1988; it is suggested that MBM may have been 
first contaminated in the late 1970s. A north-south gradient was observed during the 
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epidemic, with more BSE cases seen in cattle from the southern counties of England; 
Stevenson et al. comment that this may relate to regional variations in the rendering 
process causing “differential rates of amplification of the infectious agent” in the 
MBM (113). The initial source of contamination remains unknown; hypotheses 
include contamination of MBM by either scrapie material or a sporadic, atypical 
occurrence of BSE, before subsequent amplification by further recycling of affected 
carcasses. 
 
Following the identification of BSE, several steps to try to control the epidemic were 
introduced by the UK government and livestock farming industry.  These included 
the withdrawal of cattle feed containing mammalian protein in 1988; the removal 
from animal and human food chains of tissues of cattle, sheep and goats likely to be 
infective, in particular tissues of the CNS and other “specified risk materials” in 1989 
(the impact of this ban is discussed in the vCJD section of this chapter, page 19; see 
also https://ec.europa.eu/food/sites/food/files/safety/docs/sci-com_ssc_out22_en.pdf, 
accessed 29.08.18); and the ban on sale for human consumption of any cow older than 
30 months in 1996.  Similar measures followed worldwide, and the totality of changes 
resulted in significant reductions in disease transmission both to animals and 
humans. 
 
Some details about the scale of the BSE epidemic, and the spread of BSE outside the 
UK have already been covered earlier in this work in the section concerning vCJD 
(page 21). To summarise, one million cattle are thought to have been infected during 
the BSE epidemic, with over 400,000 of these animals estimated to have entered the 
human food chain (39). BSE did not occur in isolation in UK cattle herds, as it is 
thought that MBM or infected cattle were exported to other EU countries, but the 
numbers of infected cattle were far smaller outside the UK, as can be seen in Figure 
1.3 on page 20, with the EU peak occurring 10 years after the UK BSE epidemic peak. 
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Atypical forms of BSE in cattle (called H- and L-type BSE) have been identified. They 
are believed to occur sporadically, are typically found in older cattle and are 
associated with different clinical and neuropathological findings.  They have been 
found in most countries with BSE surveillance and account only for a very small 
number of total BSE cases. They may represent a zoonotic risk to human health, 
although this is unclear (115). 
 
Chronic Wasting Disease: 
Chronic wasting disease (CWD) was first identified in north Colorado in 1967 among 
a captive population of a single species of deer (116). Subsequently it has been 
identified in both wild and farmed animals across a number of cervid species 
throughout North America and elsewhere, with cases identified in South Korea in 
2002 (117), and more recently Norway in 2016 (118). 
 
The first origins of CWD are not known. However, it has since spread through 
translocation of infected animals and animal products by farmers and hunters. 
Outbreaks appear to be self-sustaining, with transmission likely to occur in the 
presence of live infected animals or as a result of the infectious agent persisting in the 
environment. The disease presents with slowly progressive weight loss, mobility and 
behavioural changes (including a loss of fear of humans), excess salivation due to 
difficulty swallowing, and thirst, leading to urinary frequency (119).  Animals often 
die of aspiration pneumonia, as a complication of the dysphagia, combined with the 
thirst. Incubation periods based on inoculation of mule deer are thought typically to 
be in the 2-4 year range (120), but the disease has been identified clinically in a 17 
month old animal, suggesting the lower limit may be shorter than 2 years. Most 
animals survive for a period of weeks up to 4 months from the point of diagnosis.  
PrPSc (sometimes more specifically called PrPCWD in the literature) is found in high 
levels in CNS and lymphoid tissue, as well as being detectable in other body tissues 
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and fluids, even in presymptomatic animals. Moreover, infected animals express 
PrPSc in their saliva, blood and urine resulting in environmental contamination (121). 
 
Once in the environment, the PrPSc binds to soil and vegetable matter and may be 
consumed by other animals (122). Any attempts to contain the disease by culling 
cervid populations in North America would be extremely costly due to the reclusive 
nature of healthy wild cervids, the remoteness of their habitats, and the wide 
distribution of the disease. Such a cull would cause extensive ecological damage, due 
to cervids’ key role as a large land mammal in their ecosystems, as well as not 
addressing the environmental contamination, which could lead to reinfection of 
migrating animals which moved into the region cleared by the cull, meaning 
eradication in North America is unlikely (119). In contrast, in Norway, due to the 
much smaller scale of the outbreak there, a cull of wild reindeer was completed 
around February 2018; as reindeer return to the area, close surveillance for reinfection 
from environmental PrPSc contamination will be critical. Efforts are being made to 
restrict the movement of those cervids controlled by human activity – i.e. those that 
are farmed or herded. For a summary of ongoing surveillance and control activities 




In addition to concerns related to the impact of CWD on local ecology and the 
environment, CWD may pose a risk to human health. Hunting may help in spreading 
disease (as some hunters import and use deer urine as an attractant), but is also a 
concern because many enthusiasts butcher and/or consume the animals they kill.  The 
recent occurrence of CWD cases in Norway (118) is of particular concern in Europe 
and moreover includes the first instances in reindeer, which, unlike previous 
naturally affected cervid species, live in huge herds, migrate across vast areas of land 
and form the staple diet of many indigenous people. It is highly likely that humans 
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have already consumed CWD prions, raising concern that we may witness another 
zoonosis (in the manner of vCJD) in the years ahead. Animal transmission studies 
have shown that CWD may be transmitted to squirrel monkeys (123), but other 
studies suggest the presence of a significant species barrier for interspecies 
transmission of this prion disease (122). To date, no transmission to humans has been 
identified, although it remains to be seen whether the species barrier will be sufficient 





Although human prion diseases are rare, their long incubation periods, 
transmissibility, and the risk posed by asymptomatic carriage of PrPSc in the general 
population, with the possibility that further cases of vCJD may occur in the future 
due to past food-borne infections in mostly unaffected codon-129 genotypes or as a 
result of secondary person-to-person spread, caution against complacency (49). 
Compounding these concerns is the absence of a validated test that can be used to 
identify subclinical infection, and the lack of effective instrument decontamination 
methods for use in routine surgical practice that can fully remove the prion agent 
from instruments (74, 125, 126), although progress continues to be made in both these 
areas. In the meantime, in the UK and many other countries, a range of public health 
measures have been put in place to protect the human and animal food chains, and 
to reduce the risk of person-to-person transmission in medical settings. These 
measures include universal precautions to better safeguard the supply of blood, 
organs and tissues for transplantation; to mitigate against the risk of transmission 
through surgery; and also potential occupational exposure. Further precautions may 
be adopted for high risk situations in relation to the handling of surgical instruments 
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and the identification and notification of those with a specific exposure to infection 
through surgery, through treatment with blood or blood products or with a genetic 
risk (106).  
 
The possibility of animal sources of future human prion disease also cannot be 
excluded. There is no evidence that either scrapie or atypical scrapie in sheep is 
transmissible to humans, but we remain vigilant to this possibility. While the BSE 
epidemic is at an end, atypical cases may represent an ongoing zoonotic risk to human 
health, although this is unclear (115). The possibility of a widespread epidemic of 
CWD in cervids has elevated concerns for human health as well as impact this may 
have on animal health and the environment (118, 121, 122, 124). 
 
Sporadic forms of human prion disease have varied phenotypes which, as 
demonstrated by VPSPr (29), are challenging to diagnose in rarer or atypical cases. It 
is possible that some of these rarer forms thought to be of idiopathic origin may, in 
fact, reflect transmission of atypical or novel infections from a yet unknown source, 
or that iatrogenic transmission through means not previously reported may be 
missed, or misclassified as a sporadic form of prion disease (something addressed in 
the chapters that follow), even though there is no evidence to date that this is the case.  
 
Continued scrutiny of clinical-pathological phenotypes and epidemiological risk 
factors for prion disease in the general population and at-risk groups, as part of 
national prion disease research and surveillance initiatives, is essential to help 
address the uncertainties and inform the subsequent management of risk.  








Evidence for Blood and Blood Product 
Transfusion Transmission of sCJD 
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Chapter 2 Introduction 
 
This chapter comprises two papers which have been published, as reported in the 
Declarations on pages 1 and 2 (1, 3). Some adaptations have been made, including 
adaptations of regional spelling changes (the second paper was published with 
American English spellings), standardising abbreviations and nomenclature as used 
elsewhere in this thesis, and adjusting the references to fit into the thesis reference 
collection. Since publication of the first paper, I reviewed the first codon 129 MV 
heterozygote patient who subsequently died of neuropathologically confirmed 
variant CJD; this individual’s presentation and epidemiological significance was 
published as a case report (46). As such, some aspects of the first paper are no longer 
accurate in this regard, so corrections have been made where necessary. Each paper 
includes its own abstract, introduction and conclusion, but in addition, I have 
included a chapter introduction and conclusion. 
 
The first successful transfusion of blood was reported in 1666 between two dogs (127). 
Early efforts to transfuse humans were hampered both by issues around sterility and 
bacterial contamination, and by transfusion reactions, which were reduced 
substantially following the work by Karl Landsteiner in 1902 in identifying the first 
three blood groups, A, B, and O (then called C), for which he was awarded the Nobel 
Prize for Medicine in 1930. The UK National Blood Transfusion Service (NBTS) was 
created on 26 September 1946. At this point, around 200,000 donations were collected 
each year. Prior to the creation of NBTS, blood donation was organised on a local 
level. Blood donations have increased over time, and in 2016, the 70th anniversary of 
the NBTS, around 900,000 donors made around 1.6 million donations. On average, 
each donation is used in the creation of blood products used by three recipients (for 
more information, see https://www.blood.co.uk/news-and-campaigns/news-and-
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statements/70-years-of-life-saving-blood-donations/ accessed 25.07.18). 
Unfortunately, blood transfusion has resulted in iatrogenic transmission of HIV (first 
reported in 1982) (128)  and Hepatitis (129), with the problem concentrated among 
patients with clotting disorders many of whom were transfused with pooled clotting 
factors derived from several thousand donors and contaminated with viruses 
including Hepatitis C and HIV (130); this risk was later substantially mitigated using 
donor viral screening. 
 
The possibility of blood transfusion transmission of CJD was considered in light of 
known transmissibility of other prion diseases, including scrapie, and known 
iatrogenic transmission of CJD through neurosurgery and other means (73). vCJD 
transmission by blood transfusion has been detected in 3 patients (2), while a 4th 
individual was found to have PrPSc deposition in splenic tissue at post mortem, and 
is thought to represent a preclinical transmission (60); this transmissibility of vCJD by 
blood is thought likely to have occurred due to the increased deposition of PrPSc in 
peripheral tissues in this form of prion disease when compared to other forms. 
 
The potential for transmission of sCJD by blood transfusion has been explored using 
animal models, at first using human prion diseases adapted to the experimental 
animal species (131), and later using transgenic mice which express human PrPC (132). 
Epidemiological evidence has been collected in the form of case control studies and 
lookback studies. One case control study found blood transfusion more than 10 years 
before onset of clinical symptoms was more common in the sCJD group than in non-
CJD controls (22), but similar work in the UK did not replicate those findings (57), 
and look back studies have not shown any support for sCJD transmission by blood 
(23, 133). The paper which comprises the first half of this chapter is the update to the 
Transfusion Medicine Epidemiological Review (TMER) (2), a lookback study utilising 
NCJDRSU patient details and the UK Blood Services records of blood products. 
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The threat of transmission of CJD by pooled, fractionated blood products is of 
particular concern due to the potential for one contaminated donation to infect 
multiple recipients. These fractionated blood products are used primarily by the 
clotting disorder patient cohort, a group who have already suffered considerably 
through iatrogenic HIV and Hepatitis C transmission, as discussed above. Lookback 
studies have found no evidence of sCJD transmission among haemophilia patients 
(134, 135). The fact that no cases of sCJD had been seen among patients with clotting 
disorders has been previously used as evidence of safety of these products in relation 
to sCJD (136).  The second half of this chapter, a case report of two patients with 
clotting disorders, who were both treated with pooled plasma products, and who 
both subsequently developed sCJD is therefore of significant public health interest. 
 
In light of the concern regarding blood product transmission of CJD, several public 
health steps were implemented in the UK to minimise the risk of onward 
transmission, in particular of vCJD (137). These steps include leucodepletion, 
implemented by autumn 1999, and following which there have been no further 
transfusions implicated in blood product transmission of vCJD. This is a process to 
remove the buffy coat, a fraction of whole blood containing the majority of leucocytes 
(white cells) which can be separated by centrifugation; this step is likely to have 
reduced the infectivity of any donated blood contaminated with PrPSc. 
 
From 1998, UK derived fractionated plasma production ceased, following 
recommendations that non-UK sourced product should be used for individuals born 
after 1995 (who would not have been exposed to BSE from contaminated meat 
products), imported plasma products have been used thereafter. A parallel 
development reducing the risk from clotting disorders has been the move towards 
recombinant clotting factors, preventing the risk of any human to human iatrogenic 
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transmission for patients requiring these products. Recombinant Factor VIII products 
were licensed for haemophilia A in 1992, while factor IX products for individuals with 
haemophilia B followed in 1997 (see http://www.hematology.org/About/History/50-
Years/1524.aspx accessed 01.09.18) 
 
Finally, in part since importation of fresh blood products such as packed red cells or 
platelets was not feasible, and thus there was still a need for UK sources for these 
products, restrictions were placed on blood donors so that anyone deemed at 
increased risk of CJD would no longer be allowed to donate blood. This includes 
individuals diagnosed with CJD, those considered at increased risk of developing 
CJD (including those 2 or more relatives with CJD, or those known to be at risk of 
fCJD, recipients of dura mater grafts, human pituitary hormones, or corneal grafts, 
and those informed they have been put at risk through medical procedures). To 
prevent potential onward propagation of CJD through blood transfusion, any 
individual who has received a blood transfusion may no longer donate blood. The 
government statement concerning these interventions can be read at 
https://www.gov.uk/government/news/measures-currently-in-place-in-the-uk-to-
reduce-the-potential-risk-of-vcjd-transmission-via-blood - accessed 01.09.18, while 
additional details are located in the UK Blood Services Joint Professional Advisory 
Group Position Statement on vCJD, which can be read at 
www.transfusionguidelines.org/document-library/documents/jpac-position-
statement-vcjd-may-2015/download-file/position statement on vcjd may 2015.pdf - 
accessed 01.09.18. 
 
Outside the UK, many other countries have introduced similar measures, with the 
additional step of preventing those resident in the UK during the BSE epidemic from 
donating blood. For example, the FDA published their recommendations to reduce 
the risk of CJD transmission by blood products, which can be read at 
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https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceReg
ulatoryInformation/Guidances/Blood/UCM307137.pdf accessed 01.09.18. 
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Abstract 
Background and Objectives 
This paper reports the results to 31 May 2015 of an ongoing UK study to look for 
additional cases of variant Creutzfeldt–Jakob disease (vCJD) transmission by blood 
transfusion, and to seek evidence whether other subtypes of Creutzfeldt–Jakob 
disease (CJD) may be transmissible via blood components. 
Materials and Methods 
All vCJD cases of appropriate age and any sporadic CJD (sCJD) or familial CJD (fCJD) 
cases with a history of blood donation or transfusion are notified to the United 
Kingdom Blood Services (UKBS). Donation records are sought, and the usage of all 
donations is determined by look back. Death certificates are obtained for all donors 
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to patients with CJD and recipients of transfused components from patients with CJD 
who are deceased. 
Results 
The study identified 29 sCJD blood donors, of 370 reported, with transfusion to 211 
recipients. Five of these recipients were reported to have died with or of dementia, 
but were not believed to be cases of CJD. The vCJD arm found 18 vCJD blood donors 
who had donated blood which was issued for clinical usage, of 24 traced donors from 
177 UK vCJD cases. To date, 3 cases of vCJD have occurred in 67 recipients identified 
in this recipient group, and one recipient had post‐mortem confirmation of abnormal 
prion protein deposition in the spleen (all previously reported). 
Conclusion 
The results of the ongoing TMER study show no new cases of transfusion‐associated 





Creutzfeldt–Jakob disease (CJD) is an untreatable and invariably fatal member of a 
group of neurodegenerative conditions known as prion diseases or transmissible 
spongiform encephalopathies (TSEs). Prion diseases are recognised in both humans 
and other mammals and have a number of aetiologies including sporadic, acquired 
or familial forms. Despite this apparent heterogeneity, there is a unifying hypothesis 
linking all prion diseases: the “protein hypothesis” described by Prusiner (4), which 
proposes that a post-translational change occurs in the normal prion protein (PrPC – 
cellular) forming the infective form of the prion protein (PrPSc – Scrapie). PrPSc 
essentially replicates by catalysing further transformation of PrPC into PrPSc. 
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The variant form of Creutzfeldt–Jakob disease (vCJD) is the zoonotic form of bovine 
spongiform encephalopathy, a prion disease in cattle, which entered the human food 
chain in the UK between 1980 and 1996. vCJD has been transmitted by blood 
transfusion on three occasions (2), as well as one non-symptomatic transmission (60). 
The most recent UK primary case of vCJD at the time of publishing this paper had 
symptom onset in 2012 and died in 2013; subsequently, I reviewed the first 
neuropathologically confirmed MV heterozygote patient with vCJD in 2015, before 
his death in February 2016 (46). Surveillance to look for further cases of vCJD 
continues. In contrast, sporadic Creutzfeldt–Jakob disease (sCJD), the most 
commonly occurring human subtype, is believed to be a spontaneous illness with no 
identified causative event or exposure. There has been one epidemiological study, 
which has suggested blood transfusion may be a risk factor for the development of 
sCJD (22), but this has not been supported by a similar study in the UK (24)  or 
through look-back studies (2, 23, 138). The familial form of CJD (fCJD) is caused by a 
mutant copy of the PRNP gene, encoding a form of endogenous PrPC prone to 
spontaneous conversion to PrPSc. fCJD is inherited in an autosomal dominant pattern, 
but family history may not be present in some cases due to loss of contact, non-
paternity, variable penetrance, etc. 
 
This study updates the 2006 Transfusion Medicine Epidemiology Review (TMER) 
paper (2) and describes the results of the UK study on blood transfusion and the 
development of CJD, for all CJD subtypes.  
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Study design and methods 
 
CJD surveillance: 
The National Creutzfeldt-Jakob Disease Research & Surveillance Unit (NCJDRSU) 
was founded in Edinburgh, UK, in 1990 to identify all cases of CJD in the UK and to 
look for evidence of a link between BSE in cattle and CJD in humans. The 
methodology of the surveillance process has been described previously (139) and 
includes referral of suspected cases to the Unit from clinicians from a number of 
professional backgrounds, including neurologists, psychiatrists, other physicians and 
neuropathologists. The referred cases are seen, where possible, by a neurologist from 
the Unit, who carries out a detailed interview with the family of the patient and 
reviews the specialist investigations. The interview includes details about past 
medical history, blood transfusion and donation. Cases are categorised according to 
WHO diagnostic criteria (140).  
 
TMER: 
The Transfusion Medicine Epidemiology Review (TMER) was created in 1997 as a 
collaboration between the NCJDRSU and the United Kingdom Blood Services (UKBS) 
to try to seek any evidence that CJD had been transmitted via blood transfusion in the 
UK. 
 
Notification of CJD cases with a history of donation: 
sCJD and fCJD cases with a reported history of blood donation, including cases where 
a family may be uncertain, are notified to UKBS retrospectively, following the visit 
by the NCJDRSU clinician. All vCJD cases old enough to be a blood donor are notified 
to UKBS at diagnosis irrespective of whether they have a reported history of blood 
donation. Following this notification, all computer and any archived paper records 
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are searched at blood centres for evidence of the documented donation – using name, 
date of birth and address at time of donation as identifiers. If available, information 
about dates and places of donation is used to target the search. If donor records are 
identified, a list is generated of all components issued for clinical usage. The outcome 
for each component is determined from hospital transfusion laboratory records, with 
the names of recipients of these components cross-checked against the NCJDRSU 
database of known CJD cases and flagged with NHS Digital (formerly the Health and 
Social Care Information Centre (HSCIC), and prior to that the Office of National 
Statistics (ONS)) to collect data from death certificates regarding cause and date of 
death. 
 
Notification of CJD cases with a history of transfusion: 
Where relatives have indicated any patient with fCJD, sCJD or vCJD is suspected to 
have received blood or blood components, the information collected is passed to the 
relevant blood service, which contacts the hospital transfusion laboratories to 
confirm, if possible, details of the transfusion. The transfused components are 
identified from records and details passed back to the blood centre for attempted 
identification of the donors. As above, the donor details are checked against the 
NCJDRSU database and flagged with NHS digital. 
 
Further information: 
UKBS and hospital transfusion records prior to 1980 are extremely limited, making 
such historical searches frequently unrewarding; records are still poor until after 
1990. For cases where NHS Digital data list potentially relevant diagnoses on the 
death certificate (e.g. dementia, Alzheimer’s disease) but the individual concerned 
has not been seen by the NCJDRSU clinician, we have sought further information 
where possible regarding the nature of this illness, from either general practice 
records or hospital notes. 
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Results 
 
sCJD blood donors: 
A total of 370 sCJD cases (from the 1597 sporadic CJD patients seen by the NCJDRSU 
between 1990 and end of December 2014) were reported to have been blood donors, 
with 204 of these believed to have donated after 1980. In only 29 of 204 cases were 
these individuals traced as blood donors; blood components from these donors were 
transfused to 211 recipients. The sCJD donor (and recipient) figures are represented 
in Figure 2.1 overleaf. 
 
Fate of recipients from sCJD blood donors: 
To date, 143 individuals (67.8%) of the 211 recipients identified in this study have 
died, 44 (20.9%) were alive, and 24 individuals (11.4%) were of unknown status due 
to insufficient information to identify the individual, or relocation of that individual 
abroad. For each of the 143 who had died, death certificates are available. The 
underlying causes of death for all cases are listed in Table 2.1, and these figures are 
represented in the flow diagram below: Figure 2.1. Five of 143 had dementia 
(including Alzheimer’s disease) listed on their death certificates but are not thought 
to represent cases of CJD. These five cases are represented graphically in Figure 2.2. 
They had mean age at death of 88 years, and in each case, dementia was not listed as 
the primary cause of death. In one of these five cases, dementia was considered a 
relevant comorbidity, rather than the underlying cause of death on the certificate; 
hence, only four dementia deaths are listed in Table 2.1. The first case received whole 
blood donation about 21 years before becoming symptomatic of dementia; and had a 
6 year, slowly progressive probable neurodegenerative illness, dying 26 years after 
receiving the transfusion. The donor became symptomatic of CJD nearly 21 years after 
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the donation. The second dementia case received red cells (non-leucocyte depleted) 
10 months prior to death, while the donor became symptomatic of sCJD almost 4 
years after donation (more than 3 years after the recipient died). The third case 
received red cells (non-leucocyte depleted) 8 years before death; the donation 
occurred 4 1⁄2 years before the donor became symptomatic of sCJD. The fourth case 
received fresh frozen plasma 28 months before death; the donor became symptomatic 
5 1⁄2 years after donation. The fifth case received red cells (non-leucocyte depleted) 
18 years before death; the donor became symptomatic 15 ¾ years after donation. 
 
Figure 2.1. sCJD cases with blood donation and blood transfusion histories, and the 
recipients and sources of those components. 
  




Figure 2.2 illustrates the five cases who died of dementia and are discussed above, 
showing time intervals from the point of blood transfusion (at year 0), to the onset of 
dementia symptoms (at the end of the solid medium blue bar, data for case 1 only), 
or survival after donation (striped blue bar), and to the development of sCJD 
symptoms in the donor (solid grey bar).  















Figure 2.2: Recipients of blood products from sCJD donors who 
subsequently died with dementia
Recipient asymptomatic Recipient survival Donor asymptomatic
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Table 2.1: Underlying causes of death in recipients from sCJD donors 
Cause of Death Number 
Cancer (non-haematological) 39 
Leukaemia, myeloma, myelodysplasia, myelofibrosis, 
sideroblastic anaemia 
34 
Ischaemic heart disease, other cardiac disease 25 
Pneumonia 10* 
Stroke 7 
Liver disease 5 
Dementia (including Alzheimer’s) 4 
Abdominal aortic aneurysm 3 
Chronic obstructive pulmonary disease 2 
Old age 2 
Renal failure 2 
Atherosclerosis (not otherwise specified) 1 
Diverticulosis and bowel angiodysplasia 1 
Haemorrhage 1 
Multiple sclerosis 1 
Peritonitis 1 
Polytrauma 1 
Pulmonary embolism 1 
Septicaemia 1 
Small bowel obstruction 1 
Vasculitis (and thrombotic thrombocytopaenic purpura) 1 
*In one case, Alzheimer’s was recorded as a co-morbidity  
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At least three other recipients of blood from sCJD donors listed in Table 2.1 could be 
regarded as “of interest”, even without a listing of dementia on the death certificate: 
the deaths from Atherosclerosis (not otherwise specified), Multiple Sclerosis and 
Vasculitis. It is interesting that the death certificate for the unspecified atherosclerosis 
individual did not specify which organ was affected by the atherosclerosis – where 
mentioned elsewhere, certificates listing atherosclerosis indicated either cerebral or 
cardiac. No further details are available for this individual, but if this was a 
cardiovascular process, this would be unlikely to represent a misdiagnosis of a 
symptomatic sCJD presentation. By extension of the same interest in that patient, the 
other 7 patients with stroke might also be of concern. Stroke-like presentations of 
sCJD are well recognised, are the subject of numerous case reports (e.g. (141)), and 
are one of many potential early misdiagnoses in patients not yet known to be 
symptomatic of sCJD. These usually present as acute, or sometimes subacute, 
presentations of focal cortical deficits, rather than causing death immediately, and 
then subsequently progress after the first presentation; this progression usually 
follows the more typical rapidly progressive dementia and would be expected to 
prompt further investigation and hopefully the correct diagnosis being reached, 
although this cannot be assumed always to occur, and it is certainly possible that 
some cases of sCJD are misdiagnosed as successive stroke episodes, particularly in 
individuals with either prior stroke or extensive other cardiovascular disease.  
 
The death certificate for the individual who died from vasculitis also listed 
thrombotic thrombocytopaenic purpura (TTP) as a secondary cause of death; the two 
conditions can co-occur and be interrelated (142, 143). This detail was removed from 
the TMER publication as it was considered superfluous, but such detail may in fact 
be helpful in explaining why this individual is not thought likely to represent a 
missed diagnosis of sCJD. While both vasculitis and TTP can present with 
neurological symptoms, given this individual’s TTP, other systemic features must 
have been identified, which would not be seen in sCJD. These features usually include 
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fever, microangiopathic haemolytic anaemia, thrombocytopaenic purpura and renal 
involvement (144). Neurological manifestations of vasculitis can be very variable 
(145), but the majority have different clinical features and investigation findings when 
compared to sCJD (146).  It is considered unlikely this diagnosis represented a missed 
case of sCJD, but using only death certificate data, it is not known how extensively 
the vasculitis was investigated. 
 
No further details are available for the patient with multiple sclerosis (MS), but with 
ready access to contrast MRI brain scanning in the UK (as well as the possibility to 
look for oligoclonal bands in the cerebrospinal fluid (147)), it would be unusual to 
mistake MS for sCJD. The rapidity of progression in patients with sCJD would not be 
expected in MS patients, and should prompt further investigation, as in the stroke-
like presentations. White matter involvement on standard clinical magnetic 
resonance imaging sequences is very rare in sCJD (148), in contrast to those MR 
sequences used in research, such as diffusion tensor imaging (149). White matter 
disease in sCJD is seen in the panencephalopathic subtype (150), but this is 
exceptionally rarely seen outside Asia, and the white matter appearances in 
panencephalopathic sCJD would be highly atypical for MS, while oligoclonal bands 
would be not be positive in sCJD. It is unlikely that the MS patient represents a missed 
sCJD diagnosis, but there no data are available regarding the accuracy and clinical 
certainty in this diagnosis. 
 
Eighty-eight of 143 (61.5%) recipients of blood from sCJD donors died less than 1 year 
after transfusion, 25 (17.5%) between one and 5 years after transfusion and 28 (19.6%) 
more than 5 years after transfusion (range in this group 5.77– 26.10 years, median 
8.97); for two recipients, the transfusion date was unknown. 
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Of the 44 recipients still alive as of May 2015, all have survived more than 9 years 
from the date of transfusion. Twenty-two (50%) of these recipients received donations 
from eight donors who donated less than 5 years before they became symptomatic of 
sCJD (range 0.23 – 4.92 years, median 2.21). None of these living recipients have 
developed sCJD and been referred to the NCJDRSU. 
 
vCJD blood donors: 
Of the 177 UK cases of vCJD, 167 were old enough to have been blood donors. In 32 
of the 167 cases, family reported to the NCJDRSU clinician a possible history of blood 
donation. A further four cases not reported by the families as donors appear on UK 
databases, but only one of these four had donated. In total, 24 of the 167 cases old 
enough to have donated had records with the UKBS, but only 18 of these 24 had 
donations which were subsequently used clinically. Sixty-seven blood components 
from these 18 donors were traced to identified recipients; a further six components 
known to have been issued could not be traced. These figures are represented in a 
flow diagram in Figure 2.3 below. 
 
Fate of recipients from vCJD blood donors: 
Thirty-four (50.7%) of the 67 successfully traced recipients died within 5 years of their 
transfusion – none were thought to have died from CJD, but none of these cases had 
post-mortem examination to look for PrPSc deposition. Three cases (4.5%) of vCJD 
have already been reported from this cohort of 67 (2); these three developed vCJD 
between 6 ½ and 8 years 4 months after their transfusion. Five (7.5%) of the 67 died 
more than 5 years after transfusion and had post-mortem examination including 
examination for PrPSc – only the single case already reported tested positive (60), with 
PrPSc deposition in the spleen. A further 11 recipients who died more than 5 years 
after transfusion did not have post-mortem examination to look for PrPSc deposition. 
To date, 14 of the 67 recipients remain alive. At the time of first publication, it was 
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believed that one recipient had moved abroad, and that the fate of that individual 
was unknown; this was inaccurate, as two individuals have now moved overseas, 
and even those individuals overseas are followed up periodically by Public Health 
England; these two are included in the 14 living patients. These 14, including the two 
overseas, have now survived more than 10 years after receiving transfusion from 
vCJD donors. There have been no new cases of vCJD identified by the NCJDRSU 
among the recipients of blood from vCJD donors. These figures are represented in a 
flow diagram in Figure 2.3 below. 
 
Figure 2.3: Flow diagram of vCJD patients showing those who donated and received 
blood and blood products. 
 
 
fCJD blood donors: 
Of the 17 familial/genetic cases reported to have been donors, four were traced by the 
UKBS, one with a D178N mutation, one with an E200k mutation and two with 
Page 63 of 220 
 
octapeptide repeat insertion mutations. Fifteen recipients were traced, and of these 
eight have died, all of a non-neurological disorder, other than one with a history of 
stroke. Four are alive and three could not be identified. Blood transfusions took place 
between 1977 and 2002, and four recipients are alive more than 13 years after the 
transfusion. None of the recipients appear on the NCJDRSU database as CJD cases. 
 
Transfusion history in sCJD recipients: 
A total of 199 sCJD cases (from the 1597 sporadic CJD patients seen by the NCJDRSU 
between 1990 and end of December 2014) were reported to have received blood or 
blood component transfusion, 111 of these after 1980. The records were traced in 23 
(20.7%) of these 111 cases, with 214 donors identified. This implies 9.3 donors per 
sCJD transfusion recipient and is considered in the discussion. I do not have access to 
further details concerning the distribution of donor exposures, although this may be 
of interest and could be explored when the TMER is next updated. These 23 cases 
received their first blood or blood components between 0.3 and 14.2 years before 
becoming symptomatic of sCJD (mean 3.89, median 2.61). These figures are 
represented in Figure 2.1 earlier in this chapter. 
 
Fate of donors to sCJD transfusion recipients: 
To date, 205 (95.8%) of the 214 donors are still alive, four (1.9%) have died, and five 
(2.3%) were of unknown status due to insufficient data (four) or relocation abroad 
(one). These figures are represented in Figure 2.1 earlier in this chapter. The surviving 
donors ranged from 25 to 82 years of age (median 56). Three of the four deceased 
donors died of causes other than dementia (intracerebral tumour, liver disease and 
suicide in an individual who had suffered depression for decades), but for one 
individual, dementia was listed on the death certificate; this donor died almost 12 
years after the donation, aged 76, and was thought likely to have vascular dementia, 
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rather than CJD. The other three donors died aged 54, 59 and 63 years, respectively 4, 
10 and 12 ½ years after their donations. 
 
Transfusion history in vCJD recipients: 
Fifteen of the 177 UK vCJD cases were reported to have received blood or blood 
components. Transfusion laboratory records were traced in 10 of these 15 cases 
(corresponding to the 10 cases discussed in Checchi et al. 2016 (151)), which include 
the three cases of transfusion-associated vCJD previously published (2) and listed 
earlier in this study). One of the 10 recipients had onset of symptoms less than 1 year 
after transfusion and is unlikely to represent possible transfusion-associated vCJD 
given the timings of the three known cases. Four of the 10 received blood components 
from 112 donors; the remaining two recipients received a total of six blood 
components, but it was not possible to identify the donors in these cases. These 
figures are shown in the flow diagram Figure 2.3 above. 
 
Fate of donors to vCJD transfusion recipients: 
Six of these donors have died of causes unrelated to CJD (Table 2.2), 104 are currently 
alive, and the fate of two is not known (one having moved abroad). These figures also 
are shown in the flow diagram Figure 2.3 above. 
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Table 2.2: Cause of death in six donors to vCJD recipients: 
Donor Cause of Death 
1 Haemorrhage due to abdominal aortic aneurysm 
2 Hypertensive heart disease 
3 
Pulmonary Embolus/deep vein thrombosis/ischaemic heart 
disease 
4 Bronchopneumonia/disseminated sigmoid colon carcinoma 
5 Complication of heart valve surgery 
6 Bronchopneumonia/atrial fibrillation/ischaemic heart disease 
 
Transfusion history in fCJD recipients; 
None of the familial human prion disease cases who were reported to have had a 
history of having received a blood transfusion were traced by UKBS. fCJD patients 
are not seen by the NCJDRSU clinicians (these families are diagnosed and cared for 
by the National Prion Clinic); I do not have access to the figures of reported blood 
transfusion in this group. Potential reasons for lack of tracing by UKBS are considered 




This study has not identified any new cases of transmission of vCJD by blood 
transfusion, with only four documented infections to date, as described in the earlier 
TMER publication in 2006 (2). The possibility that there are significant numbers of 
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missed transfusion cases is judged to be unlikely, not least because the great majority 
of vCJD cases have no history of blood transfusion (2, 152). It is surprising that there 
have been no further transfusion-transmitted cases in view of the estimated 
prevalence of abnormal PrPSc positivity of 1/2000 in the general UK population, 
derived from an anonymised survey of routine appendix tissue (51). At the time of 
first publication, all clinical cases of vCJD with data on genotype had been methionine 
homozygotes at codon 129 of the PRNP gene, but, since then, the first confirmed MV 
heterozygote case has been identified and published (46). Analysis of the codon 129 
distribution in the UK population indicates that 44% are MM homozygotes, with 45% 
MV heterozygotes and 11% VV (valine homozygotes) (18). It is possible that 
individuals who are either heterozygotes or valine homozygotes may experience a 
longer pre-symptomatic phase before developing clinically evident vCJD and all 
codon 129 genotypes were represented in the positive appendix samples in the recent 
prevalence study. It is more than 20 years since the onset of symptoms in the first case 
of vCJD and only a single definite case of vCJD in a non-MM homozygous genotype 
individual has been identified in the UK (46); no other MV heterozygote cases have 
been reported to date, and no VV homozygous individuals have been identified. It 
remains to be seen whether more non-MM homozygous cases will present in the 
future. 
                     
The codon 129 genotype is known in 19 of the 67 recipients, including the three vCJD 
cases (MM homozygotes) and the preclinical infection (MV heterozygote). Four 
deceased recipients with no evidence of abnormal PrP in brain or peripheral tissues 
have been genotyped. These four individuals had survived for 6.3–15.9 years post-
transfusion, and the intervals from donation to the onset of clinical symptoms in the 
donors was between 2 months and 6.8 years. Two were MV heterozygotes and two 
were MM homozygotes. Two further cases without post-mortem examination were 
MM homozygotes. Nine recipients who are currently alive have been genotyped. Five 
are MV heterozygotes and four are MM homozygotes. One of the MV heterozygote 
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recipients had a tonsil biopsy, which showed no evidence of abnormal PrP 
deposition. This recipient received a transfusion from an individual from whom 
earlier donations were implicated in two of the three known transfusion-transmitted 
cases, who were, as previously stated, MM homozygotes. It is of interest that in three 
surviving asymptomatic MM homozygotes, red cells had been leucodepleted, a 
policy introduced in the UK as a vCJD risk-reduction measure in 1999. In addition, 
the fourth surviving asymptomatic MM homozygote had received cryo-depleted 
plasma. 
 
The high proportion (50.7%) of blood transfusion recipients who died within 5 years 
of transfusion reflects the underlying conditions which led to blood transfusion, and 
any comorbidities. Extrapolating from other acquired prion diseases, kuru and non-
CNS exposure iatrogenic CJD, the minimum incubation periods are at least 4.5 years 
(73, 153) (the incubation period ranges are shorter for dura mater grafting, 
neurosurgical and EEG depth electrode usage, but these do not reflect transmission 
through peripheral tissue contamination and are not a direct comparison), and it is 
unlikely that this group would have manifest symptoms of vCJD prior to death, even 
if infected. The observed interval from transfusion to symptom onset in the identified 
transfusion cases was 6 ½ – 8 years, 4 months. It is also likely that there may be 
variable levels of infectivity in blood from vCJD donors relating to the proximity of 
the time of the donation to symptom onset in that individual and early donations 
might have a lower level of infectivity, which could be associated with a longer pre-
symptomatic phase in recipients. 
 
Recipients of any blood transfusion are now deferred from themselves donating 
blood, which prevents the potential propagation of a transfusion vCJD epidemic, 
which is important if some donors have a subclinical infection. It is of note that 
laboratory transmission studies using splenic tissue from the subclinically infected 
Page 68 of 220 
 
vCJD case have confirmed the presence of infectivity and this case was a codon 129 
heterozygote (63). 
 
In contrast to the vCJD group, as yet there have been no cases of sCJD with definite 
epidemiological evidence to support a transfusion link. Evidence of an increased risk 
through blood transfusion in sCJD with a lag period of more than 10 years in an 
Italian study (22) was not replicated by a similar analysis of UK data (24). In our study 
of sCJD, there has been a total of 1194 patient-years survival following transfusion 
from a sCJD donor with no evidence of transmission via blood transfusion. The 
absence of any observed cases supports the hypothesis that blood infectivity, should 
it be present at all, is lower in sCJD than vCJD. This would be compatible with the 
extensive PrPSc deposition in lymphoreticular tissues in vCJD, which contrasts with 
sCJD where there is comparatively much less peripheral PrPSc. Nevertheless, animal 
studies using transgenic mice overexpressing human PrPc have suggested there can 
be infectivity in sCJD blood (132) and work is ongoing to attempt to use amplification 
techniques, such as real-time quaking induced conversion (RT-QuIC), to identify a 
positive signal in blood in sCJD. The identification of positive findings in sCJD blood 
using highly sensitive techniques may be difficult to interpret in relation to actual 
risk, and epidemiological data remain important in assessing risks for public health. 
 
As in the recipients of blood from the vCJD donor group, early mortality among 
recipients of blood transfusion is high in the sCJD study and it is possible that some 
of these recipients could be in the pre-symptomatic phase of sCJD infection at time of 
death. Post-mortem uptake is low in the UK, and, unless explicitly looked for, the 
changes of early sCJD may be missed. The combination of these factors raises the 
possibility of as yet undetected transmission of sCJD by blood transfusion, although 
this is unlikely given the negative data in this study and similar findings from other 
studies (2, 23, 138). The cumulative data from look-back studies in sCJD suggest that 
transfusion transmission of sCJD is a rare event, should it occur at all. 
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It is interesting to note that 23 sCJD recipients received blood components from 214 
donors. This reflects several factors: it is rare to transfuse only a single unit of packed 
red cells, or any other blood component, many individuals requiring transfusion will 
continue to need transfusions in the future for the same conditions; also, many blood 
components are pooled from multiple donors, such as platelets, where each unit to be 
transfused is pooled from the platelet fractions of (typically) 4 individuals’ donations 
(for more information, see https://www.transfusionguidelines.org/transfusion-
handbook/3-providing-safe-blood/3-3-blood-products accessed 15.08.18). 
 
The data on fCJD show no evidence of transfusion transmission and, although the 
data are very limited, there is some evidence of restricted peripheral pathogenesis in 
hereditary forms of human prion disease similar to sCJD. 
 
The study has some limitations. Both the sCJD and fCJD arms depend on relatives 
reporting blood transfusion or donation at the time of the NCJDRSU clinician 
interview; if the relative was uncertain or believed a patient may have possibly 
donated blood or received a transfusion (e.g. intraoperatively), this was still flagged 
to the UKBS. Despite this it is likely that some patients with sCJD and fCJD who had 
either donated blood or received transfusion were not identified by the current 
methodology. By comparison, all vCJD cases of donation age are flagged to UKBS, 
reducing potential under-reporting. Investigation of all sCJD and fCJD cases, whether 
or not they have been reported to be blood donors or recipients, has been considered, 
but follow-up of cases is labour intensive, and investigating these cases regardless of 
the transfusion history is unlikely to provide much additional information. 
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A further limitation is that no transfusion or donation records have been identified 
for some cases. In some instances, this may be because the possible donors or 
recipients as reported by the family had never donated or received blood, but these 
cases are in the minority. The lack of centralised computer records, particularly prior 
to 1980, and the tendency of many hospital trusts to destroy old, unused, medical 
records means a large pool of potentially useful data has been lost. This problem is 
compounded in the non-vCJD group, as these patients tend to be older and are 
therefore more likely to have had their contact with the UKBS prior to the 
improvement in record keeping. This missing data therefore is more prevalent in 
transfusions earlier in timepoint prior to clinical disease. Given the fact that 
peripheral infectivity with PrPSc is substantially lower in sCJD, if sCJD was to be 
transmitted by blood transfusion, this might result in a smaller dosage of PrPSc 
transferred, and potentially a longer incubation period. The missing data is likely to 
be “missing not at random”, and this may introduce a bias against the detection of 
sCJD transmission by blood, were such a thing to have occurred. It may be possible 
to perform a multiple imputation assessment of the blood dataset, but this would 
require direct access to the UKBS data, and a statistician, both no longer possible at 
this stage; this further analysis could be considered as an additional possibility for 
future research (154). 
 
The reliance on data derived from death certificates is also a limitation as the final 
diagnostic classification of identified cases relies on the conditions listed on the death 
certificate. There have been widely variable estimates of inaccuracy on death 
certificates. An Office for National Statistics survey suggested inaccuracy in 22% of 
certificates, with under-reporting of common underlying conditions including heart 
disease and cancer (155). It is likely that dementia of any cause is also under-reported, 
and CJD may not be diagnosed in life, with symptoms attributed to an alternative 
cause of dementia. Review of death certificate data on CJD since 1990 at the NCJDRSU 
suggests that the sensitivity and specificity of a correct diagnosis on death certificates 
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is about 80%. It is also likely that not all UK cases of CJD are referred in life or 
identified through death certificates or post-mortem findings. 
 
Despite these caveats, the data presented in this paper has provided no evidence that 
cases of sCJD have developed the condition as a result of prior blood transfusion. 
                 
The unexplained mismatch between the observed data in vCJD and prevalence 
estimates in the general population and the recent experimental evidence of 
infectivity in sCJD blood underline the importance of continuing the epidemiological 
studies of blood transfusion in all forms of human prion disease. 
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Sporadic Creutzfeldt-Jakob disease (sCJD) has not been previously reported in 
patients with clotting disorders treated with fractionated plasma products. We report 
2 cases of sCJD identified in the United Kingdom in patients with a history of 
extended treatment for clotting disorders; one patient had haemophilia B and the 
other von Willebrand disease. Both patients had been informed previously that they 
were at increased risk for variant CJD because of past treatment with fractionated 
plasma products sourced in the United Kingdom. However, both cases had clinical 
and investigative features suggestive of sCJD. This diagnosis was confirmed in both 
cases on neuropathologic and biochemical analysis of the brain. A causal link between 
the treatment with plasma products and the development of sCJD has not been 
established, and the occurrence of these cases may simply reflect a chance event in 
the context of systematic surveillance for CJD in large populations. 




Human prion diseases are a group of rare and fatal neurodegenerative diseases that 
include idiopathic (sporadic), genetic (inherited), and acquired (infectious) disorders 
(4). All are associated with the accumulation of an abnormal isoform of the prion 
protein (PrPSc) in the central nervous system (4). The most common human prion 
disease is the sporadic form of Creutzfeldt-Jakob disease (sCJD), which occurs 
worldwide with a relatively uniform incidence of 1–2 cases per million population 
per year, a peak incidence in the 7th decade of life, and a median duration of illness 
of 4 months. The relatively consistent mortality rates associated with sCJD, the overall 
random spatial and temporal distribution of cases, and the absence of any confirmed 
environmental risk factor have led to the hypothesis that sCJD occurs because of the 
spontaneous generation of PrPSc in the brain (4). In contrast, variant Creutzfeldt-Jakob 
disease (vCJD) (32) is an acquired disorder that is most likely caused by the 
consumption of meat or meat products contaminated with the bovine spongiform 
encephalopathy agent. The median age at death in vCJD is 28 years, with a median 
duration of illness of 14 months (15). Most cases of vCJD have occurred in the United 
Kingdom, which has had the largest epizootic of bovine spongiform encephalopathy 
in the world. Of the 178 UK vCJD cases, 3 have been identified as cases of secondary 
transmission caused by the transfusion of non-leucodepleted red blood cell 
components from vCJD-infected blood donors. 
 
Lookback studies have shown no evidence of transmission through blood transfusion 
in sCJD (1, 23), despite the identification of PrPSc in some peripheral tissues (156), and 
experimental evidence, which demonstrated infectivity in blood (132) by using 
intracerebral inoculation of highly sensitive transgenic mice. The absence of clinical 
cases causally linked to past treatment with fractionated plasma products has been 
used as evidence of the safety of these products in relation to sCJD (136). These 
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products are generally manufactured from the pooled plasma from several thousand 
donors; production using UK plasma was discontinued in 1999. 
 
We describe 2 cases of sCJD in patients who had previously received treatment with 
UK plasma–sourced plasma products; both patients had been informed that they 
were at increased risk for vCJD because of that treatment. The clinical features and 
investigations in these cases were typical of sCJD; the neuropathologic diagnosis in 




The UK National CJD Research and Surveillance Unit has been carrying out 
systematic epidemiologic studies of CJD since 1990. The methodology of this study 
has been published previously (139). In brief, patients with suspected CJD are 
referred by clinicians and visited by a research registrar, who obtains details of the 
clinical history and investigations, information on a range of possible risk factors, and 
past medical history. The Transfusion Medicine Epidemiology Review study 
investigates potential links between donors and recipients of labile blood components 
and, in cases of sCJD, investigates patients who have a history of blood donation or 
having received a blood transfusion. 
 
Coordinated surveillance of CJD has been undertaken in the European Union since 
1993 (157). National surveillance programs for CJD also are in place in several other 
countries, including Australia, Canada, Japan, and the United States. 
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Case 1: 
In 2014, a 64-year-old woman suffered a rapidly progressive dementia with 
deterioration in driving skills and balance disturbance, then limb coordination 
deficits with handwriting impairment. In the second month, her gait deteriorated, 
becoming shuffling and unsteady, she struggled to dress herself, and she had onset 
of daytime hypersomnolence. She became distractible, had visual misperceptions, 
emotional lability, and spatial memory problems. She was hospitalised at the 
beginning of the third month of her illness and had onset of cortical blindness, 
myoclonus, and akinetic mutism. She experienced rapid decline and died after a total 
illness duration of 3 months. 
 
An electroencephalogram performed during the final stages of illness showed 
background slowing and runs of periodic complexes, and a magnetic resonance 
imaging (MRI) brain scan showed high signal in the caudate heads with posterior 
cortical ribboning. A cerebral spinal fluid (CSF) 14–3–3 assay and real-time quaking-
induced conversion test for PrPSc both were positive. Prion protein gene (PRNP) 
sequencing showed no mutations with methionine homozygosity at codon 129. 
 
Post mortem examination of the brain showed widespread spongiform 
encephalopathy of predominantly microvacuolar type. Immunocytochemistry (a 
common laboratory technique used for anatomical visualisation of a specific protein 
(158)) for prion protein gave a widespread positive reaction in a granular/synaptic 
pattern in brain tissue (Figure 2.2). No plaques or plaque-like structures were 
identified. Results of immunocytochemistry for disease-associated prion protein were 
negative in peripheral nerve, liver, lymph node, appendix, and spleen. Western blot 
analysis of frontal cortex and cerebellum confirmed the presence of protease-resistant 
prion protein with a type 1A isoform. For an overview of pathological and 
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biochemical features of CJD subtypes, please see Ritchie et al. 2015 to which I 
contributed as third author (159). 
 
Figure 2.2: Results of neuropathologic examinations of the brains of the 2 patients 
with sporadic Creutzfeldt-Jakob disease, United Kingdom, 2014. 
A) Microvacuolar spongiform change in the frontal cortex (case 1). Haematoxylin and 
eosin stain; original magnification ×400. 
B) Fine granular/synaptic accumulation of abnormal prion protein in the cerebral 
cortex (case 1). 12F10 antiprion protein antibody; original magnification ×400. 
C) Microvacuolar spongiform change with neuronal loss and gliosis in the frontal 
cortex (case 2). Haematoxylin and eosin stain; original magnification ×400. 
D) Focally intense granular/synaptic accumulation of abnormal prion protein in the 
cerebral cortex (case 2). 12F10 antiprion protein antibody; original magnification ×400. 
 
Page 77 of 220 
 
 
The patient had been diagnosed with von Willebrand disease in childhood. Her early 
therapies include numerous transfusions of red blood cells and platelets; in more 
recent years, she received plasma-derived and recombinant factor VIII and additional 
blood component transfusions at times of haemorrhage. Factor VIII was administered 
on 4 occasions in the 1990s and during 2000–2004, and von Willebrand factor/factor 
VIII (Haemate-P) during 2001–2013. Because of her history of exposure to UK-sourced 
plasma products, for public health purposes she had been informed that she was at 
risk for vCJD, although she was not known to have been exposed to factor VIII 
derived from a batch including a vCJD donation. She had no history of potential 
iatrogenic exposure to CJD through recognised routes (e.g. no history of dura mater 
grafting, human growth hormone usage, etc.)  and no family history of CJD. 
 
Donors for all blood or platelet transfusions since 2001 have been identified. Of the 
107 donors, 106 are still alive, with a median age of 55 years (range 27–80 years). 
(Table 2.3). One donor of leucodepleted platelets, which were transfused 12 years 
before clinical onset in the recipient, died in 2013 at 76 years of age, and the diagnoses 
on the death certificate were vascular dementia and bladder cancer; it has not been 
possible to review the case notes for this individual. Identification of donors for 
transfusions before 2001 has not been possible, and due to the lack of available 
records, particularly from childhood, any attempt to estimate the number of 
transfusions and donors would be highly insubstantial. 
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Table 2.3: Selected characteristics of blood donors to the patient with sporadic 













3 RBC LD 4 4 0 
6 RBC LD 6 6 0 
7 RBC LD 19 19 0 
9 RBC LD 3 3 0 
10 RBC LD 4 4 0 
12 
Whole blood LD; 
RBCLD; platelets LD 
2; 27; 42 2; 27; 41 0; 0; 1 
*LD - leucodepleted; RBC - red blood cells. Median age of donors: 56 years (range 27–80 years). 
 
Case 2: 
In 2014, a 64-year-old woman reported day/night reversal of sleep patterns and, 3 
months later, excessive tearfulness, for which she was started on antidepressants. She 
then had onset of writing problems, followed during the next few days by increasing 
language problems that led to expressive dysphasia. She deteriorated rapidly 
thereafter, requiring assistance with her activities of daily living and having 
coordination and memory problems, jerking movements suggestive of myoclonus, 
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and itching in both arms. She was admitted to the hospital and experienced a 
probable focal seizure with secondary generalization. She had onset of a 
homonymous hemianopia and limb rigidity and then became bedbound and mute, 
dying 7 months after the onset of symptoms. 
 
An electroencephalogram performed during the final stages of illness showed 
widespread slowing, more evident on the left. An MRI brain scan showed left-sided 
caudate head and anterior putaminal high signal. Diffusion weighted imaging 
showed areas of cortical high signal. Results of a CSF 14–3–3 assay and real-time 
quaking-induced conversion tests were positive. Consent for full sequencing of the 
PRNP was not obtained; methionine homozygosity at codon 129 was identified. 
 
Post mortem neuropathologic examination of the brain showed a widespread 
spongiform encephalopathy with microvacuolar spongiform change, neuronal loss, 
and gliosis. Immunostaining for prion protein showed widespread positivity with a 
granular/synaptic pattern (Figure 2.2). No amyloid plaques were identified. Western 
blot analysis confirmed the presence of protease resistant prion protein with a type 
1A isoform. There was no evidence of abnormal prion protein accumulation in spleen 
and appendix either on immunocytochemistry or high sensitivity Western blot 
analysis. 
 
The patient was known to have haemophilia B since 1964 and had received plasma-
derived and recombinant factor IX during 1984–2012. For public health purposes, she 
had been informed that she was at risk for vCJD and in 1991 had received factor IX 
derived from a pool containing plasma from a donor who subsequently developed 
vCJD. She had no history of potential iatrogenic exposure to CJD and no family 
history of CJD. 
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In 1985, the patient received 6 units of fresh frozen plasma (FFP). Tracing of donors 





This report describes 2 cases of sCJD in patients with a history of treatment with UK-
sourced plasma products, 1 with a history of haemophilia B and 1 with von 
Willebrand’s disease. To our knowledge, no previous case of sCJD in a person with a 
history of extended exposure to plasma products has been reported. It is clearly of 
concern that there have been 2 such cases in a relatively short period in the UK, where 
many plasma product recipients have been informed that they are at increased risk 
for vCJD. However, a causal link between the treatment with plasma products and 
the onset of sCJD has not been established, and the occurrence of these cases may 
simply reflect a chance event in the context of systematic surveillance of CJD in large 
populations. 
 
Both patients had been informed that they were at increased risk for vCJD, and 
considering the evidence for the type of CJD in the 2 cases is important. Both patients 
had a clinical phenotype suggestive of sCJD, including a short duration of illness, 
typical early symptoms, a suggestive MRI scan, and, in 1 patient, a typical EEG. (The 
typical clinical features of each type of CJD are discussed in the thesis introduction 
Chapter 1; details regarding diagnostic criteria can be read in Appendix 2 and details 
about investigations are covered in the references (160, 161) and can be read at 
https://www.cjd.ed.ac.uk/sites/default/files/investigations.pdf accessed 25.08.18.) 
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Notably, both patients had a positive real-time quaking-induced conversion (RT-
QuIC) test result for PrPSc in CSF (Table 2.4) (162); this test has not been positive in 
any case of vCJD evaluated in the NCJDRSU laboratory (RT-QuIC performed at the 
NCJDRSU has been optimised and validated for detection of sCJD; this work is 
covered extensively elsewhere (163-165)). 
 
Neuropathological examination was critical; it showed appearances typical of sCJD 
in both patients and no evidence of peripheral pathogenesis on immunostaining of 
lymphoreticular tissues, a feature that is observed in all tested specimens of vCJD 
patients to date (90). Furthermore, both patients had a type 1A isoform PrPSc on 
Western blot consistent with a diagnosis of sCJD subtype MM1 (166). Neither patient 
had a history of potential iatrogenic exposure or a family history of CJD, and for the 
case for which sequencing of the PRNP was performed, no mutations were detected. 
In both cases, an MM genotype occurred at codon 129 of PRNP, which does not 
distinguish between sCJD and vCJD; methionine homozygosity is seen in 44.1% of 
the UK population, and 59.5% of UK sCJD patients (18), as well as all but one vCJD 
patients (46). Laboratory transmission studies to provide evidence of agent strain in 
the cases have not been possible. 
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Table 2.4: Selected characteristics and clinical features of the 2 patients with sporadic 
Creutzfeldt-Jakob disease described in cases 1 and 2, United Kingdom, 2014 
Characteristic/clinical 
feature 
Case 1 Case 2 

















RT-QuIC* + + 
Genotype MM MM 
Diagnosis Definite sCJD Definite sCJD 
Duration 3 months 7 months 
*RT-QuIC, real-time quaking-induced conversion. 
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One patient had received multiple transfusions of blood components over an 
extended period, and the other had received 6 units of FFP 19 years before clinical 
onset, raising the possibility that these cases could have resulted from secondary 
transmission through blood components. In the case of the patient with von 
Willebrand disease, 107 donors have been traced, and none appear in the register of 
cases of CJD kept at the National CJD Research and Surveillance Unit. However, it 
has not been possible to obtain information on blood transfusions for this patient 
before 2001 nor on the FFP transfusions for the patient with haemophilia B. This 
missing data could potentially contain donors who did subsequently develop sCJD, 
and might have passed on sCJD iatrogenically, but it is impossible to be certain; I am 
not able to quantify the amount of missing data. If further work was to be performed 
in relation to these cases, this would certainly be a topic to explore with a statistician. 
As in the TMER, the missing data is more prominent for earlier blood products, and 
this may introduce bias. Any contamination of pooled product with PrPSc would 
convey only a tiny dose, and such a small dose would be expected on the basis of dose 
dependence to convey a prolonged incubation period (167, 168), meaning those 
earliest products might be the most relevant. The implications of leucodepletion 
(introduced in 1999) for the potential for infectivity from pooled plasma products are 
not clear; pooled plasma products are prepared from plasma after removal of all 
whole cells, including the leucocytes (otherwise removed by leucodepletion, which 
was primarily a step to reduce infectivity of fresh blood products). Animal studies 
have indicated that leucodepletion may have significantly reduced infectivity of vCJD 
blood (169), but there is no similar data concerning sCJD. 
 
Lookback studies in the United States and United Kingdom have provided no 
evidence of transfusion-transmission of sCJD (1, 23), and although 1 study suggested 
an increase in risk after a lag period of 10 years (22), this finding was not confirmed 
in another study (24). The balance of evidence indicates that, if sCJD is transmitted by 
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blood transfusion, it must be a rare event, if it happens at all, and transfusion 
transmission is probably not the explanation for the 2 cases we describe. 
 
Systematic surveillance for CJD, including a coordinated study in Europe (98), has 
been carried out in many countries over the past 25 years and is continuing. Many of 
these studies obtain information on potential risk factors, including details of past 
medical history. To date, no case of sCJD has been reported in a person who has 
received treatment for a clotting disorder. In fact, the absence of such a case has been 
used to argue against the possibility that plasma-derived products pose a risk for 
sCJD transmission (136). CJD surveillance centres are aware of the relevance of this 
issue, and sCJD patients with a history of treatment with plasma products probably 
would have been identified and reported if they occurred. Although it is surprising 
that 2 cases of sCJD have been identified among a population of 4,000–5,000 patients 
in the UK who have been treated for clotting disorders with fractionated plasma 
products, the total population under surveillance for CJD in Europe and 
internationally exceeds 500 million. Assuming an annual incidence rate of sCJD of 
1.5–2.0 per million population (170), the occurrence of 2 cases of sCJD in this total 
population may not imply a causal link between the treatment and the occurrence of 
the disease. The 2 cases were identified over a period of months, and no further cases 
have been found since 2014; however, continuing to search for such cases through 
CJD surveillance programs is essential. 
 
As an approximate calculation, the combined prevalence worldwide of the 4 most 
common clinically symptomatic hereditary clotting disorders (Haemophilia A, 
Haemophilia B, Haemophilia C and clinically significant Von Willebrand) is 
approximately 268.5 cases/million population (171). “Clinically significant Von 
Willebrand” disease (VWD) is specified to reflect the spectrum of severity of VWD, 
and only to include those who are symptomatic of the condition to the point they may 
require blood products. This value may be a slight underestimate, as the prevalence 
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figures for Haemophilia A and B are given in the literature for males only, as they are 
X-linked conditions, however, as case 2 highlights, both are seen on occasion in 
females, although this is not considered for the purposes of this calculation; this 
calculation also does not consider the extremely rare subset of patients with multiple 
clotting disorders, which may to some degree offset the earlier omission of female 
patients with Haemophilia A and B. Within the population under surveillance for 
CJD (exceeding 500 million), this indicates approximately 134,250 patients are likely 
to have clotting disorders, although it is less clear whether all of these patients would 
have received treatment using pooled blood products. Using the upper limit of sCJD 
incidence at 2 cases/million per year, we might expect to see as many as 0.2685 cases 
of sCJD among the clotting disorder community each year. As a further very crude 
estimate, with surveillance ongoing since 1990, more than 27 years have passed, and 
we might have expected to have seen around 7 patients in this time window; of 
course, not all CJD surveillance systems worldwide were established by 1990, so the 
multiplication for observation over 27 years is not entirely valid, but nevertheless 
given earlier clotting disorder iatrogenic epidemics (including HIV and Hepatitis 
(172)), the clotting disorder patient cohort have been under closer scrutiny by 
haematology doctors for longer than routine CJD surveillance. As such, this crude 
estimate of around 7 cases indicates that the two reported sCJD cases among the 
clotting disorder patient group may not be all that unexpected as a chance occurrence 
of sCJD. 
 
Further consideration using rare event statistical modelling may help to explore the 
significance of the detection of these two patients within a short time period within 
the UK, but on discussion with my supervisors and co-authors, and consultation with 
statisticians while preparing this work for publication, it was agreed that such work 
is beyond the remit of this thesis (and indeed of the publication). Any such further 
work would benefit from careful input from a statistician, particularly if additional 
cases are detected in the future.  
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Chapter 2 Discussion 
 
The two papers presented in this chapter attempt to address the epidemiological 
evidence acquired by the NCJDRSU pertaining to potential acquired transmission of 
CJD by blood transfusion, and both feature their own discussion sections. The TMER 
update covers all forms of human prion disease where blood transfusion is believed 
to occur, and the aspects of that paper pertaining to vCJD are of relevance given this 
is the only form of CJD known to have been transmitted by blood product transfusion. 
Overall, there is no evidence that sCJD has been transmitted by blood transfusion 
from the TMER lookback, but there are individual cases where accessing further 
information beyond that provided by death certificates would be interesting; the 
limitation of accessing death certificate information only is clear. 
 
The two individuals with clotting disorders are both believed to have developed sCJD 
by chance, with no data either on pathological examination or on lookback of the 
products they have received to suggest that blood products were responsible. Crude 
estimates about sCJD prevalence and the number of patients under observation 
would suggest we may see other patients in this cohort with sCJD in the future, and 
perhaps we even should have seen more by this stage. Given the scrutiny this cohort 
of patients face following earlier iatrogenic viral exposures, it seems unlikely that 
other prion cases might have been identified but not published. It may be possible to 
perform statistical modelling to explore the temporally close presentation of these 
two patients, but this was not performed in this thesis. 
 
Both studies are limited considerably by data availability of the medical records 
tracing blood products, substantially reducing the ability of either study to identify 
Page 87 of 220 
 
potential linkages, and potentially causing bias, as earlier blood records are more 
likely to be missing, particularly so prior to 1990. As the quality of availability of 
blood donation and transfusion records has increased over time, repeating the 
analysis for the TMER in future years, as new CJD patients are reviewed by the 
NCJDRSU may provide more complete data. As clotting disorder patients age, if we 
do see further CJD cases, the improved quality of blood product data may not be as 
helpful as with the TMER, since these patients may only have been exposed to human 
derived plasma products earlier in their life, with the roll out of recombinant factors. 
Should a future individual patient who has received only recombinant clotting factors 
(and no transfusion or other blood products) subsequently develop sCJD, this case 
would clearly not be caused by blood transmission.  
 
A development of great interest since the two publications from this chapter is the 
development of a blood test which has identified PrPSc in stored blood from vCJD 
patients, including two preclinical samples from patients who subsequently 
developed vCJD (66, 67) – this test is mentioned in Chapter 1 in the vCJD section. This 
test is based on protein misfolding cyclic amplification (PMCA), another protein 
amplification technique with some similarity to RT-QuIC (also mentioned very 
briefly in the case report section of this chapter), and appears to offer high sensitivity 
and specificity for the detection of PrPSc in vCJD. The test has not identified PrPSc in 
blood from sCJD patients, which may be considered further evidence that blood is of 
low – if any – infectivity in sCJD. It is not yet clear whether it will be possible to scale 
this test up to the point it could be used to screen UK blood donors and other donors 
from countries with prior vCJD cases, nor whether at that stage the test would be 
affordable. With vCJD cases appearing to have dwindled, and given the 
disappearance of CJD from the public eye (on the basis of family reactions to my visits 
to see patients while working in the NCJDRSU), there may neither be a strong public 
health case, nor a political will to encourage adoption of such measures; however, a 
pilot prevalence study (similar to the appendix studies discussed in later chapters 
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(51)) of UK, French and/or Irish blood donors, if performed, might provide additional 
evidence as to whether scaling up the test would be potentially beneficial on public 
health grounds.  








Evidence for Organ and Tissue Transplant 
Transmission of sCJD 
  





While sporadic CJD is believed to occur as a result of a spontaneous protein 
misfolding event (4), the possibility of person-to-person transmission cannot be ruled 
out. Iatrogenic transmission of CJD has been recognised in recipients of cadaveric 
dura mater or human growth hormone and in a few instances related to surgery, EEG 
depth electrodes and corneal transplantation (73). It remains possible that at least a 
small number of apparently sporadic CJD cases may in fact represent unrecognised 
iatrogenic transmission through tissue or organ transplantation due to infectivity 
intrinsic to the transplanted material. The possibility of transmission by blood or 
blood product transfusion is addressed in Chapter 2, while surgical instruments are 
considered as another potential means of transmission in Chapter 4. 
 
Transplant may convey a greater risk of transmission of PrPSc than surgery not 
involving transplantation due to the prolonged contact with the material from the 
donor/source affected by sCJD, and the greater quantity of PrPSc implanted with the 
organ or tissue, when compared with whatever small quantity could have adhered to 
a surgical instrument and remained despite sterilisation procedures; both factors 
would increase the dosage of PrPSc implanted into the recipient, and a dose dependent 
model of transmission has been postulated in explaining some observed prion 
transmission characteristics (167, 168).  
 
Approximately 4000 whole organ transplants are performed in the UK each year; for 
example, between 1 April 2016 to 31 March 2017, 1413 individuals donated organs, 
resulting in 3675 transplant surgeries, involving 4025 organs (173) (see Figures 3.1 and 
3.2 below). The discrepancy between these figures can be explained for a number of 
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reasons, including that one donor (in the case of non-living donations) may donate 
more than one organ, and the fact that multiple organs may be transplanted during a 
single surgical procedure, such as in combined liver, kidney and pancreas 
transplantation. Other chains of procedures are possible such as domino transplants 
– where a recipient with a lung pathology receiving a combined heart and lung 
transplant may themselves donate their unaffected heart to another individual. In 
addition, non whole organ, human derived materials are used as a variety of tissue 
grafts, including for corneal grafts, tendon, bone, skin and heart valves; these result 
in numerous graft procedures, including 3564 corneal transplants in the UK between 
2010-2011 (174) (see Figures 3.3 and 3.4 below).  
 
The rates of whole organ donation have fluctuated over the years, but the overall 
trend is increasing. Full details of UK donor activity can be read on the NHS Blood 
and Transplant website https://www.nhsbt.nhs.uk/what-we-do/transplantation-
services/organ-donation-and-transplantation/ accessed 02.09.18, but I have extracted 
two graphs showing the frequency of deceased and living whole organ donors in the 
UK into Figures 3.1 and 3.2, overleaf.  Figure 3.1 shows HB (heart beating), NHB (non-
heart beating) and living donors, while Figure 3.2 uses the terms DBD (deceased 
donors after brain death), DCD (deceased donors after circulatory death) and living 
donors. The change in terminology reflects contemporary parlance and the 
importance of communicating brain death to families prior to consideration of organ 
harvest. Living organ donation has increased almost 5-fold over 21 years, while there 
have also been modest increases in deceased organ donation of around 2/3 over the 
same time window, with the increases seen predominantly in the deceased donors 
after circulatory death category (formerly non-heart beating). Both living and 
deceased donor organ donation from an individual in a presymptomatic phase of 
sCJD might convey a risk of transmission of sCJD, but the opportunity subsequently 
to detect transmission from an asymptomatic donor would be greater from a living 
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donor, as that individual may survive to the development of clinical symptoms, and 
subsequent referral to the NCJDRSU.











Figure 3.1 shows the trends in UK organ donation from 1996-2006 inclusive. Copied 










Figure 3.2 shows trends in UK organ donation from 2007-2017 inclusive. Copied from: 
NHS Blood and Transplant: Overview of Organ Donation and Transplantation, 2017 
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(173). Note that living donors are grey on both charts, while the colours for HB/DBD 
and NHB/DCD are reversed comparing the two graphs. 
 
Separate from whole organ donation is the category of tissue donation, mentioned on 
Page 90. This comprises several different tissues from multiple different organs. 
Corneal grafts are considered first, as they are a recognised means of transmission of 
CJD. Corneal grafts are used in ophthalmology to replace diseased or damaged 
corneas for indications such as keratoconus, failure of the corneal endothelium (as in 
Fuchs’ dystrophy, or following cataract surgery), infection, injury, ulceration, or 
corneal opacification; corneal grafts are usually sourced from cadavers, as it is 
infrequent for an eye to be removed from a living patient unless it is sufficiently 
diseased that usually its tissues would be unsuitable for donation (174). Figure 3.3 
and 3.4 (overleaf) show those corneal graft donations and implantations in the UK by 
year which are reported to the UK Transplant Registry (not all cases are, so the 
complete figures will be higher, but the figures nevertheless show an indicative 
trend); rates of corneal donation and implantation are increasing over the observed 
21 year period. The UK Transplant Registry figures for 2015-2016 record 3,045 corneal 
donors, 2,675 of these donated corneas only, and 370 donated corneas and solid 
organs (173). In that time period, 25% of solid organ donors after brain death, and 
30% of solid organ donors after circulatory death also donated corneas. 
  












Figure 3.3 shows the trends in UK cornea donation and implantation from 1996-2006 
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Figure 3.4 (on preceding page) shows trends in UK organ donation from 2007-2017 
inclusive. Copied from: NHS Blood and Transplant: Overview of Organ Donation 
and Transplantation, 2017 (173). Note the reversal of the colour scheme compared to 
Figure 3.3. 
 
The first documented case of corneal transplant transmission of CJD was described 
in 1974 by Duffy et al., from a donor who died of pathologically confirmed CJD; the 
recipient became symptomatic 18 months after the transplant (177). A second case 
was published in 1997 by Heckmann et al. of a patient who died of CJD 30 years after 
receiving a corneal transplant from a donor who died of an illness with typical clinical 
and neuropathological features of CJD (86). It is not clear exactly how many cases of 
corneal transmission of sCJD have occurred, with differing totals within the literature. 
In 2006, Brown et al. reported that there were 3 additional possible cases in addition 
to those already described above  (as a supplementary one line comment attached to 
a table within the paper) (178). Maddox et al. wrote in 2008 that there had been 6 such 
cases in total, referencing the Brown et al. paper, and also Hammersmith et al. – the 
latter’s paper explains that they were unable to locate any records relating to the 
donor of the potentially implicated cornea (179, 180). The Maddox paper also 
described an additional four patients who received corneal transplantation and 
subsequently died from CJD, each of whom is suspected to have had sporadic CJD 
without any association with their transplant, reflecting a coincident development of 
the rare neurodegenerative disease among a growing population of transplant 
recipients (the larger the pool of transplant recipients becomes, the more likely that a 
disease which occurs sporadically is likely to be represented and potentially 
reported). The disparity in reported numbers reflects the difficulty of proving 
causality when an individual received a transplant and subsequently developed CJD. 
The two cases (published by Duffy et al.  and Heckmann et al. and discussed above) 
widely accepted to represent corneal transmission of CJD had incubation periods of 
1.5 and 30 years between exposure and onset of symptoms, and neuropathological 
Page 97 of 220 
 
confirmation of sCJD in the donor. A summary of the 6 cases reported by Maddox et 
al. to represent suspected corneal transplantation transmission of sCJD is below 
(Table 3.1). 
 




Country Incubation period 
for each case (years) 
Duffy et al. (85) 1974 USA 1.5 
Uchiyama et al. (181) 1992 Japan 1.25 
Heckmann et al. (86) 1996 Germany 12 and 30 
Rabinstein et al. (182) 2002 USA 2, 4, and 6 
Hammersmith et al. (180) 2002 USA 14.5 and 23.67 
Heinemann et al. (183) 2005 Germany 13 
 
 
Other, non-corneal graft materials (not associated to date with CJD transmission) are 
listed below. Tendon grafts are primarily used in orthopaedic surgery, such as for 
repair of ruptured ligaments (commonly cruciates, less commonly pectoralis major, 
biceps or triceps), and also for management of joint instability at the knee and elbow. 
Tendon grafts are usually donated from deceased donors, and the harvested 
materials are often processed to reduce the likelihood of rejection after grafting, using 
freezing, freeze-drying or cryo-preservation, as well as irradiation; since the graft 
contains mostly proteinaceous material, and the desired outcome of the graft is 
retention of its mechanical properties after implantation, the steps involved in 
processing are designed to avoid too much protein damage, which would otherwise 
weaken the graft, but such a restriction on processing would reduce the likelihood of 
inactivation of any infectious prion particle (184). 
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Bone grafts are used in orthopaedic, spinal and maxillofacial surgical procedures, 
usually to replace large areas of bone removed or damaged by infection, neoplasm, 
radiotherapy, etc. and thought unlikely to regrow; bone grafts are also used for 
fixation procedures, such as vertebral fusions, and as a cement to stabilise joint 
prostheses and encourage host bone regrowth. Bone grafts can be prepared in a 
number of ways, similar to those methods used in preparing tendon grafts, but again, 
intact protein structure is integral to bone strength, meaning such processing cannot 
cause too much protein degradation, and removal or inactivation of prion is unlikely. 
Bone grafts are harvested from cadaveric donors, but also from living donors such as 
from the head of the femur, removed from patients undergoing total hip replacement 
(185-187). Bone grafting was considered one possible risk factor for vCJD 
transmission, in part due to probable contamination on any bone graft with blood, 
and several health protection measures were introduced during the vCJD epidemic 
to try to protect the population, including no longer manufacturing pooled bone 
grafts from multiple donors, and also the exclusion of blood transfusion recipients 
from bone graft harvest (188). 
 
Skin allografts are used in patients with severe skin damage (usually burns) who have 
insufficient unaffected skin to allow for harvest and use of autologous grafts. The 
grafts are cadaveric in origin, and are gamma irradiated and freeze dried to reduce 
immunogenicity (PrPSc is resistant to both treatments); they may only be used 
temporarily until autologous skin grafting is possible, or may be sloughed off once 
sufficient wound granulation has occurred under the allograft, allowing wound 
healing by secondary intention (189, 190). 
 
Iatrogenic transmission of sporadic CJD has been recognised in recipients of 
cadaveric dura mater grafting (where the process in manufacturing the graft 
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materials was contaminated with PrPSc) and corneal transplants (where individual to 
individual transmission has occurred), both of which are procedures with 
transplantation of tissue, as well as in recipients of cadaveric pituitary derived 
hormones (growth hormone and gonadotropin), and cases of reuse of contaminated 
neurosurgical instruments and EEG depth electrodes (73). Cases associated with dura 
mater grafting and growth hormone continue to be reported. 
 
Some case report publications in the field of suspected tissue and organ 
transplantation of CJD demonstrate a failure of understanding, such as Hashoul et al. 
(191). The authors describe a patient with a probable diagnosis of a subtype of 
sporadic CJD, who had received a bovine bioprosthetic heart valve; they attempt to 
make a connection between the bovine valve (which might conceivably be regarded 
as means of transmission of BSE prion) and the patient’s illness, perhaps confused by 
the terminology “Heidenhain variant”, which is a subtype of sporadic CJD where the 
patient presents with isolated cortical visual symptoms, rather than indicating variant 
CJD. Such papers highlight the need for caution in the interpretation of case reports. 
 
Other (non-transplant) associated transmission of CJD is described in the 
introduction to this thesis (Chapter 1). At least 238 cases of dura mater graft related 
transmission of CJD (iatrogenic CJD) have been identified worldwide as of 2015 (74), 
with a mean incubation period of 12 years (range 1.3 – 30 years) (73). It is important 
to recognise that Lyodura® (the brand of cadaveric dura mater graft processed and 
sold by B Braun Melsungen AG and predominantly associated with such 
transmission) was not solely used in neurosurgical procedures, but also in other 
domains of surgery, including gynaecological, ENT (ear nose and throat), 
orthopaedic, dental, urological and cardiac procedures, fields not associated with 
iatrogenic transmission of CJD to date (192). Coincidentally, there have also been at 
least 238 identified worldwide cases of cadaveric-derived pituitary Human Growth 
Hormone associated transmissions of iCJD, with mean incubation of 17 years (range 
Page 100 of 220 
 
5-42 years). Four cases of cadaveric-derived Gonadotropin iCJD transmissions are 
reported, with mean incubation 13.5 years (range 12-16 years) (74).  
 
Although PrPSc is found in the highest concentrations in central nervous system (CNS) 
tissues and the pituitary gland in sCJD patients, the pathological protein is not 
restricted solely there, and has been identified in tissues other than the CNS. The 
Advisory Committee on Dangerous Pathogens Transmissible Spongiform 
Encephalopathy subgroup (ACDP TSE) published a useful summary on tissue 
infectivity in CJD in 2003, updated in 2012 (89), and summarised in Table 3.2, below. 
The high risk tissues are brain, spinal cord, cranial nerves, cranial ganglia, the 
posterior segment of the eye and pituitary gland. Nevertheless, other tissues can also 
express lower levels of PrPC, and have been found to contain PrPSc in sCJD patients, 
and, as such, spinal ganglia and olfactory epithelium are considered medium risk, 
while other tissues are classified as low (rather than no) risk. The ACDP data is largely 
derived from the WHO, which in turn collated the results of multiple studies using 
both Western blot detection of PrPSc and animal transmission studies (in primates and 
mice) (5). The data in relation to vCJD are included in Table 3.2 for completeness and 
comparison. 
 
The development of highly sensitive in vitro amplification techniques such as RT-
QuIC has allowed identification of seeding activity in a variety of non-CNS peripheral 
tissues which are not recognised as high risk in CJD (5, 193, 194). Rubenstein and 
Chang suggested that non-CNS PrPSc distributions in sCJD patients may not be vastly 
different to those seen in vCJD, where lymphoreticular involvement is common (195). 
It should be noted that the mere presence of PrPSc does not necessarily imply 
infectivity of these tissues; however, animal studies have indicated the potential for 
infectivity of at least some non-CNS tissues, including recently bone marrow (196).  
The early recognition of corneal transplant transmission of CJD identified a route of 
CJD transmission in humans other than exposure to CNS materials, although the 
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possibility remains of contamination of corneal graft tissue at the time of tissue 
harvest with retina (which arguably should be considered a CNS tissue). 
 
Table 3.2, overleaf, is sourced from the ACDP TSE Subgroup 2012 publication (89), 
with minor adjustments for formatting only. The original can be viewed at 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/444
243/Annex_A1_update.pdf accessed 05.09.48. 
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Table 3.2 (89): 
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There are many unknown factors about the early stages of sCJD. For example, it is not 
known how long it may take from the first spontaneous conversion of a molecule of 
PrPC into PrPSc to the clinical development of the disease, nor do we know at what 
stage in the disease process PrPSc may be identified in peripheral tissues; furthermore, 
while it may be hypothesised in sCJD that the first spontaneous conversion to PrPSc 
would occur in CNS tissues, where the host PrPC is found in highest concentrations, 
this is not certain. As such, there is the potential that a presymptomatic individual 
may die of a cause unrelated to sCJD and their organs be used for transplantation, or 
they may donate organs or tissues in life prior to becoming symptomatic of sCJD, but 
after the biochemical onset of the disease. Even if symptomatic of sCJD, due to the 
disease’s variable and rapid presentations, and the potential to mimic other more 
common neurological illnesses, it is possible that patients may die without a diagnosis 
and their organs still be used for transplantation – the features of dementia and other 
neurodegenerative diseases are not in themselves sufficient to exclude patients as 
donors once they die. The Joint UK Blood Transfusion and Tissue Transplantation 
Services Professional Advisory Committee requirements concerning organ and tissue 
donation stipulate: 
“Must not donate if: 
1. Diagnosed with any form of CJD, or other human prion disease. 
2. Identified at increased risk of developing a prion associated disorder. This 
includes: 
a) Individuals at familial risk of prion-associated diseases (have had two or 
more blood relatives develop a prion-associated disease or have been 
informed following genetic counselling they are at risk). 
b) Individuals who have potentially been put at increased risk from surgery, 
transfusion or transplant of tissues or organs. 
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c) Individuals who have been told that they may be at increased risk because 
a recipient of blood or tissues that they have donated has developed a prion 
related disorder. 
d) Recipients of dura mater grafts. 
e) Recipients of corneal, scleral or other ocular tissue grafts. 
f) Recipients of human pituitary derived extracts. 
g) Since January 1st 1980: Recipients of any allogeneic human tissue.” 
Reproduced from www.transfusionguidelines.org (197). 
 
The Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) 
provides similar, but more detailed guidance in their publication “Guidance on the 
Microbiological Safety of Human Organs, Tissues and Cells used in Transplantation”, 
including a table titled “Exclusions from organ and/or tissue donation based on 
possible TSE exposure”, which I have copied into Appendix 3. The full guidance can 
be read at https://bts.org.uk/wp-content/uploads/2016/09/Guidance-on-the-
microbiological-safety-of-human-organs-tissues-and-cells-used-in-
transplantation.pdf accessed 16.09.18.  
 
Aims: 
I have looked for evidence of tissue or organ transplantation associated transmission 
of sporadic CJD in the UK among sCJD patients seen by the NCJDRSU between 1st 
January 2010 and 31st December 2015 inclusive. 
 
The method described below looks for a link between known transplant recipients.  
As explained above, any patient known or suspected to have CJD is prohibited from 
donating tissue and organs. If this study is to identify transplant associated 
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transmission of CJD, then the donor of any organs (and therefore source of PrPSc) must 
not have been known to be suffering from the disease – either they might be in a 
presymptomatic phase, or their organs were donated after becoming symptomatic, 
but before the diagnosis was considered. If in a presymptomatic phase, transmission 
would be suspected if the donor and recipient both subsequently developed sCJD 
and were referred to the NCJDRSU. If the donation occurred at the end of the donor’s 
life and sCJD was not diagnosed, to demonstrate evidence of tissue or organ 
transmission, that donor would need to donate organs to more than one individual, 
and at least two of the recipients of those organs would themselves need to go on to 
develop CJD and be referred to the NCJDRSU. Given the likelihood that transplant 
transmission of sCJD is a rare event (with only 2 cases of corneal transmission 
identified), it is very unlikely that this method will identify a connection between two 
recipients of organs from the same donor. However, if such a connection was 
identified, this would be highly suspicious for iatrogenic CJD transmission. 
 
Other dementias are not regarded as an exclusion for organ donation, and CJD may 
be misdiagnosed either as another dementing illness, or other neurological disease 
(e.g. stroke). If a hypothetical donor was indeed in a preclinical phase of sporadic CJD, 
then the highest concentration of PrPSc would be expected to be located in the CNS. 
Other than dura mater grafts and pituitary hormones, no other CNS material is 
intentionally transplanted. The lower concentrations of PrPSc in other, non-CNS 
organs, and lack of exposure of the transplanted material direct into the recipient’s 
CNS (as is often performed in animal transmission studies) is likely to result in longer 
incubation periods than seen in established transmission of iatrogenic CJD. 
 
  





UK CJD Surveillance Process: 
UK Clinicians are asked to refer to the NCJDRSU any patients in whom CJD is a 
possible diagnosis.  Such clinicians come from multiple different specialties, 
including Neurologists, Psychiatrists, Geriatricians and General Physicians.  These 
clinicians may refer for many reasons, and in doing so, they obtain expert diagnostic 
advice and support, as well as access to the national cerebrospinal fluid analysis 
laboratory (within the NCJDRSU) for 14-3-3, S-100b and RT-QuIC assays (which are 
vital parts of the CJD diagnostic process). 
 
NCJDRSU data collection: 
For patients in whom CJD is considered a possible diagnosis, an NCJDRSU clinician 
travels to assess the patient, interview their relatives, and to review the hospital notes 
and diagnostic tests.  The visiting NCJDRSU clinician completes a standardised 
questionnaire with information obtained primarily from the patient’s family (in rare 
circumstances, also from the patient themselves – regrettably, by the point of referral, 
it is unusual for patients to be able to communicate clearly or recall accurately).  
Where possible, consent is obtained from the family (or patient) to access further 
information from the General Practitioner medical records.  Patients were classified 
according to standardised diagnostic criteria (see Appendix 2); these criteria have 
been adapted over the years as new diagnostic tests have been developed and 
validated. Throughout the study period, the 2010 “Rotterdam modification” to the 
1999 “WHO diagnostic criteria for CJD” (198, 199) was applied; in 2017, these 
diagnostic criteria were updated as the “Euro CJD diagnostic criteria” with inclusion 
of RT-QuIC on CSF, a highly specific diagnostic test (164, 200, 201) (also included in 
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Appendix 2); this updated classification criteria has not been retrospectively applied 
to the cohort under study in this thesis as it was not in use when I saw these patients, 
when the data was extracted, and when the analysis was performed. Retrospective 
application of the updated criteria would generate a new, slightly larger cohort 
involving more patients, and requiring a complete reanalysis for both this chapter 
and Chapter 4. The updated classification will be applied retrospectively to the entire 
NCJDRSU database by those staff still employed there, and any future NCJDRSU 
studies will include these updates when formulating their cohorts. 
 
NCJDRSU case classifications for individual patients are, however, updated as tests 
which are included in the diagnostic criteria in use at that point become available. For 
example, a case seen in life by the NCJDRSU clinician might be classified as an 
uncertain diagnosis, possible or probable sCJD, or (exceptionally rarely) as definite 
sCJD if a brain biopsy had been obtained; those cases not classified as definite are 
recoded as definite sCJD after neuropathological data is acquired if this confirms the 
diagnosis – usually following a post mortem examination. Similar changes in coding 
would occur if results relating to a patient who had already been seen – at that stage 
without positive diagnostic testing – later became available; such delays were not 
uncommon while I worked in the NCJDRSU in relation to 14-3-3 CSF testing, which 
was performed only once weekly, and required transport of CSF while frozen from 
the referring hospital to the NCJDRSU reference laboratory, but were rare for MRI 
scans or EEG tracings. These changes are unlikely to have impacted on the cohort 
under study, as sufficient time (11 months) passed after December 2015 before final 
data extraction to ensure that neuropathological results were available for every 
patient who had undergone post mortem. 
 
The standardised family questionnaire includes details about any surgical procedure 
which the family (or patient) can recall the patient undergoing.  The visiting 
NCJDRSU clinician collects information about the name of the hospital where the 
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procedure was performed, and the name and year of the procedure.  We try to include 
even minor procedures, including removal of minor skin lumps or bumps, 
endoscopies, and stitches – such as after a laceration or episiotomy tear.   
 
For those cases where we obtain consent to access the GP records, it usually takes 
weeks to months to access these.  Typically, we wait until after the death of the 
patient, for completeness of this record, and on occasion this can add an additional 
complication, as the physical notes for deceased patients are often moved from an 
individual GP practice to a central storage location.  Once the notes are obtained 
(either the originals, which are promptly processed and returned, or photocopies), 
they are reviewed (either by one of the NCJDRSU clinicians, other senior NCJDRSU 
staff with appropriate backgrounds, or by trained medical students completing a 
research project in the NCJDRSU) and compiled into a standardised GP history form.  
The data extracted are then entered into the NCJDRSU clinical surveillance database 
by administrative staff members. For each operation, the surgical procedure is 
recorded as a free text field, along with the name of the hospital, location (town), and 
year of the procedure. Both the GP history form and family questionnaires are 
available online as part of the NCJDRSU protocol document, 
https://www.cjd.ed.ac.uk/sites/default/files/NCJDRSU%20surveillance%20protocol-
january%202017.pdf accessed 01.09.18. The family questionnaire is titled “Clinical 
and  epidemiological review” and can be found from page 23 onwards, while the GP 
history form is located from page 62 onwards of the protocol document. 
 
For each completed questionnaire, the operations are categorised into the following 
surgical types: neurosurgery, eye, ear, abdominal, orthopaedic, gynaecological,  
tonsillectomy, carpal tunnel, spine/disc, appendicectomy, transplant, 
cardiology/cardiovascular, stitches, nose/throat, varicose vein, dermatology/minor 
lumps, vasectomy/testicular, breast, plastics, dental surgery, urological, and other 
(including endocrine, salivary gland surgery, lymph node excision not covered by 
Page 109 of 220 
 
other categories, bone marrow aspiration, nail surgery, and thoracic surgery).  A copy 
of the guide for procedure classification used at this stage is included in Appendix 1. 
The process of operation coding is suggested at the time of data entry onto the family 
questionnaire or GP notes form, as the form requires entries to be written into the 
appropriate box; but this coding is formalised by administrative staff in the NCJDRSU 
using the procedure classification guide. The guide for operation coding was first 
developed in the NCJDRSU for use in case-control studies, and still has significant 
similarity to that used in the 2006 variant CJD case-control paper (42). The guide 
document has developed iteratively since then, as, over the years of ongoing 
surveillance, for any surgical procedure which the administrative team found 
difficult to fit into an established category, this would then be queried with a clinician 
as to how best to classify that procedure. These decisions are recorded, and the 
document has gradually become more comprehensive. The recording of these 
decisions ensures that operations should be classified consistently, reducing the risk 
of variability of individual interpretation impacting on this aspect of data entry. 
 
For all patients referred to the NCJDRSU between January 2010 and December 2015 
inclusive who were classified as either definite or probable sporadic CJD, all surgical 
procedures identified from either the GP records or family questionnaire were 
extracted from the surveillance database to a Microsoft Excel spreadsheet. This data 
set was also used for analysis of surgical instrument transmission of CJD, described 
in Chapter 4. The efforts required to improve data completeness and to identify and 
correct errors are also set out in Chapter 4, as they are more pertinent to the 
subsequent analysis of time-place associations, covered in that chapter. In brief, 
efforts were made to ensure as many records as possible from both family 
questionnaires and GP records were completed and included in the data set. All data 
obtained by 1st December 2016 were included in the analysis. 
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Examination of the extracted data for suspected tissue and organ transplantation: 
The spreadsheet was sorted by operation category in the first instance; all surgical 
procedures listed in the transplant category were highlighted for review.  The 
remaining categories were assessed for the possibility of use of tissue or transplant, 
first by scrutiny of the surgical procedure to identify possible operations of interest, 
and thereafter by accessing the hospital records and any supportive information from 
the GP notes for every procedure deemed likely to include tissue usage or 
transplantation.  This step was performed to allow for the possibility that some 
procedures might have been miscoded (i.e. not coded as transplantation despite this 
being the primary purpose of the surgery), or coded appropriately but still included 
tissue usage (such as skin cancer excision where a skin graft might have been used).  
This was performed in the same manner as the analysis of transplant procedures, i.e. 
considering the operation type, and further reference to any other available data 
sources for any procedure identified as “of interest”. 
 
Processing the extracted tissue and organ transplant procedures: 
With all procedures identified which were deemed likely to include tissue or organ 
transplantation, these were then classified as to whether they included artificial graft 
materials only, autologous transplantation only (i.e. the patient themselves was the 
“donor” of all tissues used), xenograft usage (for grafts derived from animal tissues, 
including bioprosthetic grafts), or allografts (where tissues or organs were donated 
from other individuals). In operations where the procedure name entered into the 
NCJDRSU surveillance database did not stipulate the nature of the graft used, the 
original GP notes and hospital notes (where available) were consulted to see whether 
any further detail could be extracted to allow clarification. 
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Exploring potential links with other sCJD tissue and organ recipients: 
In order to consider whether there may be any potential connection between those 
patients identified within the 2010-2015 cohort who underwent transplant procedures 
and any other UK sCJD cases, a second data set was extracted from the NCJDRSU 
surveillance database of all patients classified as definite or probable sCJD who had 
been reported to have had transplant surgery. To avoid missing any potential 
miscoded procedures (particularly given the iterative improvements and adaptations 
to the procedure coding document, and the period prior to the 2006 case-control study 
from which it was developed), all ophthalmological, cardiac, abdominal and 
urological procedures were also extracted, and the procedure names were scrutinised 
to look for any procedures involving transplant. These additional transplant 
procedures were then compared to the transplants identified from the studied cohort, 
to look for any potential links where multiple organs might have been harvested from 
the same donor, indicating the possibility of potential transplant associated 
transmission of CJD. 
 
For patients who received relevant tissue or organ transplantation, where available, I 
review the clinical presentations and neuropathological findings, where available, to 
try to identify any features which might be considered atypical for sCJD, such as those 
described in a subset of the Japanese dura mater graft associated iCJD cohort (202-
204). 
  






579 cases of definite or probable sporadic CJD were reported to the NCJDRSU 
between January 2010 and December 2015 and were included in this study.   
 
Both family questionnaire and GP record data were collected for 488 patients (84.3%), 
family questionnaire data only for 49 patients (8.46%), GP record data only for 3 
patients (0.518%) and no data for 39 patients (6.74%). One, or both, data sources were 
available for 540 (93.3%) of the cases (illustrated below in figure 3.5).  
 
Figure 3.5: Data sources for the 579 definite or probable sCJD cases 2010-2015 
  
 
1326 surgical procedures were recorded in the family questionnaire data and 3111 in 
the GP record data, giving a total of 4437 surgical procedures when combining the 
two; this total includes any duplicates. These figures are represented in flow diagram 
Figure 3.6 below. 
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Figure 3.6: Flow diagram illustrating the surgical procedure data, and the 




Identifying transplant procedures: 
From the 4437 procedures, 68 were identified as “of interest” – deemed likely to 
involve tissue or organ transplantation.  30 of these came from the family 
questionnaire entries and 38 from the GP records. There was considerable duplication 
between the flagged procedures from the family questionnaire and GP record data 
sources. After removal of these duplicates, this left 45 reported tissue or transplant 
related procedures, involving 36 of the 540 patients for whom we had data, described 
in Table 3.3 and below. These figures also are illustrated in Figure 3.6, above. 
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Donors: 
One patient donated a kidney, 30 years before onset of symptoms of sporadic CJD; 
the donor is of course at no risk of acquiring CJD from this organ since that individual 
was the source of it. The details of the recipient are not known to the NCJDRSU, but 
the only recipient of a renal transplant known to have developed sCJD in the UK is 
the other patient in this cohort, for whom the source of the organ is known and was 
not from this donor (furthermore, the two surgical procedures were separated by 29 
years). No other non-autologous donation surgeries were identified.  
 
Transplant recipients: 
One patient was reported to have undergone a “bowel graft” in the late 1960s, 
according to the family questionnaire.  No corresponding entry was identified from 
the GP notes, with only a variety of minor gynaecological procedures listed a few 
years either side of the year that this procedure allegedly occurred; none of the 
gynaecological procedures are likely to have included any tissue graft or organ 
transplant.  The procedure was performed 55 years prior to symptom onset, and there 
are no extant hospital records. Bowel transplantation was first performed in humans 
only 4 years before the reported procedure, and was not survivable until the 
development of ciclosporin and other immunosuppressants to prevent organ 
rejection, around two decades later (205). While it is not clear exactly what this 
reported “bowel graft” surgery represents (some bowel resection and/or anastomosis 
might be plausible), it is more likely there is some inaccuracy in the reported 
procedure name. Overall, it is highly unlikely that the procedure represents any tissue 
or organ transplantation; this report was judged to be spurious and was removed 
from further analysis. 
 
After removal of duplicate entries where procedures were listed in both the GP 
records and family questionnaire, most patients (30 of the 34 remaining patients after 
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exclusion of the kidney donor and “bowel graft” patient) underwent only a single 
procedure involving tissue or organ transplantation. 4 patients were listed in the data 
set with more than one procedure (details of these can be found below). 
 
The procedures were divided by type of organ or tissue used.  The largest category is 
for patients who received either autologous grafts or harvest procedures relating to 
(potential) subsequent autologous reimplantation: 23 patients and 26 procedures 
were identified. One patient underwent a dental procedure to relocate a tooth that 
had erupted in the wrong location. Two patients each underwent two autologous 
bone marrow related procedures (one patient had a bone marrow harvest and 
subsequent reimplantation, and the other underwent two harvest procedures, but 
there is no record of reimplantation). Eleven patients underwent coronary artery 
bypass grafting (CABG) without any paired procedure (see the paragraph concerning 
xenograft materials below). One patient underwent a tendon graft procedure; this is 
believed to have been an autologous graft based on the limited details available. Six 
patients underwent seven skin graft procedures; although full details are not 
available concerning the nature of the graft for six of the seven procedures, they are 
presumed all to be autologous, as the grafts were performed for small surgical 
wounds (such as skin cancer removals), rather than for extensive burns (where 
allografting has occasionally been used). One patient underwent a bone graft 
following a fracture; review of the notes suggested this was autologous. One patient 
underwent a cycle of in vitro fertilisation and had reimplantation of the fertilised eggs; 
it is arguable whether or not this represents a transplant, but it is removal of material 
from the body, with subsequent reimplantation and is included in the autologous 
category for the purposes of this study. 
 
A single patient was identified who had undergone an entirely artificial graft, with a 
metallic heart valve inserted. 
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Five patients underwent procedures involving bioprosthetic xenografts. Four of these 
patients underwent combination coronary artery bypass grafting (autologous) with 
bioprosthetic valve insertions in the same procedure; three were porcine valves, and 
one valve was constructed from bovine pericardium. These patients became 
symptomatic at 0, 15, 65 and 135 months after their surgical procedures (mean 53.75 
months). One patient underwent a non-valvular cardiac surgical procedure – 
resection of an atrial myxoma – with bovine pericardium used as a patch material, 24 
months prior to CJD symptom onset. Both patients who received bovine pericardial 
materials had post mortem examinations, with findings typical of sporadic CJD. 
 
Five patients were identified who are believed to have received allografts. One patient 
received seven corneal transplants, between three and 20 years prior to symptom 
onset. One patient received a transplanted kidney, two years prior to onset of 
symptoms; the organ was donated by a living relative, who has not to date been 
referred to the NCJDRSU.  Three patients were identified who underwent procedures 
during which it is suspected dura mater graft material may well have used; two of 
these were neurosurgical procedures, the third was a skull base surgery performed 
under the ENT (ear, nose and throat) surgical speciality.  These three procedures were 
performed 21, 26 and 40 years before symptom onset. The procedures were recorded 
as “transanthral ethmoidectomy and repair of CSF leak” (surgery to repair CSF leaks 
commonly used graft material); “left modified radical mastoidectomy (graft used)”; 
and “excision of frontal laceration, suturing of bones, artificial dura”. Further clinical 
and (where available) pathological details about each of these patients are provided 
below.  
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Table 3.3: NCJDRSU sCJD 2010-2015 Cohort. Tissue and transplant procedures, 
organs or tissues involved, data sources, patient numbers, year range between 
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Additional transplant connections: 
On searching for additional transplant procedures undergone by sCJD patients 
referred to the NCJDRSU between 1990 and 2016, but not included within the 2010-
2015 cohort, who were classified as either definite or probable cases, four additional 
whole organ transplant or tissue allograft recipients were identified. One liver 
transplant, one heart transplant, one renal transplant and one corneal graft. Several 
autologous grafts were also identified, but these are of no relevance to this work. On 
comparing to the dates of the corneal transplant procedures for the individual from 
the 2010-2015 cohort, there were no occasions when any other sCJD patient received 
another organ which might have been sourced from the same individual donor 
within the same or adjacent years.  
 
Clinical phenotypes of the three suspected dura mater graft recipients: 
The first suspected dura mater recipient was 57 when she became symptomatic. She 
had suffered a head injury aged 31 and underwent neurosurgery with a transanthral 
ethmoidectomy and repair of a CSF leak. She recovered well, and had no other past 
medical history other than a short depressive illness 3 years prior to clinical 
symptoms, and from which she made a full recovery. She experienced a two month 
neuropsychiatric prodrome with anxiety, paranoia, social withdrawal, followed by a 
rapid cognitive decline with dysphasia, myoclonus and visual hallucinations. She 
died 4 months after onset of symptoms. When reviewed by the NCJDRSU clinician 
late in the disease course, she had developed some cerebellar findings on 
examination. EEG, MRI and CSF examination were all typical of sporadic CJD, as 
were neuropathological changes at post mortem. 
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The second suspected dura mater recipient was not seen in life by the NCJDRSU 
clinician due to the death of the patient before arrangements could be made to visit. 
MRI brain in life showed changes suggestive of sCJD with typical basal ganglia DWI 
high signal. The family agreed to meet the NCJDRSU clinician as a “late visit” after 
post mortem results became available confirming findings typical of sCJD. The 
patient was 67 when he became symptomatic of a rapidly progressive cognitive 
decline with memory and language deficits. He developed myoclonus and ataxia, and 
died 5 months after symptom onset. He developed mastoiditis 21 years prior to 
symptom onset and underwent a mastoidectomy with an unspecified graft material 
used. 
 
I reviewed the third suspected dura mater graft recipient shortly after starting in the 
NCJDRSU. She was a 63-year-old woman who experienced a 10 month progressive 
cognitive decline, presenting with frontal behavioural changes, apathy and 
hypersomnolence. She developed dizziness around the fifth month, followed by 
ataxia, myoclonus and dystonic posturing. Around the ninth month of her illness, she 
deteriorated acutely with unilateral stroke-like motor deficits, and was found to have 
developed two acute intracerebral haemorrhages on CT brain. She progressed rapidly 
from that point towards akinetic mutism, before her death. At the age of 22, she 
sustained a skull fracture in a road traffic collision, for which she underwent 
neurosurgery including the usage of artificial dura mater graft. Investigations in life 
included a non-specific EEG with encephalopathic changes, MRI evidence of high 
basal ganglia DWI and FLAIR signal, as well as gliosis in the region of her 
neurosurgery, and areas of microhaemorrhage suggestive of amyloid angiopathy. 
CSF markers were typical for sCJD. Post mortem examination revealed changes 
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Clinical phenotype of the corneal transplant recipient: 
I met the family of the corneal transplant recipient after the patient’s death; she had 
not been referred to the NCJDRSU in life. She was a 72-year-old woman who 
experienced a 3 ½ month rapidly progressive dementia which presented with 
dysphasia, frontal behavioural changes, and shortly afterwards ataxia and cortical 
visual impairment. She deteriorated rapidly, developing myoclonus, dysphagia, and 
subsequent akinetic mutism. EEG and MRI were both typical of sCJD. CSF was not 
analysed, and there was no post mortem examination. Her corneal transplants were 
initially for Fuchs’ corneal dystrophy, but she had problems with corneal graft 
rejection and infection, leading to successive reoperations. 
 
Clinical phenotype of the kidney transplant recipient: 
The renal transplant patient was a 67-year-old woman who experienced an 8 month 
progressive illness with early hypersomnolence. Around 3 months into the illness, 
more overt neurological symptoms manifested, with unsteadiness, dizziness, 
followed a month later by falls, overt ataxia, low mood and visual blurring. By month 
6 she became paranoid, obsessive and confused, and bedbound, with choreiform 
movements. She developed perseverative behaviours and a sweet tooth, as well as 
visual hallucinations and misperceptions, and continued to deteriorate rapidly. She 
had received a renal transplant from her daughter 2 years prior to symptom onset for 
an IgA nephropathy. Her daughter (the donor) was present at the visit by the 
NCJDRSU clinician. Investigations in life included positive CSF 14-3-3 protein, and 
MRI changes suggestive of frontal cortical ribboning. She underwent post mortem 
examination which demonstrated typical sCJD changes only. 
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Neuropathology: 
9 of the 11 recipients of either allografts (including the cases discussed above) or 
xenografts underwent post mortem examination. Each post mortem identified typical 
changes for sCJD, including on immunocytochemistry. There were no unusual post 
mortem features identified to indicate any prion pathology other than sCJD. In 
addition, amyloid angiopathy and intracerebral haemorrhages were seen in the third 
probable dura mater graft recipient as described above. For those patients in whom 
genetic analysis was performed, their codon 129 status correlated with the 
neuropathological phenotype, as would be expected in sCJD (100).  





Consideration of data quality and completeness: 
In comparison to the (other, predominantly non-transplant) surgical procedures 
examined in Chapter 4, the GP record and family data reported similar numbers of 
procedures (for reference, for non-transplant surgery, GP data reports almost four 
times as many procedures as the family questionnaire). This may have occurred 
because of the memorability of transplant procedures (when compared to other 
surgical procedures). Most families try to rationalise as to why their relative 
developed CJD and would consider the implications of the donated organs. 
 
The two data sets did not show total concordance; the most obvious discrepancy 
occurred in the allograft category, where the family questionnaire data reported only 
half as many procedures as were identified from the GP record data of the same 
patients. Two of the “missed” procedures in the family data occurred for the patient 
who received the corneal transplants, as her family had found it very difficult to keep 
track of how many grafts the patient had received; during the interview, they 
produced their best guess, and they were reassured that we would seek confirmation 
from the GP record. Such omission is unsurprising. Due to the coding strategies 
developed for the surgical category classification process, one operation was split into 
two entries on the GP data set (which is why there were 11 procedures after removal 
of duplicates despite 12 GP record reported procedures). The other three “missed” 
procedures in the family data were the three suspected dura mater graft recipients. 
For the two suspected neurosurgical uses of dura, the family reported neurosurgery, 
but were not aware of, or did not recall, the graft usage; the situation was similar for 
the patient who underwent skull base surgery, as the family were aware of the 
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surgery, but not graft usage. The variations between the two data sources supports 
the usage of both to try to minimise omissions. 
 
Chapter 4 uses the same data set, and discusses the methods used to try to improve 
the completeness of the data set, and some reasons why a small proportion of data 
was not available. Discussion of this topic is more relevant to that chapter, and it is 
not repeated here. For those patients where no family or GP data was available, it is 
possible we may have missed a patient who had undergone relevant transplant 
surgery; it is also possible that a transplant recipient might have not been diagnosed 
with sCJD, and never been referred to the NCJDRSU. Given the small numbers of 
potential overlapping recipients of other organs from the same donor, missing even 
a single relevant case would prevent this study from identifying a positive 
connection. Incomplete case acquisition is unavoidable, while incomplete data 
acquisition might become addressed in the future if health records ever become 
digitised, centralised, and stored indefinitely – however, the past failures of large 
scale NHS IT projects do not inspire much confidence that this will occur in the near 
future.  
 
Summary of key results: 
Among the 2010-2015 cohort, 43 relevant procedures were identified with reported 
(or suspected) tissue or organ transplantation, involving 34 patients. This study 
identified five patients among the cohort who are believed to have received 
transplanted organ or tissue from human sources, including one patient who received 
a kidney transplant, one who received seven corneal transplants, and three patients 
who are suspected to have received dura mater grafts. Five patients received 
xenografts during cardiac surgery, four of these tissue heart valves (three porcine, 
one bovine), and one a bovine pericardial patch. These cases are considered further 
below. 
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Several types of procedures which are of no risk of sCJD transmission were also 
extracted, including autologous transplants, artificial grafts, and spurious data; these 
cases are not discussed further. The kidney donor’s organ was harvested in life, 30 
years prior to onset of symptoms – the recipient has not been referred to the 
NCJDRSU and given the protracted time interval between donation and symptom 
onset, it is unlikely that the donor was infective at that stage. 
 
Allograft recipients – suspected dura mater grafts: 
The records for the three patients who are suspected to have received dura mater graft 
materials in two neurosurgical and one ENT procedures are limited, and it was not 
possible to obtain information to determine whether Lyodura® or another brand of 
cadaveric dura mater graft was used, or whether a non-cadaveric derived substitute 
graft material was used, for example a purely artificial (206, 207) or autologous 
substitute. Although the term “artificial dura” was located in the GP notes for one 
patient, without being able to determine exactly which graft material was used, we 
cannot be certain that this guarantees this was not a cadaver-sourced graft, only that 
it makes autologous grafting unlikely (208). The term “artificial dura” has been used 
to describe processed graft materials which were still originally cadaver-derived, and 
those cadaver-derived dura grafts were in widespread usage around the time of this 
procedure. As was seen in the xenograft results, bovine tissues were sometimes used 
for grafting requiring connective tissues (such as repairs to the dura), with bovine 
pericardium either used directly or produced following extraction of collagen from 
the pericardium and manufactured into dura graft substitutes; such grafts may also 
be termed “artificial dura” (209). Typically bovine pericardium was used in cardiac 
surgery, but it has been used in neurosurgery (210). The choice of graft material was 
dependent on the surgeon and material availability.  
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These three suspected dura graft procedures were performed 21, 26 and 40 years 
before symptom onset, in 1991, 1984 and 1973 respectively. In 1987, B Braun 
Melsungen AG instituted an additional sterilisation step in the production of 
Lyodura®, immersing the graft material in sodium hydroxide, reducing the 
infectivity of any PrPSc in the material. There have been fewer cases of iatrogenic CJD 
associated with Lyodura® formulated after the addition of this step. Lyodura® usage 
stopped around 1992 (192, 211). Although it might seem that one of the procedures 
occurred after the addition of sodium hydroxide, the shelf life of Lyodura® was 5 
years (and indeed some appear to have been used beyond this) (82). It is possible, 
therefore, that all three suspected dura mater recipients may have received Lyodura® 
grafts manufactured prior to the implementation of sodium hydroxide processing, 
and if so, they would then represent iatrogenic CJD, albeit transmitted through a 
recognised means of transmission. 
 
One of these three patients had the surgery outside the UK, and while we attempted 
to access health records internationally through communication between the 
NCJDRSU and the local surveillance system, our international colleagues were 
unable to locate any operation notes. In one of the UK cases, the hospital notes had 
been destroyed in a flood, and the (still retained) theatre log books did not contain 
any details about the graft materials used. For the remaining case we were also unable 
to obtain further details, and it is believed the records have been destroyed. After 
careful discussion of each case with Professor Will in the NCJDRSU (two cases by 
colleagues prior to my employment at the NCJDRSU, one by me), it was felt given the 
lack of definite evidence of cadaveric dura mater grafting for each of the three 
patients, that they should remain coded as sCJD, rather than being recoded as iCJD 
(see Appendix 2 for diagnostic criteria, including iCJD). If any of these cases did 
represent iatrogenic transmission, two would have occurred towards the upper end 
of the known spectrum of the incubation period following CNS exposure to PrPSc, 
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and the third (where artificial dura was used) occurred 40 years after usage of this 
material, outside the range recognised for dura mater iCJD (73, 82). 
 
As explained in Chapter 1, more than 60% of dura mater graft iCJD has occurred in 
Japan (83). The Japanese CJD surveillance system have invaluable experience within 
this subset of iCJD, and have described particular clinical and pathological 
phenotypes in a subset of dura mater graft CJD cases which would be unusual in 
sCJD. These features include a prolonged isolated cerebellar ataxic syndrome at onset, 
the detection of florid plaques at post mortem, and non-concordant features when 
comparing the patient’s codon 129 polymorphism on genetic testing to expected 
codon 129  status on the basis of neuropathological phenotype at post mortem (202-
204, 212). Were any of these features to be present in any of these three patients, this 
would have provided some evidence to suggest they represent dura mater related 
iCJD; however, none of the three patients had any of these features. The work in Japan 
does indicate that many dura mater iCJD patients have more typical sCJD-like 
presentation and pathology, so the absence of such features in these three individuals 
is inconclusive. 
 
During the 2010-2015 period, I visited a fourth patient who was believed to have been 
exposed to dura mater grafting during ENT surgery on the middle ear. This 
individual was not included in the data set (or results) for this study, as the case was 
classified as possible CJD on the diagnostic classification in use at the time (rather 
than the probable or definite classification required to be included when the cohort 
was generated – see Appendix 2). If the recent revision to the diagnostic classification 
was used in this thesis, incorporating RT-QuIC results (the Euro CJD classification, as 
discussed above on page 106, rather than the 2010 modified WHO diagnostic criteria), 
then this patient would be classified as a probable sporadic case, and would then have 
been included in this cohort. This patient’s family reported that he received some 
graft material in 1980 as part of a reconstructive process to repair damage to his 
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middle ear, 34 years prior to symptom onset, and within the time window where 
Lyodura® was used, prior to the sodium hydroxide preparation. The surgery was not 
performed in the UK, and the CJD surveillance system of the country where the 
surgery occurred were unable to locate any operative details, so again, unfortunately 
we cannot be certain whether or not dura mater graft was used in this surgery, as 
other (non dura mater) materials were also used in similar procedures in this time 
window. This individual did not have a clinical course similar to that reported in the 
Japanese iCJD subset, and did not have a post mortem. 
 
Allograft recipients – corneal transplants: 
The patient who received 7 corneal transplants is of considerable interest. It is worth 
noting that the temporal spacing of the 7 procedures indicates the corneal grafts must 
have been from 7 different donors. As discussed in the introductions of both this 
thesis and this chapter, corneal graft transmission of CJD has been reported in at least 
2 patients (179). The family of the corneal transplant patient reported during the 
interview that the Ophthalmologist who operated had commented that one of the 
later transplant surgeries required a deeper resection of the prior, failed graft, and a 
more extensive graft than would be typical for such procedures. Due to the anatomy 
of the eye, the anterior structures do not come into contact with retina, but the deeper 
the graft, the greater the chance of including contamination by posterior eye material, 
such as retina; regarded as a high risk tissue for transmission of CJD (89). 
 
Corneal grafts are usually used within four weeks of harvest (213). Other solid organs 
must be used more rapidly. These time constraints allowed for comparison of the year 
entries for when this individual underwent each graft against the list of organ 
transplants received by other patients seen by the NCJDRSU since 1990 to look for 
other transplant being performed in the same year, or adjacent years (in case the 
transplant surgery occurred near the beginning or end of calendar year, as the 
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NCJDRSU surveillance database only contains whole year values (rather than specific 
dates) about surgical procedures). The process for this comparison is explained 
extensively in Chapter 4, as it is very similar to the space-time association assessment. 
Harvested organs and tissues are distributed geographically widely, so it was not 
reasonable to filter the transplant procedures on the basis of location. There was no 
evidence of any connection between the corneal transplant recipient and any other 
sCJD organ recipients, for each of the 7 graft procedures that this individual 
underwent.  
 
As was mentioned in the introduction to this chapter, the majority of corneal donors 
do not donate other organs (88%) (173). This reduces the potential to identify a 
connected case of a whole organ recipient being identified. If a similar proportion of 
this patient’s corneal grafts came from donors who donated only corneas, the 
population of other recipients of organs from the same donors might be only 
approximately 7 other cornea recipients (from each donor’s other eye), and perhaps 
one of these donors might have also donated whole organs, which are, on average, 
donated to 3 recipients. The number of “co-recipients” is likely to be reduced further 
by the observation that only around ⅔ of harvested corneas are implanted. With such 
small numbers, combined with the rarity of transplantation transmission of CJD (with 
only two accepted cases – dura mater and pituitary hormone cases aside), it is likely 
that the sensitivity of the method used in this study in detecting pairs of iatrogenic 
transmission is extremely low. 
 
The work by Maddox et al. suggested that in the US, they should expect to see one 
case of sCJD developing by chance in a corneal transplant recipient approximately 
every 18 months (179). This figure was calculated on a sCJD incidence of 1 
case/million population/year. The incidence of sCJD in UK data is thought to be 
around 1.8 cases/million/year. Corneal transplant procedures in the UK number 
around 10-fold less than the US, and as a crude approximation, therefore, we might 
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see a similar case of sCJD in the UK every 8 ⅓ years. A single observed case in this 
cohort is not unexpected, therefore. The identification of this patient offers little more 
than “unproven association”, to quote Hogan et al. in their correspondence (214) in 
relation to Rabinstein’s corneal transplant CJD case report (182) (listed in Table 3.1). 
 
Allograft recipients – renal transplant: 
This individual’s kidney was donated by her daughter, who was present at the visit 
by the NCJDRSU clinician. Her daughter was asymptomatic of any neurological 
disease at the time of the interview, and has not since developed CJD and been 
referred to the NCJDRSU. This organ transplant is not related to the subsequent sCJD 
development by the recipient. 
 
Xenografts recipients: 
There is no known naturally occurring (or intensive farming induced) porcine prion 
disease (although animal studies have indicated that pigs may be susceptible to BSE 
PrPSc inoculation, particularly direct injection to the brain (215), there was no known 
dietary transmission of BSE to pigs), and therefore the porcine valve recipients are 
highly unlikely to have xenograft associated transmission of any form of CJD. Bovine 
tissues could conceivably be contaminated by BSE prion, although both patients who 
received bovine pericardium underwent surgery considerably after the cessation of 
the BSE epidemic in the UK, and bovine pericardium is sourced from non-UK cattle 
(216). Both these patients had post mortem examinations, with findings typical of 
sporadic CJD and their codon 129 polymorphism status correlated with the 
neuropathological features as would be expected; there is no suggestion that they 
could have had variant CJD. Neither bovine nor porcine material is a potential vector 
for tissue transplantation transmission of sporadic CJD between human patients.  
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Limitations of the method: 
The process reviewing the extracted database of named surgical procedures is an 
inherently flawed means of identification of all transplanted materials, particularly 
for non-whole organ tissue grafting. Neither the GP record nor family questionnaire 
collects detailed information about the nature of any surgical procedure than the 
name of the operation, and the classification of surgery type. On occasion, the GP 
record includes whether autologous material was used, but in the cases of spinal and 
orthopaedic surgery, for example, the operation name never includes what material 
may have been used, for example, to help to cement a prosthetic joint in place, or fix 
two vertebrae. We lack sufficient data, therefore, to know whether synthetic cements 
or donated bone graft may have been used, meaning any patient undergoing such 
procedures could be exposed to allograft material, and this would not be recorded in 
the NCJDRSU database. Similarly, tendon graft materials may be missed. Even in 
cases where grafts are recorded, the details of type of those grafts often are not 
available, as was evident in the suspected dura mater cases. There is no “gold 
standard” data set to compare to quantify any missed graft procedures. 
 
It is far less likely that we missed any other whole organ transplantation among the 
patients for whom data was obtained, as mentioned above, these tend to be highly 
memorable procedures and the name of the surgical procedure explains the 
transplanted organ, meaning the recording of such procedures in medical records 
(and onward coding to the NCJDRSU database) is also likely to be reliable.  Some 
xenografting may have been overlooked if not listed in the procedure name as part of 
the data extracted from the NCJDRSU database, or in a procedure where such 
grafting may not be commonplace.  Bovine pericardium was used in fields outside 
cardiothoracic surgery (the surgical category covering all identified uses found 
among the cohort in this study); some procedures performed by specialities including 
gynaecology, ophthalmology and ENT surgery (216), particularly in reconstructive 
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procedures, but no non-cardiothoracic usages were identified within this patient 
cohort.  
 
Potential improvements and future work: 
This slightly circuitous way we have looked for transplant or tissue transmission of 
CJD could be avoided if it became routine practice to perform brain biopsy or CSF 
analysis on all non-living donors, but any such change in policy requiring further 
samples could potentially reduce the uptake of organ donation. On observation of 
family behaviours around the topic of post mortem in patients suspected to have 
sporadic CJD, many families are very resistant to the idea of any procedure which 
requires accessing brain tissue, even when their loved one may have expressed a 
desire to be an organ donor. Many families and individuals are very protective 
against any intrusion to the face or head after death, more so than other body regions 
– this is reflected by the choice of many UK organ donors to opt out of corneal harvest 
while accepting other organ donation (author’s personal observations on discussion 
with friends, colleagues and family). Any such compulsory post mortem analysis 
would come with ethical difficulties in the event of a positive result – the timeframe 
for turnaround of neuropathological and biochemical tests on brain or CSF would 
mean any harvested organs would already have been transplanted into their 
recipients before results were available. A positive result would force the recipients 
to be informed of their new “at risk” status for the future development of CJD, and 
some might request that their organ be removed – at least for those individuals where 
organ replacement therapy (such as dialysis for renal transplant recipients) was 
available, or an alternative organ donor could be found. Indeed, this has already 
occurred in the UK, with a patient developing symptoms of sCJD shortly before 
death, symptoms which were incorrectly believed to represent brain metastases prior 
to later neuropathological confirmation of sCJD (217). These two factors mean any 
change to current donation practice would seem unlikely to be accepted, unless it had 
a positive protective benefit for those individuals who were about to receive 
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potentially contaminated organs. Future improvements in assays such as the RT-
QuIC (which currently offers high sensitivity and specificity for the detection of sCJD, 
but requires at least 5 days to produce a result in the NCJDRSU laboratory) to 
improve speed of production of results, and access of alternative tissues such as the 
olfactory mucosa (218), potentially avoiding the need for brain tissue or lumbar 
puncture, might not only begin to offer more timely screening, but also be better 
accepted by families around the time of organ harvesting. The group of donations 
where this would be likely to have the earliest benefit would be the heart beating 
brain-dead donors, where suitable swabs and samples could be obtained prior to 
organ harvest. 
 
To try to identify other allograft and xenograft recipients would require review of the 
operative notes for every surgical procedure for each patient thought to have sporadic 
CJD, rather than the current approach of identifying procedures thought likely to 
include graft materials.  When hospital records are accessed by the NCJDRSU, these 
are usually those from the hospital where the individual was diagnosed and referred. 
Patients that have moved from one region to another many have had operations in 
multiple other hospitals, and on moving, any earlier notes might become inactive and 
over time be destroyed – unlike the medical records from General Practice, which 
tend to follow patients.  An alternative would be a prospective register of graft 
recipients, with that information passed to the NCJDRSU to cross check against our 
patient group.  Such a register would probably require support from the graft/implant 
manufacturers, and would risk breaching patient confidentiality, but there would be 
an arguable public health benefit from better record access.  
 
There exists no formal process for the NCJDRSU to look into potential transplant 
transmission of sCJD, in contrast to the ability to explore high risk surgical procedures 
(through the public health/health protection teams) and blood transfusion (through 
the TMER (1, 2).  Such a formal structure would need to review the source of all 
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materials transplanted into any sCJD patient, to determine the recipient of any 
material donated by any sCJD patient, and thereafter to access and review the other 
party’s medical records to look for evidence of sCJD, follow them up for subsequent 
symptom onset, and also to identify any other at risk individuals who may have 
received potentially contaminated tissues or organs.  A prospective follow up of this 
type would improve the likelihood of identifying any potential organ or tissue 
transplant associated transmission of CJD compared to the method in this study. A 
look back study of this sort has previously been performed, but only of a single case 
of a vCJD patient who received a liver transplant (57); this would be a useful direction 
of further work for the cornea transplant patient seen in this study. 
 
Implication of increasing donors/donation: 
As illustrated in Figures 3.1 and 3.2 earlier in this chapter, organ donation in the UK 
has doubled over the last two decades. As the number of recipients is likely to follow 
a similar trend, there will be an increasing population of individuals at exposed to 
potential organ transplantation associated CJD transmission, and more opportunities 
to identify connections between recipients if they indeed exist. At the same time, with 
a larger population of organ recipients, the number of chance occurrences of sCJD in 
this group will also increase. It may be difficult to disentangle any future organ 
transmission of CJD from the increased noise of any chance occurrences. 
 
Future directions in organ transplantation: 
It seems that induced pluripotent stem cells have been hailed as a panacea for almost 
every medical condition over the last decade. Something that was once a science 
fiction dream – growing an individual a cloned replacement organ which would not 
require immunosuppression – may start to become reality in coming decades (219, 
220) At that stage, organ harvest from donors may no longer be required. Until that 
point, the potential for iatrogenic transmission of prion diseases remains.  




There is no robust evidence of tissue or transplant associated transmission of CJD 
among the sporadic CJD cohort from 2010 to 2015 inclusive. Three patients are 
suspected to have received dura mater graft, but due to limitations in retained data, 
we are not certain for two of the cases whether dura mater grafts were definitely used, 
while for the third we know only that “artificial dura” was used, but not whether this 
was cadaveric derived, purely artificial or potentially even a xenograft. The recipient 
of artificial dura became symptomatic 40 years after the neurosurgery, which is 
outside the range reported with dura mater iCJD (73, 82). A fourth individual is 
mentioned in the discussion, who was not included as part of the studied cohort, may 
also have been exposed to dura graft material for middle ear surgery. It is impossible 
to know how to interpret each of these cases, due to the lack of contemporary 
operative records to indicate the materials used. They may each represent missed 
iCJD cases, incorrectly classified as sCJD, or the procedures they have undergone may 
not be relevant. 
 
The recipient of 7 corneal transplantations could potentially also represent corneal 
transplant associated iCJD, but the only means of exploring this with NCJDRSU data 
is to look for other patients who might also have received transplant materials from 
the same donor among the sCJD cohort. No such other patients were identified. 
Additional studies to access the health records and death certificates of the donors 
would be of benefit in determining their cause of death, and whether any had 
neurological symptoms; it would also be of interest to track the recipients of any other 
organ or tissue recipients from the same donor. These adaptations to the study would 
mirror the TMER process (as described in Chapter 2). At present, there is no such 
structure to facilitate this style of look back study. An estimate of the incidence of 
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sCJD among corneal graft recipients indicates this patient could represent such a 
chance development. 
 
The cases identified at most represent circumstantial evidence that some iCJD 
transmission may be missed among the sCJD cohort. The NCJDRSU will continue to 
monitor for future transmission through organ transplantation, but the methods used 
are unlikely to be particularly sensitive for what is thought to be a rare occurrence. 
 
Whether or not transplanted materials continue to transmit CJD and are hidden 
among suspected sCJD cases, a quote from Dr Peter Bennett’s work concerning risks 
of vCJD transmission in bone and tissue (188) is of equal relevance to sCJD and 
expresses an appropriate sentiment on which to close this chapter: 
 
“such transplants are carried out with good reason. Many procedures are life-
saving, and the rest are substantially life-enhancing. Any response to the 
theoretical risk of [CJD] transmission must be set against the clinical need for 
such procedures. Many tissues and organs are already in short supply, 
shortages that are often compounded by the need to match would-be 
recipients with suitable donors. There is often no alternative to the use of 
donated tissue: even where artificial alternatives are available (as with heart 
valves, for example) these are not always clinically suitable. In this complex 
area, there is thus the necessity to balance the potential risk of [CJD] 
transmission against the clear and immediate risk of not being able to 
undertake essential procedures.” 
  








Evidence for Surgical Transmission of sCJD 
  





Sporadic CJD is the most common human prion disease. It is believed to occur as a 
result of a spontaneous protein misfolding event of the PrPC host protein into PrPSc. 
The PrPSc then propagates by causing remaining PrPC to undergo the same 
misfolding, as per Prusiner’s prion hypothesis (4). This leads to neuronal loss, 
symptom onset and subsequent death. The abnormally folded PrPSc protein is 
believed to be the infectious particle that transmits CJD between individuals in 
iatrogenic CJD and Kuru (transmitted by implantation of contaminated material, 
either by medical instruments and tissue or human derived hormones, or in the case 
of Kuru, by endocannibalism as a funeral rite) (75). These known vectors of 
transmission of CJD raise the possibility of person-to-person transmission as a 
potential cause for a small number of cases currently believed to be sporadic, through 
interventions such as surgery.  
 
The recognised causes of iatrogenic transmission of CJD include dura mater grafting 
(with Lyodura® being the most implicated brand), cadaveric pituitary derived 
human growth hormone, cadaveric gonadotropin hormone, and a few instances 
related to neurosurgery, EEG depth electrodes and corneal transplantation (73); the 
evidence for tissue and transplant transmission is covered in Chapter 3, while the 
EEG and neurosurgical cases are considered below. Additionally, variant CJD has 
been transmitted via contaminated blood from donors who were in a pre-clinical 
phase of variant CJD (58); further details about blood and blood product transmission 
of CJD can be found in Chapter 2. 
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In the cases of known surgical instrument transmission of sCJD, EEG depth electrodes 
were used in an individual symptomatic of CJD, and reused in two individuals 2 and 
3 months later, who subsequently themselves developed CJD (91). Will and Matthews 
provided further details relating to non-EEG electrode neurosurgical transmission of 
CJD which occurred between two individuals operated on the same day of a 
neurosurgical list, with the second individual becoming symptomatic 17 months after 
the surgery; and also in two other individuals, who both underwent operations 2 
weeks after surgery on two other CJD patients, before becoming symptomatic 19 and 
40 months later (94). There are also numerous reports where patients with CJD have 
undergone neurosurgical procedures in close proximity, but where causality has not 
been definitely proven, such as Stricof et al. who reported two patients who 
underwent neurosurgery, using the same drill, but different drill bits – the first 
patient was symptomatic at the time of surgery, while the second patient was 
diagnosed with CJD 6.5 years later (221). This may be similar to the cases of corneal 
transplantation in sCJD patients, discussed in Chapter 3 and by Maddox et al. (179). 
 
Other than blood transmission of vCJD, and corneal transplantation, the other 
recognised transmission routes for iatrogenic CJD are all associated with central 
nervous system (CNS) contact or contact with pituitary hormones (while not strictly 
a CNS tissue, the pituitary is located within the skull vault, in very close anatomical 
proximity to CNS). This reflects the distribution of PrPSc in affected individuals – the 
host PrPC is mainly located in the CNS, and the PrPSc, after transformational change, 
largely remains there.  The Advisory Committee on Dangerous Pathogens 
Transmissible Spongiform Encephalopathy (ACDP TSE) subgroup summary on 
tissue infectivity in CJD has already been discussed in Chapter 3 (89): see Table 3.2. 
To recap a little, the high risk tissues are brain, spinal cord, cranial nerves, cranial 
ganglia, the posterior segment of the eye and pituitary gland. Other tissues can also 
express lower levels of PrPC, and have been found to contain PrPSc in sCJD patients, 
and as such spinal ganglia and olfactory epithelium are considered medium risk, 
Page 139 of 220 
 
while other tissues are classified as low (rather than no) risk. It is known that PrPSc 
can adhere to surgical equipment, and it may be highly resistant to traditional 
sterilisation techniques (74, 125, 126). The combination of non-CNS PrPSc and this 
resistance to sterilisation means it could be theoretically possible for sCJD to be 
transmitted between patients by contaminated surgical instruments. 
 
Prior epidemiological studies of sporadic CJD have produced mixed results with 
respect to surgery as a risk factor; most of these have been case-control studies and a 
review of these follows. Those with positive results have implicated differing sets of 
surgical procedures as potentially being associated with surgical transmission of 
sCJD. 
 
Collins et al. found in their Australian case control study there was an association 
between surgery in general and sCJD development, but no specific association 
between specific anatomical operation sites and sCJD (222). Ward et al. found that in 
the UK sCJD cohort, a history of having undergone surgery was associated with 
increased risk of sCJD, but that this association was only found in the miscellaneous 
category of surgical procedures, including skin stitches, removal of lumps and 
bumps, and nose and throat operations (19). Mahillo-Fernandez et al. used the Danish 
and Swedish sCJD cohort and found an association between surgery ≥ 20 years earlier 
and sCJD. Their surgical category data indicated peripheral vessels, the 
gastrointestinal tract and gynaecological surgery were associated with increased 
sCJD risk. Hamaguchi et al. assessed the Japanese cohort and found no association 
between surgery and sCJD; the authors also comment that 4.5% of sCJD patients 
underwent operations after onset of clinical symptoms without any special 
precautions, but with no identified transmission of sCJD related to these procedures 
(223). 
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de Pedro-Cuesta et al. reported different positive risk factors for sCJD development 
among surgical categories in specific time windows (224). For example, retinal and 
optic nerve surgery was a risk factor at ≥ 1year, and peripheral nerve and skeletal 
muscle surgery between 10 and 19 years prior to disease onset. Two later papers from 
the EUROSURGYCJD Research Group (again from Danish and Swedish registry 
data) add interesting nuance and complexity to the understanding of surgery as an 
epidemiological risk factor in sCJD. Cruz et al. suggest that particular surgeries are 
more common in sCJD patients around the time of (and shortly prior to) disease onset 
– potentially exposing others to contaminated instruments (225). de Pedro-Cuesta et 
al. suggest that there may be an age-dependent transmission in sCJD: i.e. a young age 
at exposure to surgery – and therefore potentially contaminated instruments – may 
increase the possibility of transmission of sCJD. An age-dependent model is one 
hypothesis for the pattern of cases seen in vCJD, which predominantly affects 
individuals exposed to BSE in early life. 
 
A recent systematic review by López et al. highlights many of the issues concerning 
surgical risk factors for sporadic CJD (226). This review found some evidence that 
cardiac and vascular surgery might be associated with sCJD risk, but also postulated 
that this could represent a prodrome of vasculopathy prior to clinical disease onset, 
rather than the cardiac surgery necessarily representing a means of transmission. The 
authors explain that the published case control papers are of low quality of evidence, 
and are generally at risk of being affected by bias – including recall bias – or of being 
impacted upon by poor matching of controls. For example, it is typical to obtain the 
history of surgery from a family member in patients suspected to have sCJD, but most 
control histories relate to the individual him or herself answering the questionnaire.  
 
Other than case control studies, the other type of publication covering potential sCJD 
surgical transmission is that of case reports. Most case reports are unable to prove 
causality in any observed pair of CJD cases with a neurosurgical connection, and the 
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best option is to track individual instruments, and if possible, perform animal 
transmission experiments with any implicated instruments, such as was reported by 
Gibbs et al. with depth EEG electrode transmission of CJD (227). López et al. also note 
that relatively few incidents have been published relating to re-use of neurosurgical 
instruments after earlier usage in a patient subsequently identified to have CJD, but 
that several such incidents have been reported by colleagues at international prion 
conferences without having been published (221). 
 
The López et al. paper features a comprehensive details concerning different surgical 
types implicated as potential sources of surgical transmission for CJD, including 
forest plots (figures 4 and 5 in their paper) covering the different surgical types 
indicated as potential risk factors for CJD transmission in 13 different case control 
papers (226). I have not reproduced their work here to avoid plagiarism or copyright 
issues. Overall, the epidemiological results are inconsistent, but trend towards 
identifying some association between (different) surgical procedures and sCJD; 
however, the quality of evidence across these studies of low, and there is high 
susceptibility to bias in each. 
 
Aims: 
I aimed to look for any evidence that some UK sCJD definite or probable patients 
referred to the NCJDRSU between 2010 and 2015 (inclusive) may have been exposed 
to potentially contaminated surgical instruments which had been used on another 
patient within the cohort under study. Additionally, I looked for any suggestion that 
any UK sCJD definite or probable patient referred to the NCJDRSU since 1990 may 
have come into contact with potentially contaminated surgical instruments used in a 
high risk surgical procedure which were used on another sCJD patient between 1990 
and 2015 inclusive. 
  




UK CJD Surveillance and NCJDRSU data collection: 
The process of UK CJD Surveillance and the initial steps of data collection are covered 
in Chapter 3 on tissue and organ transplant associated CJD. In summary, data is 
collected via a family questionnaire, completed by the NCJDRSU clinician at the time 
of meeting the patient and their family. As one of the NCJDRSU clinicians I saw many 
of the patients included in this cohort, and completed family questionnaires for all 
the patients I visited. After obtaining permission from the family (or patient, when 
possible), the GP records are accessed after the death of the patient, these are 
reviewed and each surgical procedure entered onto a GP questionnaire. Procedures 
from both data sources are entered into the NCJDRSU clinical surveillance database 
by administrative staff. 
 
Part of the data entry procedure, both when completing the questionnaires and on 
entry of the data into the clinical surveillance database, includes allocating a code of 
operation category: neurosurgery, eye, ear, abdominal, orthopaedic, gynaecological,  
tonsillectomy, carpal tunnel, spine/disc, appendicectomy, transplant, 
cardiology/cardiovascular, stitches, nose/throat, varicose vein, dermatology/minor 
lumps, vasectomy/testicular, breast, plastics, dental surgery, urological, and other 
(including endocrine, salivary gland surgery, lymph node excision not covered by 
other categories, bone marrow aspiration, nail surgery, and thoracic surgery).  A copy 
of the guide for procedure classification used at this stage is included in Appendix 1. 
In considering the instruments likely to be used in each surgical procedure, these 
categories are not necessarily mutually exclusive; some categories may potentially be 
totally subsumed within another (i.e. appendicectomy can be incorporated into 
abdominal surgery, vasectomy/testicular is a form of urological surgery, and 
tonsillectomy into the nose and throat category), for these groups, the smaller 
Page 143 of 220 
 
category was recoded into the parent category. Details about which categories were 
moved within others can be found in table 4.3 of the results section. 
 
There is also the potential for overlap between categories for certain procedures, 
either through the usage of the same sets of instruments within more than one 
category (such as some neurosurgical spinal procedures using the same instruments 
as certain spine and disc surgeries, since operating near the spinal cord requires 
access past the same bony structures operated on within the spine/disc category). 
Some of these type of associations are possible because more than one group of 
surgeons may perform similar surgery (for example carpal tunnel surgery may be 
performed by either orthopaedics or plastics, or both depending on local policies and 
individual skills/training); instrument sets may be shared between such procedures 
and other surgical procedures performed by the same group of surgeons, and we lack 
sufficient detail to know which surgical specialty performed each particular 
procedure in each hospital across the UK. There is the potential for these sorts of 
overlaps to occur between the following pairs of surgical categories listed in Table 
4.1. 
  
Table 4.1: Surgical categories in data set with potential category overlaps  
Surgery category Potential overlap with 
Neurosurgery Spine/Disc, Carpal tunnel 
Orthopaedics Spine/Disc, Carpal tunnel 
Spine/Disc Neurosurgery, Orthopaedics 
Plastics Carpal tunnel 
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The potential for such overlaps between categories means that, rather than separating 
all procedures by the category, and then looking for “surgical time-place 
associations” (see below) only within each category, it is necessary to look beyond the 
category, considering potential overlaps as listed above, for example between carpal 
tunnel and neurosurgery, and possibly others not listed above but arising due to 
variation in local practices.  The number of possible inter-category overlaps were 
potentially very high, and resulting analyses numerous and complex. Including them 
was considered beyond the scope of this thesis, but will be considered in future 
analyses.  
 
An additional issue is that the categories are entered into the NCJDRSU database as 
a result of human interpretation of the procedure name, and some operations may be 
coded into one category where with only a minor change to the operation name they 
could be coded within another, this is particularly problematic with multistage 
operations (such as combined coronary artery bypass grafting and aortic valve 
replacement, often performed as a single procedure, where the latter aspect could 
potentially be coded as a transplant procedure, instead of cardiothoracic surgery). 
 
Data extraction: 
The process of creation of the 2010-2015 sCJD cohort data set is covered in the 
methods section of Chapter 3. The same data set was used for both chapters. In 
summary, a list of all surgical procedures undergone by every patient in the cohort 
as reported by either the GP record data or the family questionnaire was extracted to 
a Microsoft Excel spreadsheet from the NCJDRSU database. The extracted data 
included the name of the procedure, the code of operation category described above, 
the year of the procedure, the name of the hospital, and town where the procedure 
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occurred. The recording of year of procedure only, rather than an exact date, has 
limitations for subsequent utility of this data, discussed below.   
 
“Surgical time-place association”:  
For this study, I examined the operative histories for all patients classified as either 
probable or definite sCJD cases (by WHO diagnostic criteria) referred to the 
NCJDRSU between January 2010 to December 2015 inclusive to look for potential 
links between the surgeries performed. 
 
The potential for infectivity of surgical instruments will be dependent on the degree 
of exposure to prions of the instrument, the sterilisation procedures the instruments 
undergo, and the number of times they undergo usage and sterilisation cycles 
between patients. While data on instrument sets is tracked in theatre records, this 
information is not usually entered in the medical records of those individuals 
undergoing surgery. Unfortunately, we are unable to collect this data concerning the 
usage of individual instruments; therefore, we are unable to show any direct link 
between sCJD patients in terms of the specific instruments used in their operations, 
and the number and nature of any sterilisations those instruments underwent 
between those operations. As such, it was necessary to develop a surrogate measure 
of interconnection between cases. The implications of this surrogate measure are 
analysed in the discussion section below. 
 
I defined a “surgical time-place association” as an occasion when two different 
patients underwent an operation within the same surgical category, or overlapping 
surgical categories (as listed above) within one year of each other, at the same 
hospital.  The period of +/- 1 year was selected to accommodate the limitations of the 
data accuracy, since the NCJDRSU database recorded operative dates only by year; 
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for example, it was conceivable that a pair of patients might have undergone surgery 
on 31st December of year X, and then the other patient on 1st January of year X+1, with 
only one day separating them – consideration of surgeries based on only the same 
calendar year would therefore fail to recognise such a pairing as an association. Prion 
infectivity after adherence to surgical instruments is unlikely to be limited by time to 
a single year of storage, but without the ability to track the number of usages and the 
sterilisation techniques deployed on each instrument, a +/- 1 year range was decided 
to be the most reasonable approach in attempting to use this data – a wider range 
became too unwieldy to assess for surgical time-place associations. However, in the 
known cases of neurosurgical instrument and EEG electrode transmission of CJD, 
patient exposures to instruments were separated  by weeks or months, meaning this 
date range may be reasonable (91, 94).  
 
Errors in data extraction and efforts to improve completeness: 
For the purposes of the following paragraphs relating to the errors in the data 
extraction process, “we” represents the NCJDRSU. On two occasions, I prematurely 
processed the data looking for surgical time-place associations with incomplete 
datasets, due to failing to try to ensure the data set was as complete as possible. On 
the first occasion, an error in the parameters entered into the NCJDRSU database 
when extracting to the Excel spreadsheet resulted in approximately one third of cases 
having no surgical data extracted; once identified, this was relatively easy to rectify. 
The second premature analysis was performed prior to later efforts made to ensure 
completion of the dataset – I was missing data for those patients for whom we had 
not yet obtained the GP records, or for those patients for whom we had only recently 
received those records, but had not yet completed a GP questionnaire (the step 
immediately prior to data entry to the NCJDRSU database). This constitutes a form 
of data lag, and affected approximately 30 GP questionnaires (unfortunately, I did not 
keep exact records of this step contemporaneously). 
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After rechecking the list of cases within the 2010-2015 cohort, and crosschecking 
against those for which I already had data, I again attempted to obtain the remaining 
GP notes, arranging for an administrative colleague to contact the relevant practices 
and central storage sites or local health boards once more. For the cases where we had 
the GP notes, but had not completed the questionnaire, I completed the questionnaire 
and entered the data into the Excel spreadsheet (before passing the now-completed 
questionnaire for data entry into the NCJDRSU database). All data obtained by 1st 
December 2016 was included in the final analysis.  To ensure there had been no 
patients omitted in the list generated by the extraction process from the NCJDRSU 
database to the Excel spreadsheet, for each CJD patient for whom the extracted data 
set listed no operations in either one, or both of the family or GP questionnaire, I 
rechecked the paper copies of both questionnaires, and the scanned GP notes, to 
ensure that this patient had indeed undergone no surgical procedures.  A sample of 
10% of the CJD patient identification numbers for which data existed within the 
spreadsheet were randomly selected and rechecked by reference back to their GP 
notes, GP questionnaire and family questionnaires to ensure there were no missing 
procedures – no such omissions were identified among the sample. 
 
Data cleaning: 
All surgical procedures listed throughout the extracted data were manually checked 
to ensure they were appropriately coded, with corrections made when spurious 
entries were located – this most commonly occurred for family questionnaire entries, 
where the visiting NCJDRSU clinician occasionally recorded a procedure in the 
incorrect category, failing to follow the procedure classification document, or in 
multistage operations featuring aspects which might be coded into different 
categories. 
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One issue with the extracted data set was the variability of the reported hospital 
name.  This occurred not only through typographic errors in data entry, but, for the 
GP data, in the cases of hospitals where the trust and hospital may not share the same 
name, and (potentially for both data sources, but more so for the family data) for 
hospitals that have changed name at some point in their operating period.  For 
example, Kent and Canterbury Hospital (in Canterbury, Kent) could be entered as its 
correct name, or Canterbury Hospital, or East Kent Hospitals University NHS 
Foundation Trust, or minor combinations of this final iteration; another example is 
Hope Hospital, which was renamed to Salford Royal Hospital in 2008, while its trust 
was called Salford Royal Hospitals NHS Trust until it was renamed to Salford Royal 
NHS Foundation Trust in 2006, resulting in 4 variations on the name.  Other hospitals 
changed site and often name, while moving staff and equipment between the sites, 
such as Frenchay Hospital, in Bristol, which closed in 2014 and transferred patients, 
staff and services to Southmead Hospital.  Finally, some trusts have moved certain 
departments between their hospitals as building developments have been completed, 
such as the movement of urology from St Bartholomew’s Hospital, Smithfield, 
London, to The Royal London Hospital, Whitechapel, London after the opening of 
their new building in 2012. 
 
The dataset extracted included a variable of the reported town for each procedure, 
but this field was variably entered; for example, Salford Royal had town entries listing 
either Salford or Manchester, and for the operations when the trust name was used, 
but for a trust spread across multiple sites, the town field typically (but not reliably) 
listed the main site of the trust, rather than the correct one (for the example of East 
Kent, the main site was Canterbury, but the other hospitals in the trust, Queen 
Elizabeth Queen Mother and William Harvey Hospital, are situated in Margate and 
Ashford respectively).  To overcome the issues around naming, for any procedure 
where the trust was listed rather than a hospital, I returned to the original data and 
repopulated this field if possible; for each operative entry, I ensured that a 
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standardised, consistent town entry for each hospital site was entered, overwriting 
the ambiguous or incorrect ones for every procedure listed, if possible.  Entries where 
the hospital and town could not be accurately identified were removed before 
assessing for time-place associations.  It was not possible to track the movement of 
each department within each multi-site hospital trust, but many such movements 
remained within the same town, and it is hoped this would largely overcome this 
potential pitfall. 
 
The use of the town variable was necessary due to overlap of identically named 
hospitals in more than one location in the UK; for example, Lister Hospital could refer 
either to Chelsea or Stevenage, Royal Victoria Hospital might indicate any of Belfast, 
Blackpool, Folkestone or Newcastle, or St Mary’s Hospital could be in Colchester,  
Harborough, London, Luton, Manchester, Newport or Portsmouth. 
 
“Surgical time-place association” method: 
In order to identify the potential overlap of procedures across the differing surgical 
categories (as discussed above) it was necessary first to sort the data by operation 
category (for later convenience when reviewing the final output), then operation year, 
then the standardised operation town.  This produced a list of surgical procedures 
performed within each town, and within each town further sorted by year of the 
operation. If there were multiple surgical procedures in the same year and town, then 
they would be sorted by operation category. Reversing the order of the last two sorts, 
so that the data was sorted by town first and then year would have produced a list of 
surgery by year, but without the town clumping persisting (although within a given 
year, the town category would be alphabetised); it would not have been possible to 
analyse the data to look for time-place associations in this order.  With the data sorted, 
I then worked systematically to remove extraneous data – i.e. any which contained no 
procedures involving surgical time place associations.  The first step was to separate 
Page 150 of 220 
 
the data (using blank rows in Excel for easy visualisation) into blocks by town, with 
further separations inserted any time there was a gap of a year or more with no 
procedures.  A considerable number of operations could be removed from the list for 
having no neighbours within the same or adjacent year, in the same town, or when 
runs of consecutive procedures involved only a single patient, rather than at least a 
pair of patients.   
 
This process left clusters of operations occurring within one year of at least one other 
operation, involving more than one patient and in the same town.  These clusters 
were further broken down and re-sorted by the hospital name, and occurred in 
sufficiently small groupings to make those occasions where multiple alternative 
names (both correct, incorrect and historical) of the same hospital had been used 
readily identifiable to avoid missing an association.  Further sifting to remove 
extraneous pairs could occur on the basis of the surgical category, with care required 
in any procedure (as listed above in the methods section) where there was the 
potential for overlap of surgical instruments between categories – in these 
circumstances, clinical knowledge was required to contemplate whether there may 
be shared instruments. 
 
After producing the list of surgical time-place associations (TPAs), these were 
cumulated into categories more in keeping with the clinical practice of different 
surgical teams, rather than the categories used in data entry; for example, bringing 
“ear” and “nose and throat” and “tonsils” into an ear, nose and throat (ENT) category, 
reflecting UK surgical specialties. One issue was the inclusion of vascular surgical 
procedures within the cardiac or cardiothoracic surgery category – the associations 
identified involving these procedures were considered individually, moving non-
cardiac and non-cardiothoracic vascular surgery into the adapted varicose veins and 
vascular surgery category.  The details of these reclassifications are listed in table 4.3. 




The process of using both family and GP data to identify potential TPAs was intended 
to minimise occasions where incomplete data might mask such an overlap between 
patients, accepting a degree of duplication. It became apparent on beginning to collect 
the results together that there were substantial differences in the numbers of reported 
procedures between the two sources, and that there are likely to be inaccuracies in 
the family reported data. Using only these two sources of data on surgical procedures 
means there is no “gold standard” to use to try to assess the accuracy of each data 
source. My first attempt to present this data therefore separated the TPAs into three 
parallel results sets, with tables and graphs for each. After feedback, I have 
reorganised the results section to include the complete data on TPAs in Table 4.5, and 
using figures to plot the percentages of TPAs and surgical procedures by specialty for 
both data sources together (Figure 4.2), and when using only the GP data set (Figure 
4.3), as this is considered more likely to be accurate. The family only data set has been 
moved to Appendix 5. 
 
Removal of non-clinically plausible surgical time-place associations: 
One further level of scrutiny of the surgical time-place associations was to remove 
those that were deemed to be clinically implausible. A pair of procedures would not 
be regarded as clinically plausible if they would not use the same instrument set. For 
example, within the abdominal category were numerous endoscopic procedures 
(oesophago-gastroduodenoscopy, colonoscopy or sigmoidoscopy), as well as non-
endoscopic surgical procedures (either laparoscopic or open surgical procedures, 
such as cholecystectomy or appendicectomy). A TPA would be plausible if it occurred 
between two endoscopic procedures, or between two non-endoscopic procedures, 
but implausible if it contained one endoscopic procedure and one invasive surgical 
procedure. 
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Similar such pairs of implausible surgery could occur in the cardiac and 
cardiothoracic surgery categories, between endovascular/angiographic procedures 
(e.g. coronary angiogram and angioplasty) and open cardiothoracic surgery (e.g. 
coronary artery bypass grafting); in orthopaedics between arthroscopic and open 
surgery; in gynaecology between colposcopic/hysteroscopic procedures and more 
open gynaecological surgery (e.g. hysterectomy, oophorectomy); and in urology 
between cystoscopic/ureteroscopic procedures (e.g. transurethral resection of the 
prostate) and open urological surgeries (e.g. nephrectomy). In TPAs where at least 
one procedure was listed containing both open and endoscopic (etc.) procedures, 
naturally, this was regarded as a plausible TPA paired with either sort of procedure 
as the other half of the pair. Any TPA containing an entirely non-invasive procedure 
(such as stereotactic radiosurgery) was also discounted as clinically implausible. 
 
Two further aspects of the TPAs were considered when looking at plausibility for 
transmission of CJD. Any TPA containing at least one procedure which used only 
single use instruments or equipment were deemed implausible, such as insertion of 
a nasogastric tube, ascitic drain, etc. Any procedure which may use either single use 
or reusable instruments was presumed to use reusable. In TPAs where the two 
procedures occurred on adjacent years, and the later procedure was performed on an 
individual already symptomatic of CJD, this TPA would be discounted on grounds 
of temporal implausibility; this occurred only infrequently, but included procedures 
such as percutaneous endoscopic gastrostomy (PEG) or radiologically inserted 
gastrostomy (RIG) tube insertion on a dysphagic CJD patient, if another patient had 
already undergone an endoscopic procedure in earlier years. The limited accuracy of 
only recording year of procedure, and relatively small number of procedures 
performed on symptomatic CJD patients mean this accounted for few exclusions on 
clinical implausibility. Any TPAs where where both procedures were performed after 
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symptom onset in each patient were also discounted on grounds of temporal 
implausibility. 
 
High risk surgical procedures: 
As an additional element to this study I extracted from the list of surgical procedures 
all operations which were likely to include contact with high risk materials, as per the 
ACDP tissue classification (89). These predominantly relate to neurosurgical 
procedures around the brain, cranial nerves, cranial ganglia, spinal cord and 
ophthalmological procedures involving the posterior segment of the eye 
(predominantly retina). This extraction was performed manually on reviewing all 
surgical procedures, using the neurosurgical and ophthalmological categories as an 
indication, before removal of procedures which were unlikely to contact such tissues 
(e.g. ophthalmological procedures contacting only anterior eye tissues); I looked 
through the remaining categories for any procedures classified in other categories 
which also included high risk tissue exposure. 
 
I compared this to a list of high risk procedures undergone by all earlier definite or 
probable sporadic CJD patients reviewed by the NCJDRSU since the creation of the 
Unit in 1990 until January 2010 (the start of the cohort for this study). When planning 
to perform this additional aspect of analysis, it was believed that a list of such high 
risk tissue procedures already existed as part of ongoing work at the NCJDRSU. This 
was not the case, so identification of these procedures required extracting all surgical 
procedures for earlier cases from the NCJDRSU database, and then review of the 
operation details for consideration of whether they may involve high risk surgery, 
just as for the 2010-2015 cohort. For historically older cases reviewed by the 
NCJDRSU, the questionnaires used to collect information from patient families were 
different, and we did not request GP notes for patients prior to 2000; there were no 
additional efforts made to increase data completeness as per the 2010-2015 cohort, as 
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too much time had passed. Not all these surgical procedures were coded by category 
in the same manner as the later cohort, meaning it would have been insufficient 
simply to review procedures coded as neurosurgical or ophthalmological. 
 
With the two lists generated, I looked for surgical time-place associations among high 









The dataset used was the same as in Chapter 3 concerning tissue and transplant. I 
have repeated a few key numbers of cases and procedures in the results here for 
completeness. 579 cases of definite or probable sporadic CJD were reported to the 
NCJDRSU between January 2010 and December 2015 and were included in this study.  
Both family questionnaire and GP record data were collected for 488 patients (84.3%), 
family questionnaire data only for 49 patients (8.46%), GP record data only for 3 
patients (0.518%) and no data for 39 patients (6.74%). One, or both, data sources were 
available for 540 (93.3%) of the cases. (See Figure 3.5 in Chapter 3, which illustrates 
the data sources.) A total of 4437 surgical procedures were reported from both data 
sets (median 7, range 0-56), 1326 from the family questionnaire (median 2, range 0-
12), and 3111 from the GP records (median 5, range 0-54). A summary of these figures 
follows in Table 4.2.  
 
Table 4.2: Procedure and patient number by data source. 
Data Source Either or both GP 
/family data 
GP data only Family data only 
No. of patients 540 491 537 
No. of procedures 4437 3111 1326 
• Mean (2 d.p.) 8.22 6.34 2.47 
• Median 7 5 2 
• Mode 5 5 2 
• Range 0 - 56 0 - 54 0 - 12 
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The individual who underwent 54 GP listed procedures (explaining the wide range 
in Table 4.2) is of some interest, and I still remember meeting her family 
(unfortunately, she died before we were able to meet her) – her family reported only 
two procedures, but they were recorded as “numerous endoscopic procedures” and 
“numerous gynaecological procedures” – there had been so many that they had lost 
track, due to her extensive past medical history. 
 
Coding errors and adjustments: 
Three errors in coding were identified: a lymph node surgical procedure being 
misclassified as breast surgery, circumcision misclassified as urology (the procedure 
classification document in Appendix 1 indicates it should be put into the stitches 
group), and a flexible laryngoscopy being miscoded as abdominal, rather than nose 
and throat.   
 
Incomplete data: 
The 2 family reported events of surgery type “not known” (listed in Table 4.5) were 
removed from the data set before further analysis (each family reported that they 
knew their relative had had some sort of procedure around a particular time at a 
particular hospital, but without the details of the surgery; both families were also 
quite vague about the year of the procedure). 
 
Similarly, there were 46 surgical procedures in the combined data set without a value 
for year of the procedure (1.0% 1 d.p.), 18 (0.6% 1 d.p.) for the GP data and 28 (2.1% 1 
d.p.) for the family questionnaire data; these operations therefore could not be used 
for linkage. 
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For 443 procedures, it was not possible to identify the hospital where the procedure 
had occurred (10.0% 1 d.p.), 356 (11.4% 1 d.p.) for the GP data and 87 (6.6% 1 d.p.) for 
the family data.  This included procedures where the hospital was not known or there 
was insufficient data to identify the hospital (e.g. “a British military hospital”), 
procedures performed at GP surgeries or at the patient’s home, and procedures were 
there was an unresolvable ambiguity: for example, “Nuffield Hospital” might be 
recorded, which is a chain of private hospitals spread across many sites. I attempted 
to resolve such ambiguities by review of the GP record, and returning to the original 
entry in the family questionnaire, to see whether additional information was available 
– it was, rarely – but for the majority such efforts proved fruitless. 
 
These areas of incompleteness were not mutually exclusive, as for several data 
omissions other details were also absent (therefore the total number of incomplete 
data listed in these paragraphs is greater than the number of operative procedures 
removed from the original set, before subsequent analysis). The total remaining 
operative entries after these exclusions, therefore, was 3977 (89.6% of the original 
4437) using both data sources. 1225 of the 1326 family questionnaire procedures 
(92.4%) were usable, and 2752 of the 3111 GP record procedures (88.5%).  Where 
possible, incomplete data was still used for indicating the total number of procedures 
in each operative category, as the majority still included the name of the surgical 
procedure and therefore its category. 
 
 
Category summation and corrections: 
24 events were identified within the cardiology/cardiothoracics category which were 
better classified as vascular surgery (procedures including carotid endarterectomy, 
femoral bypass surgery and abdominal aortic aneurysm repairs).  
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Table 4.3 (overleaf) shows the number of procedures from each surgical category, and 
the amalgamation process for surgical procedures which needed to be moved from 
their original reported surgical category. The mathematical symbols of + and - are 
used to indicate the addition or removal of particular categories (and therefore 
surgical procedures) from each row. The exact values are not of great interest, but it 
seems sensible to show the division of surgical procedures among both the NCJDRSU 
procedure classification in usage (see Appendix 1), as well as the final category 
sorting used in this work when the results are presented below, particularly if some 
aspect of this work was to be repeated in the future. For any category where I did not 
move or cumulate procedures, the figures can be seen in Table 4.5 without any 
additional processing (the totals from Table 4.3 are also included in Table 4.5). 
 
Category overlaps: 
The category overlaps identified earlier which could form time-place associations 
with more than one other category proved to be an unfounded concern, as (within 
the dataset studied) none of the time-place association events included carpal tunnel 
surgery, even on the later reanalysis following the late suggestion of a potential 
overlap between neurosurgery and carpal tunnel (a category which might then link 
to either plastics, orthopaedics, or neurosurgery). Nevertheless, it was important to 
be aware of the potential when sorting for time-place associations, as without such 
consideration, if such overlaps had occurred, they would have been overlooked.  
With such overlaps excluded, the carpal tunnel and spinal categories were 
incorporated into orthopaedics when cumulating the total number of procedures. 
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Table 4.3: Number of procedures by category where category correction required, 
including subcategory numbers, and totals after category correction 








Ear + Nose and throat 
+ Tonsils/adenoids 
51 + 135 + 56 22 + 24 + 43 29 + 111 + 13 
Total 242 89 153 
Abdominal (GI) 
+ Appendicectomy 
957 + 83 194 + 56 763 + 27 
Total 1040 250 790 
Orthopaedic 
+ Carpal tunnel + Spinal 
550 + 40 +24 248 + 12 + 8 302 + 28 +16 
Total 614 268 346 
Cardiology/cardiothoracic 
- Vascular 
176 -24 65 – 9 111 -15 
Total 152 56 96 
Dermatology/minor 
lumps & bumps + Plastics 
+ Stitches 
494 +21 + 147 97 + 9 + 65 397 + 12 + 82 
Total 662 171 491 
Varicose veins + Vascular 
 
51 + 24 16 + 9 35 + 15 
Total 75 25 50 
Vasectomy/testicular 
+ Urological 
106 + 223 33 + 51 73 + 172 
Total 329 84 245 
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Figure 4.1: Flow diagram of data sources for identification of TPAs 
 
 
Figure 4.1, above, illustrates the numbers of procedures and patients and their data 
sources, and the total number of TPAs. The numbers of patients with no surgery do 
not sum as some of those with no family reported surgical history have data from the 
GP questionnaire, and vice versa. 
 
Procedures and TPAs from both data sources: 
163 potential TPAs were identified from the 4437 procedures, reducing to 110 after 
assessment of clinical plausibility (see below). 147 (27.2%) of the 540 patients for 
whom data was available were included within one (or more) of these clinically 
plausible TPAs. 
 
Procedures and TPAs from GP questionnaire only: 
3111 procedures were identified, and from this data, 63 clinically plausible TPAs were 
identified, involving 121 unique patients, 24.6% (1 d.p.) of the 491 patients in the 
cohort for whom GP record data was available. 
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Procedures and TPAs from family questionnaire only: 
1326 procedures were identified, with 15 TPAs found within this group; these 
included 27 unique patients, 5.0% (1 d.p.) of the 537 patients for whom family 
questionnaire data was available. 
 
Exclusion of clinically implausible TPAs 
53 TPAs from the combined data set were removed on grounds of clinical 
implausibility. These 53 exclusions are summarised in Table 4.4, overleaf. 
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Table 4.4: Exclusion of TPAs on grounds of clinical implausibility. 
Surgery Category No. TPAs 
excluded 
Reasoning 
Neurosurgery 2 All procedures performed after symptom onset, 
at least 3 of 4 using single use items (patients seen 
by me) 
Ophthalmology 4 Each TPA pair includes at least one purely laser 
(non-contact) surgical procedure 
ENT 1 Single use instruments only for nasogastric tube 
insertions 
Abdominal 14 2 TPAs excluded as all 4 patients already 
symptomatic of CJD 
12 TPAs excluded for pairs including 1 
endoscopic and 1 open procedure 
Orthopaedics 14 1 TPA temporally implausible (second procedure 
after symptom onset) 
13 TPA pairs with 1 arthroscopic and 1 open 
procedure 
Gynaecology 10 Each pair includes 1 purely colposcopic/ 
hysteroscopic and 1 open procedure 
Cardiology 
/Cardiothoracics 
7 1 TPA temporally implausible (second procedure 
after symptom onset) 
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TPAs by surgical specialty: 
Table 4.5 (overleaf): Number of surgical procedures by category and time-place 
associations. I have presented the results for time-place associations using data from 
both family and GP questionnaire sources, then using data only from the family 
questionnaire, and also using data only from the family questionnaire. The rationale 
for this is explained in the discussion section.  I have also attempted to represent the 
number of TPAs per surgical procedure in each category graphically, and have 
included Figure 4.2 showing TPAs using the combined data source, and Figure 4.3 
showing TPAs using the GP data only. The equivalent chart using family data is 
included in Appendix 4 for completeness, but is of limited value to subsequent 
interpretation in the discussion. 
 
The majority of TPAs occurred in the abdominal and gynaecological surgery 
categories: 55 and 26 (respectively) of the 110 associations from the combined data 
(see Figure 4.2); and 35 and 17 (respectively) of the 63 TPAs when using the GP 
records only (see Figure 4.3). 
 













































































































































































































Neurosurgery 27(0.6) 14 (1.1) 13 (0.4) 2 0 0 0 
Ophthalmology 245 (5.5) 84 (6.3) 161 (5.2) 5 1 1 0 
Ear + Nose and 
throat + 
Tonsils/adenoids 










69 55 5 35 
Orthopaedic + 















36 26 1 17 




152 (3.4) 56 (4.1) 96 (3.1) 9 2 2 0 
Dermatology/ 
minor lumps & 








13 12 2 7 
Varicose veins + 
Vascular 




329 (7.4) 84 (6.3) 245 (7.9) 5 5 1 1 
Breast 96 (2.2) 34 (2.6) 62 (2.0) 0 0 0 0 
Maxillofacial 40 (0.9) 13 (1.0) 27 (0.9) 0 0 0 0 
Other 137 (3.1) 41 (3.1) 96 (3.1) 0 0 0 0 
Surgery type not 
known 
2 (0.0) 2 (0.2) 0 (0.0)  0 0 0 0 
Total 4437 1326 3111 163 110 15 63 
Table 4.5 Procedures and TPAs by category 
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Figure 4.2: Percentages of procedures and TPA by surgery type from both data 
sources, sorted by frequency of surgical procedure. Percentages based off 4435 










% of procedures % of TPAs
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Figure 4.3: Percentages of procedures and TPA by surgery type from both data 
sources, sorted by frequency of surgical procedure. Percentages based off 3111 
procedures and 63 plausible TPAs. 
 
 
Family questionnaire vs GP record year reporting: 
Plotting the number of procedures by the final digit of the year for both GP and 
family data in Figure 4.4, overleaf, shows that family reported surgical procedures 
(blue bars) were found at higher frequencies in years ending 0 and 5. The data from 
GP records (black bars) is more even, without such clear peaks at these final digits. 
This provides some evidence that the family reported year variables may be 
inaccurate, calling into question their utility when considering TPAs where year 
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in a table in Appendix 4. As a minor aside, in the NCJDRSU database, the year 9999 
is input when no date is available – on first plotting this data, I failed to remove 
these to the “no year given” row, causing a substantial skewed in the digit 
distribution with an unexpected high frequency of 9, which was then corrected 
before creation of Figure 4.4 below. 
 
 Figure 4.4: Number of procedures by final digit of year 
  
 
These peaks at years ending 0 and 5 are likely to have occurred due to the recording 
of family provided information at the time of the NCJDRSU interview. Based on 
observations I made while collecting around 250 such records while working in the 
NCJDRSU, families often report a surgical procedure happened in a particular 
decade, which would then be recorded by the mid-point of the decade at a year 
ending 5, or otherwise gravitate towards the beginning of a decade as a more 
memorable year. It seems this has occurred for around 150 of the 1326 (11.3%) 
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Family questionnaire procedures GP data procedures
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years from the other data extracted from the NCJDRSU database with the 
information I have available. In some (but not all) cases, the recording clinician may 
document this family uncertainty, and a review of the family questionnaires to look 
at all 389 procedures recorded in years ending 0 or 5 might allow the selective 
removal of some of these estimates, but undoubtedly others will be missed as they 
will have simply been recorded as that year, without any comment or explanation. 
Since it is not possible to know which 0 and 5 year family reported procedures are 
accurate and which are estimates, it is very unclear whether or not the family data 
should indeed be used for assessment of TPAs. This is discussed further in the 
discussion section of this chapter. 
 
Supplemental analysis of high risk tissue surgeries: 
47 procedures involving high risk tissues were identified from the 2010-2015 cohort; 
31 were ophthalmological procedures involving posterior eye structures, while 16 
were neurosurgical. From the earlier group (1990-2009), a further 3834 operations 
were extracted from the NCJDRSU database, from a mixture of data collected from 
families and from GP notes for those individuals for whom these were accessed. 
Among these 3834 operations, 56 additional high risk tissue operations were 
identified, 34 were neurosurgical, one case of pituitary surgery was found 
(classified within the “other” category on the database, although it would be 
arguably more appropriate for this to be considered as a neurosurgical procedure), 
and 21 ophthalmological high risk surgeries were identified. There were 5 surgical 
time-place associations identified among this group. 2 of these associations related 
to retinal (ophthalmological) surgery, and the other 3 were neurosurgical. These 
figures are illustrated in Figure 4.5 overleaf. Details about these associations follow 
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Considerations of data quality and completeness: 
Although efforts were made to ensure the best possible completeness of data for 
this work, these efforts met with only moderate success.  We had both GP and 
family questionnaire data for only 488 of 579 cases (84.2%), and GP records were 
received for 491 of 579 patients (84.8%). 
 
There are several reasons for this incompleteness, including families declining to 
meet with the NCJDRSU visiting clinician; families meeting with the clinician, but 
requesting not to complete (or subsequent destruction after completion of) the 
questionnaire; or, in cases of CJD patients dying before a visit was possible if the 
family then decline a posthumous visit when contacted in due course (some families 
do not wish to engage with the NCJDRSU, especially without any earlier awareness 
of our unit during the life of their loved one). The process of accessing the GP record 
may also have contributed to issues with completeness. Access to the GP record is 
usually only possible after the death of the patient, and this requires tracking the 
notes.  The NCJDRSU will first contact the registered practice, and an issue can arise 
if the family gives the incorrect GP practice details.  The local practice also usually 
holds onto the notes for only a short time after the death of the patient, after which 
they are forwarded to the medical records department of the local trust/health 
board, or a third party organisation on their behalf. If the GP practice does not hold 
the records, then it may take considerably longer to obtain the records, if this is 
possible at all, adding data lag. On occasions, the process goes awry, and since we 
are reliant on external bodies or individuals in helping us to access these records, 
we may not then be able to obtain further information. There can also be a 
considerable delay in sending the records through to us, which in part is 
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administrative, as photocopies are usually sent rather than the original notes, after 
invoices and payment are arranged to cover these costs, but issues relating to 
comprehension of the law and information governance issues can also add 
considerable delay. It is likely that a few of the outstanding GP records will have 
arrived after we closed the data acquisition phase of this work, although the 
majority may never be received. 
 
For the patients for whom we had GP and/or family data, 89.6% of the reported 
procedures had sufficient detail to be usable for assessment of time-place 
associations, caused by 46 procedures not listing a year, 443 procedures listed in 
unknown or unidentifiable hospitals, and 2 procedures listed by the family of 
unknown type. At first, it might seem surprising that the family questionnaire (a 
verbal, recalled survey) yields a higher percentage of data with entries in each field 
(92.4%) – and therefore usable for TPA assessment – than the data extracted from 
the GP notes (88.5%). The difference is not vast, but is likely to occur in part from 
some creative guesswork on the part of the individual being interviewed – once 
they recall that their relative has had a procedure, they may be happy to make 
(educated) guesses about roughly when the procedure occurred and at which 
hospital. 
 
Based on my experiences while collecting this data, such guesses about dates often 
generates ranges or estimates like “early-“, “mid-“ or “late-“ [decade], or “some 
point in the 90’s” (etc.). Guesses about hospitals usually centre around where the 
individual affected was living around that time – families may simply choose the 
local hospital. Such guesswork by families raises concern about the validity of any 
subsequent assessment of time-place association using the family questionnaire 
data.  The issue is illustrated by Figure 4.4 (with the data in Appendix 4), which 
shows the final digit of each year in which every procedure reportedly occurred. 
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The family questionnaire data shows an outlying high frequency of procedures 
performed in a year ending 5 – a value which would be entered by the interviewer 
(or at the point of data entry into the NCJDRSU database) if a family recalled that a 
surgery had been performed in the middle of a decade. A smaller peak is 
identifiable for 0, another commonly selected year for such guesses. These peaks 
indicate that perhaps 150 family recalled procedures may be incorrectly recorded in 
a year ending 0 or 5. 
 
Further concern about the validity of the family questionnaire data for this purpose 
is raised in light of the substantially lower number of procedures identified from 
recall at interview when compared with data from GP notes. Family questionnaire 
procedures makes up only 29.9% of the total number of procedures (4437) in the 
studied cohort. This occurred despite having family questionnaires for 46 more 
patients than the number of patients for whom GP record data is available.  
 
The GP data is unlikely to have false procedures included in a patient’s medical 
record, although a few procedures may be omitted by error, and on occasions the 
GP record may be incomplete (such as when a patient moves practice but their 
record fails to follow them).  For the GP data set, incomplete entries (i.e. those where 
we lack year, hospital or procedure name details) occurred more frequently with 
historically older procedures, usually recorded in handwritten entries in original 
small page size paper notes. Clinician handwriting is notorious, and this was also a 
small factor. While GP surgeries have now moved to an electronic patient record, 
efforts to transfer the original paper notes are of varying quality, and in some cases 
have not occurred. Entries recorded in the GP notes about surgical procedures must 
have filtered through several sources, and could be reliant on the GP surgery 
receiving a discharge letter from the hospital, someone at the GP surgery entering 
this onto the record, and either the original record being available to us at the 
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NCJDRSU, or for the practice to have transcribed that record to the electronic one.  
This chain of events is reasonably complex, with the opportunity for human error. 
The entries in the handwritten notes not infrequently skip pertinent facts such as 
the name of the hospital, as such detail may have been either obvious or 
unnecessary at the time of the recording if a particular surgery only referred patients 
to a single hospital. 
 
Human error also plays a part in the accuracy of data input at the NCJDRSU, since 
extraction from the data sources is not error free.  We make efforts to code 
procedures using the standard template, but certain procedures have been 
miscoded, or included typographic errors. Such errors are likely to have affected 
both family questionnaire and GP record entries into the database equally, and 
while coding errors and hospital/town name typographic errors were corrected 
where identified (and corrections were fed back into the NCJDRSU database for any 
future use), any such mistake on year entry would have been overlooked if the 
incorrect entry was a plausible year. This sort of error is unavoidable unless all 
health records are perfectly digitised. 
 
Implications of missing data: 
Since the hypothesis I intended to explore with this work was that a small number 
of suspected sCJD patients may in fact have developed a form of iCJD due to 
exposure to infective prion material through surgical instruments. Since only very 
small numbers of cases of such transmission have been reported (91, 94), if this 
occurs, it is likely to be a rare event. More than 15% of GP records are missing, and 
within the available data, more than 10% of reported procedures lack sufficient 
detail to be used in analysis looking for TPAs. As such, if any such transmission had 
occurred within the studied cohort, this work may well have missed it. 
 
 




Decisions on utility of potentially inaccurate data sources and duplicate procedures: 
The concerns regarding accuracy of the family questionnaire data highlighted above 
draw into question its use in attempting to identify associations which are reliant 
on accurate time entry (albeit, only recorded to the nearest year). Ideally, an attempt 
to quantify the completeness and accuracy of each data source would allow clearer 
decisions regarding whether or not to use that data.  Such quantification would 
require a “gold standard” third data set, after which statistical comparison could be 
made.  One possible such standard is the Information Services Division Scotland 
(http://www.isdscotland.org/), who keep a surgical register for Scottish patients; if 
accessed, this would provide a small sample of the 579 patients in the 2010-2015 
cohort with a definitive list of surgical procedures, so long as those procedures were 
performed in Scotland.  Further investigation of these data was beyond the scope of 
this thesis, but is being taken forward separately as part of enhanced surveillance 
activities at the NCJDRSU.  
 
Given the suspicion of inaccuracy of the family data, I presented the results of 
procedures and time-place associations in the results section above in triplicate in 
Table 4.4, and graphically for the combined data set of 4437 procedures which has 
generated 110 plausible TPAs, a number likely to include at least some spurious 
TPAs generated by inaccurate family recollection of procedure details (Figure 4.2). 
The GP record only data set of 3111 procedures is suspected to be more accurate, 
and the 63 TPAs identified are more likely to have actually occurred (Figure 4.3).  
 
It is interesting to note on comparing the family and GP sources that the number of 
procedures in each category is consistently lower, other than for neurosurgery. This 
probably represents a recall bias of neurosurgery among patient families, and also 
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highlights that a large amount is forgotten; as a clinician, it is surprising what 
patients may not recall about their own past medical history, and relying on a family 
member adds an additional factor (this was one source of bias in several of the 
epidemiology studies discussed by López et al. (226)). The neurosurgical figures 
were very close in number between both GP (13 reported procedures) and family 
(14 reported procedures) sources, but even with this close number, attempts to 
identify pairs of the identical procedures reported by both sources was unreliable, 
mostly due to variability on year of procedure between the two sources, preventing 
any attempt to remove duplicate entries from the extracted procedure list when 
using the combined dataset in looking for TPAs. I had initially considered 
attempting to remove duplicate entries from the entire data set for each surgical 
category, to try to prevent a single procedure from flagging as two TPAs if the 
details were incorrect from one data source, but with the decision largely to 
discount the family questionnaire data, this is less relevant. 
 
Surgical time-place associations within 2010-2015 cohort: 
The two neurosurgical associations identified (in the mixed TPA analysis) were both 
brain biopsies performed in large, regional neurosciences centres; for each of the 
four procedures involved in these two associations, the biopsy was performed in an 
already symptomatic patient where CJD was considered high in the differential 
diagnosis.  Since the biopsies were performed after symptom onset in each case, 
none of these patients could theoretically have contracted CJD by instrument 
contamination from each other (they each already had the disease) meaning these 
biopsies are not clinically plausible for transmission of CJD. Furthermore, with CJD 
considered in the differential, the operating neurosurgeon should have used single 
use surgical instruments, or quarantined the instruments pending their subsequent 
destruction after neuropathological confirmation of the diagnosis, as per ACDP 
guidelines (228), although occasions where this has not happened have occurred 
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(229). I reviewed 3 of the 4 patients involved in these 2 implausible TPAs (Table 4.4); 
in each of those three cases, the brain biopsy was performed with a high clinical 
suspicion of CJD, in large regional neurosciences centres. During my visits to the 
patients, I discussed with the local Neurology team, including ensuring that 
appropriate health protection measures had been taken during the biopsy. Such 
procedures involving high risk tissues in known sCJD patients are followed up by 
the local health protection team following the NCJDRSU visit to ensure appropriate 
protocols are followed to prevent onward transmission (230). 
 
None of the ophthalmological associations (either plausible or implausible) 
involved invasive surgery of the posterior eye, which might be regarded as high 
risk in terms of tissue infectivity in a patient with CJD. 4 of the 5 were clinically 
implausible (Table 4.4), mostly involving non-invasive procedures such as laser 
macular surgery “paired” with more invasive techniques requiring penetrating 
surgery – such “pairings” will not have shared instruments and were discounted as 
clinically implausible. 
 
For the two associations involving ear, nose and throat procedures, one was a pair 
of naso-gastric tube insertions, both performed after symptom onset (for dysphagia 
approaching the end of the natural disease course of sCJD), and would have used 
single use items only – this TPA was discounted on grounds of clinical 
implausibility (Table 4.4); the other two operations were both tonsillectomies and 
are clinically plausible. However, tonsillar tissue does not include olfactory 
epithelium – the only ENT tissue considered a medium risk tissue in sCJD (89). 
 
All other (non-discussed) associations involved low risk tissues. The distribution 
among the different surgical categories broadly followed the frequency of that 
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category occurring in the procedure list, as can be seen in the charts. Those 
categories where TPAs were not identified were all categories with a smaller 
proportion of the total number of procedures (whether considering the mixed, GP-
only, or family-only data). 
 
As would be expected, limiting the data to look at GP (or family) data only (rather 
than using the mixed data set) not only reduces the number of procedures, but also 
substantially reduces the number of identified associations. While there are too few 
data points to extrapolate a clear trend, it is likely that the number of TPAs would 
not follow a linear relationship with the number of procedures. Indeed, such a 
relationship is indicated in Figures 4.2 and 4.3, as well as Appendix 4, where those 
categories with more surgical procedures have a substantially higher proportion of 
TPAs. Increasing the number of procedures increases the complexity of the system, 
and therefore the number of potential interconnections between individuals. For 
example, although the family questionnaire comprises 29.9% of the total number of 
procedures (1326 of 4437), when used in isolation to look for TPAs, it generates only 
13.6% of clinically plausible TPAs (15 of 110). The GP data comprises 70.1% of the 
total number of procedures (3111 of 4437), and generates 57.3% of the plausible 
TPAs (63 of 110). The remainder require a connection between one GP record 
procedure and one family questionnaire procedure. This concept is similar to the 
“birthday paradox”, where the probability of at least two individuals among a 
random sample sharing a single birthday reaches 100% when 367 people are 
sampled (to allow for leap year 29th February birthdays), 99.9% when only 70 
individuals are sampled, and 50% for 23 people. Whether or not any TPAs 
genuinely reflect surgical transmission of sCJD, there are likely to be chance 
associations where two patients underwent similar surgical procedures within the 
same hospital within the same or adjacent years, and these encounters become more 
likely as the sample size increases, whether from using data from multiple sources, 
or by increasing the size of the studied cohort. 
 
 




Prior to completing the analysis for TPAs, and on considering some of the surgical 
histories I obtained visiting individual patients, I anticipated that I might see many 
TPAs generated by particular individuals who underwent very frequent surgical 
procedures. This was not supported by the observed results. From the mixed data 
set, the 110 TPAs involved 147 individuals, the 63 associations from the GP record 
set involve 121 individuals, and the 15 TPAs in the family questionnaire set involve 
27 individuals. Also of interest, the individual who underwent 52 GP data reported 
surgical procedures did not feature in any of the identified TPAs. Of course, if CJD 
was transferred through surgery, each such association could only transmit CJD in 
one direction (an individual could not both be the donor and recipient of PrPSc in 
the same procedure), so the maximum possible number of individuals involved in 
TPAs who could have developed sCJD as a consequence of iatrogenic exposure to 
instruments contaminated by another patient in this cohort must be no more than 
half of these figures.  
 
The majority of associations identified were seen in abdominal (55 of 110 (50%); or 
35 of 63 (55.6% 1d.p.) using GP data only) and gynaecological surgery categories (26 
of 110 (23.6% 1 d.p.); or 17 of 63 (27.0% 1 d.p.) using GP data only). On reviewing 
these associations, a large proportion of the abdominal TPAs involve endoscopic 
abdominal procedures: 41 of the 55 (74.5% 1 d.p.) abdominal TPAs involved only 
such procedures, or 29 of 35 (82.9% 1 d.p.)  using the GP data only. By their nature, 
these are common interventions, performed as either diagnostic or therapeutic 
procedures. If an abnormality is identified then frequently these lead to serial 
surveillance procedures, or successive treatment procedures of the same 
intervention after a fixed time window. Among the gynaecological TPAs, a smaller 
proportion (5 of 26 (19.2% 1 d.p.) TPAs from both data sources, or 5 of 17 (29.4% 1 
d.p.) when using only GP data) consisted solely of hysteroscopic procedure pairs. 
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Neither the gut lumen nor female reproductive tract is regarded as a high risk tissue 
for sCJD (89), and no prior epidemiological study has identified endoscopic 
procedures as risk factors for the development of CJD (226). Ward et al. did find an 
association between gynaecological surgery and sCJD (231), but the authors 
comment these findings may be affected by bias, and the rarity of CJD diagnoses; 
subsequently, this finding has not been replicated. It may be the case that the work 
in this chapter has simply identified surgeries likely to happen repetitively. 
Nevertheless, endoscopes are difficult to decontaminate (232, 233), something 
which is acknowledged by the British Society of Gastroenterology who recommend 
that endoscopes used on variant CJD patients should be destroyed, or quarantined 
only to be used again on that individual (234), and their potential as an infective 
route of transmission of CJD should not be discounted. 
 
High risk tissue space-time associations from 1990 to 2015: 
The additional 3834 (see Figure 4.5) procedures identified from the 20-year window 
of 1990 to 2009 inclusive seems unexpectedly low, compared to the number of 
procedures – 4437 – obtained from the 6 year period of the studied cohort. This has 
occurred for several reasons. The primary factor is that GP records were not 
collected by the NCJDRSU prior to 2000; given the observation from the 2010-2015 
cohort that the GP record contributed approximately three times as many surgical 
procedures compared to the family data (there is no obvious reason this should be 
substantially different in the 1990-2000 cohort), this is likely to be the most 
significant contributor. Even after 2000, earlier efforts to chase outstanding GP 
records were not as comprehensive as the attempt to ensure data completeness for 
this study. Another, smaller factor is that referral numbers to the NCJDRSU were 
lower in the first few years of the Unit, and increased rapidly throughout the UK 
vCJD epidemic; full details can be found in the NCJDRSU annual report (235), but I 
have also included the graph of referrals (not all of which were patients with CJD) 
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to the NCJDRSU by year in Appendix 6 to show the trends. The number of 
confirmed or definite cases of CJD seen by the NCJDRSU have increased steadily 
until 2003, before dipping and later climbing again, reflecting the peak of the vCJD 
epidemic. In more recent years, the increasing number of referrals may reflect a 
greater investigation of dementia, more ready access to MRI and other diagnostic 
tests, and greater awareness of CJD following vCJD; the gradual growth of the 
population will also have contributed marginally, with more individuals under 
surveillance. 
 
Among the 3 neurosurgical associations listed in Figure 4.5, 2 were the clinically 
implausible associations of brain biopsies performed after symptom onset which 
were discussed above, and only involved patients within the 2010-2015 cohort. The 
1 remaining neurosurgical association included 3 patients, 2 from the 1990-2009 
group, and 1 from the studied 2010-2015 cohort; 2 of the 3 patients underwent only 
brain biopsy, after symptom onset, and as a diagnostic procedure, one in 2006, and 
the other in 2007; since they were both symptomatic, they cannot have conveyed 
CJD to each other. It is likely that appropriate instrument quarantine or destruction 
was followed, but we cannot be completely certain that this was the case, as this has 
happened in the past (229). These two patients were referred to the NCJDRSU, so 
CJD must have been suspected at the time of the biopsy. Patients seen by the 
NCJDRSU are referred to the local public health office at the time of review so that 
issues such as these can be followed up. The 3rd patient (from the 2010-2015 cohort) 
underwent neurosurgical removal of a meningioma in 2008, within a one year range 
of the second patient’s brain biopsy. If appropriate infection control procedures 
were followed (228), overlap of instruments with those used for the second patient’s 
brain biopsy would then be unlikely; furthermore, this individual became 
symptomatic more than 5 years after the neurosurgical procedure, considerably 
longer than the reported incubation periods for neurosurgical transmitted iCJD (73). 
Nevertheless, I have highlighted these patients to my supervisors (since I have left 
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the NCJDRSU), in case any additional efforts to clarify instrument usage can be 
made. None of the neurosurgical TPAs include Middlesbrough General Hospital, 
the hospital implicated in the past CJD brain biopsy incident mentioned above (229) 
(in any case, those potential recipients have been informed they are at risk of 
developing CJD, and I understand are under enhanced surveillance by Public 
Health England). 
 
The 2 eye surgery associations both occurred across adjacent years (i.e. first surgery 
in year X, the second in year X+1). 1 of the 2 occurred in a clinically implausible 
order on the basis of time – i.e. the second procedure was performed upon a patient 
who became symptomatic of sCJD within a year of the procedure, and more than 
10 years before the first patient in the TPA pair (who underwent the earlier 
procedure and would therefore be the potential donor). This association is highly 
unlikely to be of clinical relevance, as it would be expected that a donor expressing 
PrPSc to contaminate surgical instruments must themselves be further along 
pathogenesis of CJD than a recipient of a minute dosage of PrPSc adherent to said 
instruments. If this was to represent iatrogenic transmission, at the point of contact 
with the instruments, the recipient would only then be beginning the cascade of 
PrPC transformation leading to onset of clinical symptoms. It seems highly unlikely 
that the recipient could manifest the disease and die 10 years earlier than the donor. 
No such reversal of order of presentation has been identified in other, known cases 
of iatrogenic transmission of CJD (2, 73, 91, 94). 
 
The other ophthalmological association occurred in a temporally plausible order, 
with the first surgery occurring 7 years prior to symptom onset in the patient who 
became symptomatic first, with the second patient becoming symptomatic 15 years 
after the surgery. This is the only identified high risk tissue space-time association 
which could be of relevance in potential iatrogenic transmission of sCJD from this 
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work, but it is impossible to know whether this TPA represents any more than a 
chance encounter, and this long after the event, it is highly unlikely that it will be 
possible to acquire any potentially contaminated instruments for analysis, if any 
instruments were indeed shared between the two procedures. The only known 
ophthalmological transmission of CJD has occurred in the context of corneal 
transplantation, and is discussed in Chapter 3; the incubation period from corneal 
transplant associated CJD is believed to be between 1-30 years – see Table 3.1 (179). 
Nevertheless, I have highlighted the individuals involved in this TPA to colleagues 
in the NCJDRSU to try to see what records may still remain, and whether this can 
be taken any further. 
 
The number of these high risk surgical procedures is sufficiently small to allow a 
sensitivity analysis using the full date of the procedure to explore what effect using 
a smaller time window than +/- 1 year would have on identifying TPAs. This is of 
relevance given the significantly shorter time interval identified in existing 
neurosurgical and EEG transmissions of CJD, which is more in the range of weeks 
to months, rather than in the same or adjacent years (91, 94). Equally possible would 
be using a longer time period, something that was not possible using the full 2010-
2015 cohort, due an such change substantially increasing the complexity of the 
interconnections when using the larger data set. The NCJDRSU database (and my 
extracted data set) does not include the exact date of any procedure, only the year, 
and the level of accuracy required for such an analysis is therefore not available to 
me at this stage. This would be an area of potential further work, to look through 
the GP records (and any available hospital notes) to see whether exact procedure 
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Limitations of the surgical time-place association method: 
The absence of control data dramatically affects this study. Without control data, it 
is impossible to know whether the observed number of associations are likely to 
have occurred simply by chance, and no statistical analysis of the collected data is 
possible. Surgical time-place association is a surrogate metric which identifies 
potential linkage between cases, the results cannot indicate any firm 
epidemiological connection. Without a control group, this surrogate is of some 
interest, but does not represent a robust tool; the collection of valid control data to 
compare would improve its utility, and would turn this into a case-control study. 
Such control data would require age and sex matched controls, collected regionally 
(perhaps in the same post code region as the individual), and then access to those 
individuals’ GP records. This access would allow retrospective data collection, in a 
manner similar to the access to GP records of the sCJD cases, reducing potential 
bias. It would not be as easy to collect family questionnaire data which would be 
comparable to the studied cohort in this work, unless the family data and a new 
cohort of patients were collected prospectively, otherwise this would be reliant on 
recall significantly after the event for only the control group, and thereby 
introducing significant bias. When the concept of identifying linkage through 
surgery was first discussed, my supervisors had suggested I use historical control 
data collected for earlier NCJDRSU case control studies (19, 42, 231). However, the 
historical nature of this control data means it is not a valid comparator, and any 
attempt to use this as a control for the 2010-2015 cohort would be invalid; this idea 
was discounted. The decision was agreed to attempt this TPA analysis so that we 
could attempt to use the collected NCJDRSU data to look for surgical linkage, 
accepting that the methodological limitations would prevent any hard 
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The 6-year (January 2010 to December 2015 inclusive) time window is a further 
limitation of the study. The greatest theoretical infectivity of a patient with CJD 
must occur at the point when they have the highest load of abnormally folded PrPSc; 
this is offset by clinical presentation and subsequent diagnosis, after which efforts 
would be made to avoid surgery or prevent onward transmission. The greatest risk 
of onward transmission would therefore occur prior to disease diagnosis (225).  If 
infected, any individual undergoing surgery from contaminated instruments could 
take years before they too became symptomatic. Since it is not known what the 
incubation period would be for CJD transmitted by surgical instruments (other than 
in the reported cases of known neurosurgical transmission), we must consider the 
range associated with iatrogenic transmitted CJD, which lies between 19 months 
and 40 years (75). The 6 year inclusive date range was used to ensure the data set 
and time-place association process was workable, but limits the capability of this 
study to demonstrate clinically relevant associations for the majority of the cases – 
peripheral inoculation of small doses of PrPSc on contaminated surgical instruments 
would be unlikely to cause symptom onset in the recipient at the lower end of the 
range of incubation periods (the lower range were associated with cranial 
implantation of contaminated cadaveric dura mater grafts).  
 
Due to the non-linear association between number of procedures and TPAs, 
expanding this method to cover the complete NCJDRSU patient cohort would be 
likely to break the (already labour intensive) time-place association method, while 
the quality (and variability) of the stored data prevents using an automated process 
with this method. As was evident in the high risk tissue assessment which included 
the 1990 to 2009 patients, earlier NCJDRSU records are less complete than those 
from the later cohort; it is also possible (depending on the incubation period) that 
perhaps we have not yet been collecting case histories in the NCJDRSU for long 
enough to identify iatrogenic transmission by surgical instruments – if this occurred 
around the 40 year mark in non-CNS exposures to sCJD PrPSc, we might start to see 
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such transmission from around 2030, if the NCJDRSU is still collecting such data at 
that point.  
 
The method may be susceptible to bias from non-surgical spatiotemporal clustering. 
Prior studies, such as that by Linsell et al. (27) have indicated potential overlaps 
between sCJD patients, particularly when looking many years prior to onset of 
symptoms, and potentially hinting at an environmental trigger for the condition. If 
there was environmental clustering, then patients who lived in proximity would be 
likely to be treated at the same hospitals, potentially leading to identification of 
additional TPAs without any surgical connection. Not all such studies have had 
such positive results; see also the following: (236-238) 
 
Potential future studies: 
I discussed earlier that the observation of time-place associations was a surrogate 
metric, representing the possible reuse of surgical instruments. It is not known how 
many of these TPAs actually involved any instruments being reused across more 
than one patient. If it were possible for the NCJDRSU to access data concerning 
tracking of instruments (which should be possible, particularly since the NICE 
guidance in 2006 strengthening traceability of high risk instruments (239)), a better 
study could be performed, using details of each individual instrument, such as: 
when it was used, in which procedure, and on which particular CJD patient. This 
would allow prospective development of a database of potentially contaminated 
instruments. If an instrument could be connected to two sCJD patients this would 
be a far more tangible association and better epidemiological support of potential 
iatrogenic transmission. It would then be necessary to explore where that 
instrument had been used previously, what sterilisation the instrument had 
undergone between patients, and whether any other individuals had also been 
exposed. Such a structure would be similar to that employed in the Transfusion 
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Medicine Epidemiology Review (TMER) (1, 2), although the numbers of 
instruments could be substantially higher than the number of blood and blood 
products tracked by the TMER. 
 
A very similar process is already undertaken by Public Health England (PHE) who 
monitor patients exposed to potentially contaminated instruments from high risk 
sources (230, 240), although this could potentially be extended to procedures 
involving medium and low risk tissues. Again, there are similarities to the TMER 
which both looks at the outcome of every donated blood product from a CJD patient 
(equivalent to the activities of PHE), and the source of every donated blood product 
to a CJD patient – this potential study could look for connections in cases where 
instruments were not suspected to have been contaminated through contact. If each 
instrument was allocated a unique identifier at a national level such a repeat study 
could be entirely automated, removing a great deal of the human error inherent in 
this study. Such a process might require a national NHS IT system, or at least greater 
collaboration of sterile services departments, infection control teams, public health 
bodies and the NCJDRSU. 
 
On a local level, instrument tracking using barcodes and RFID tags does occur in 
certain centres, and is an attractive source of potential efficiency savings, since the 
tracking process can be automated (241). Much of the literature relating to this has 
been published by the manufacturers of the barcode or RFID systems, but such 
material is still illustrative (242). Similar procedures are being considered by 
Health Facilities Scotland, and if developed, a pilot study looking only at Scottish 
CJD cases could be undertaken as an intermediate future work, perhaps as a proof 
of concept initially. I have not attempted to take this further for the purpose of this 
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thesis, as the primary objective was to explore the existing NCJDRSU data set to 
which I had contributed while working in the NCJDRSU.  
 
 





This study has identified occasions where sCJD patients in the 2010-2015 cohort may 
potentially have encountered surgical instruments which were used on another 
sCJD patient. These occasions appear to occur disproportionately among 
gastrointestinal endoscopic procedures, something not previously reported in case 
control studies, but there are several potential sources of bias which may have 
triggered this. It is suspected that this method simply highlights those procedures 
performed repeatedly. 
 
The limitations of this study, in particular the absence of a control group, prohibit 
the formation of any strong conclusions. It does show that many sCJD cases can be 
linked together by past surgery overlapping in space and time, and that such 
overlaps are not infrequent. Although there is no evidence to suggest any of the 
cases studied were linked epidemiologically, I cannot rule out the possibility that 
this may have occurred, perhaps in association with other CJD cases who were not 
part of the 2010-2015 cohort.  
 
Two potential high risk tissue connections have been identified between the 2010-
2015 cohort, and those patients seen by the NCJDRUS between 1990 and 2010. One 
of these occurred through neurosurgery, but if appropriate ACDP guidelines were 
followed, this would not convey a risk of surgical transmission, and the interval 
between the surgical connection would be considerably longer than the incubation 
period reported from other neurosurgical instrument CJD transmission (although 
much wider ranges of incubation period are reported in other forms of iatrogenic 
CJD, such as dura mater grafting); as such, this connection was deemed unlikely to 
be plausible. Another high risk tissue connection was identified among 
 
 
Page 189 of 220 
 
 
ophthalmolgical surgical procedures, with symptom onset in the potential recipient 
7 years after the surgery; this overlap could be plausible, but its significance cannot 
be determined. 
 
Having reviewed around 250 patients during my tenure in the NCJDRSU, and 
completed questionnaires for each of these patients (many of which are included 
this data set), it is of immense frustration that the collected data is of such little 
utility. Further efforts to obtain appropriate control data, and then subsequent 
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This thesis comprises an introduction (Chapter 1) containing a summary of the 
neuroepidemiology of human prion diseases, with some background information 
concerning relevant animal prion diseases, followed by Chapters 2, 3 and 4 
reviewing NCJDRSU collected data concerning potential blood, tissue and organ, 
and surgical transmission of CJD respectively.  The title of this thesis was agreed on 
discussion with my supervisors at the time of the original research proposal. The 
original intent of the work was to review the data which is acquired by the 
NCJDRSU at the time of each visit to every suspected CJD patient across the UK to 
look for any evidence that at least some of the cases currently classified as definite 
or probable sporadic CJD might represent acquired transmission of CJD. If such an 
acquired transmission had occurred, this could have happened through an 
iatrogenic route of transmission, either through  blood transfusion, transfusion of 
other blood products, tissue or organ transplantation, or through contamination 
and cross usage of surgical instruments; however, other means of acquired 
transmission could conceivably be possible, including by diet, or through some 
unknown environmental transmission. In hindsight, narrowing the title of the thesis 
to reflect the work performed relating to iatrogenic, rather than environmental, 
transmission would have been helpful. 
 
I have described the current evidence relating to potential transmission of sporadic 
CJD in the UK by blood transfusion. Although the first two cases of sporadic CJD 
have been seen in patients with clotting disorders who have received plasma 
products, there was no evidence to suggest that their development of sporadic CJD 
had any relation to their transfusion and blood product history, and it is believed 
that these two individuals may have developed sCJD by chance. A crude estimate 
of the incidence of sCJD among patients with clotting disorders suggested we may 
see other patients in the future. There were significant limitations in accessing data 








The update to the Transfusion Medicine Epidemiological review has not shown any 
evidence that sporadic CJD, unlike variant CJD, has been transmitted by blood 
transfusion. Like the observation of the two patients with clotting disorders, there 
are significant limitations in availability of data, with large amounts of missing data. 
If transmission of sCJD by blood was to occur, this could easily be missed among 
the missing data. The accuracy of tracking of blood products is improving, and the 
TMER will be repeated in the future to look once more for evidence of sCJD 
transmission. 
 
The evidence of tissue or organ transplantation associated transmission in the UK 
in the 2010-2015 definite and probable sCJD cohort is inconclusive. Some 
individuals have been identified who are suspected to have received tissue grafts, 
including possibly Lyodura® dura mater grafts, and they could represent iatrogenic 
transmission of CJD through a known means of transmission. The record 
availability limits our ability this long after surgical procedures to identify which 
graft materials were used, and there are limitations associated with the means of 
data collection in the NCJDRSU (such as the GP record not including sufficient 
operative detail to know whether tissue allograft material was definitely used). A 
single patient who underwent 7 corneal transplants could represent corneal 
transplant iCJD transmission, but there was no evidence among the NCJDRSU data 
set of any other recipient of another organ from any of the corneal donors to add 
evidence of potential transmission; there is no information pertaining to the corneal 
donors. The NCJDRSU lacks a formal process to look into these patients in greater 
detail, and the development of a structure akin to the TMER might allow greater 
understanding about the nature of these potential transmissions. While there is no 
evidence to suggest tissue or organ transplant associated transmission of sporadic 
CJD in this cohort, there are cases of interest which are of indeterminate significance. 
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Once again, with considerable missing data, any such transmission of CJD by tissue 
or organs could easily be overlooked. 
 
The data we collect in the NCJDRSU concerning surgical procedures allowed me to 
identify multiple potential connections where different sCJD patients underwent 
surgical procedures within the same surgical domain, within the same hospital, 
within the same or adjacent year. This assessment of time-place associations 
highlights the potential for sCJD patients to be connected to one another through 
surgical instruments, but we lack the ability to track individual instruments – 
something that would allow far greater understanding of these potential 
connections. The evidence I have produced is of very limited utility as we lack a 
suitable control data set to use for comparison. With these limitations, this study 
cannot lead to any firm conclusions. As instrument tracking becomes increasingly 
automated, there is the potential for future studies to look into this issue with 
greater accuracy and relevance, and with less labour intensive sorting.  As in the 
other areas of the thesis, there is considerable missing data, and surgical 
transmission of sCJD could easily be missed by this method. The NCJDRSU will 
need to ensure we collect a contemporaneous control data set if any such further 
assessment is to be performed. 
 
At the time of the original research proposal, it was intended that a fifth chapter 
(fourth piece of research) would be completed to look for spatiotemporal clustering 
of patients, as a means to look for an evidence of a potential environmental factor 
leading to the development of sCJD. This fifth chapter was not completed as I 
completed my post in the NCJDRSU and returned to clinical neurology before the 
data could be processed and extracted. On discussion with my supervisors, it was 
agreed to leave such work for a future study. Such clustering could be performed 
from the residential address histories routinely collected at the time of the 
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NCJDRSU clinician visit. Such work would require conversion of the addresses to 
Ordnance Survey coordinates, and analysis for clustering using SaTScanTM, or 
similar (see https://www.satscan.org/, accessed 05.08.18), looking for clustering of 
patients both at specific time periods (e.g. calendar year), and for clustering of 
patients at time intervals prior to symptom onset (e.g. 5, 10, 20 years before onset of 
symptoms). This would be a follow up study to the paper by Linsell et al. (27).  
 
Overall, there is no convincing evidence from this work to suggest that sporadic 
CJD is an acquired disease, although it is possible that a small number of iatrogenic 
cases, transmitted by previously established means of transmission, have been 
missed and classified as sporadic CJD. There is considerable missing data in each 
section of this work, and it is also possible that the evidence of acquired 
transmission could be hidden among this missing data, or that such a case might 
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Appendix 1: Operation coding document 
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Appendix 4: Family questionnaire vs GP record year reporting 
Table: Number of procedures by final digit of year. Data for Figure 4.4 
Procedure by final digit of year Family questionnaire  GP records 
0 167 358 
1 105 318 
2 120 284 
3 113 311 
4 114 313 
5 222 283 
6 77 289 
7 117 280 
8 142 328 
9 121 329 
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Appendix 5: Percentages of surgical procedures and TPAs using 
family questionnaire data only  
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